amgn gaap accountspayableandaccruedliabilitiescurrentus gaap accountspayableandaccruedliabilitiescurrentus gaap otherliabilitiesnoncurrentus gaap xngsus gaap gaap gaap gaap gaap gaap gaap usdxbrli gaap gaap gaap gaap gaap retainedearningsmembersrt gaap accumulatedothercomprehensiveincomemembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap retainedearningsmembersrt gaap gaap gaap gaap gaap gaap gaap gaap segmentxbrli gaap otezlamemberus gaap otezlamemberamgn otezlamemberus gaap otezlamemberamgn assembledworkforcememberamgn otezlamemberus gaap nuevolutionmemberamgn kirinamgeninc kirinamgeninc kirinamgeninc kirinamgeninc kamemberus gaap kirinamgeninc kamemberus gaap usamgn enbrelmemberus gaap usamgn enbrelmemberus gaap usamgn enbrelmemberus gaap usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn otezlamemberus gaap usamgn otezlamemberus gaap usamgn otezlamemberus gaap usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn aranespmemberus gaap usamgn aranespmemberus gaap usamgn aranespmemberus gaap usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn usamgn gaap nonusmemberamgn otherproductsmembercountry otherproductsmemberus gaap otherproductsmembercountry otherproductsmemberus gaap otherproductsmembercountry otherproductsmemberus gaap usus gaap gaap nonusmemberus gaap usus gaap gaap nonusmemberus gaap usus gaap gaap nonusmemberus gaap gaap productandserviceothermembercountry gaap productandserviceothermemberus gaap gaap productandserviceothermembercountry gaap productandserviceothermemberus gaap gaap productandserviceothermembercountry gaap productandserviceothermemberus gaap gaap gaap gaap customeronememberus gaap customeronememberus gaap customeronememberus gaap customertwomemberus gaap customertwomemberus gaap customertwomemberus gaap gaap productmemberamgn gaap productmemberamgn gaap productmemberamgn gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap domesticcountrymemberamgn gaap gaap foreigncountrymemberamgn beigenememberus gaap gaap othercurrentassetsmemberamgn gaap sellinggeneralandadministrativeexpensesmemberamgn gaap sellinggeneralandadministrativeexpensesmemberamgn gaap sellinggeneralandadministrativeexpensesmemberamgn gaap costofsalesmemberamgn gaap costofsalesmemberamgn gaap costofsalesmemberamgn gaap productandserviceothermemberamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc memberamgn nonusexcludingjapanmemberamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc memberamgn usamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc memberamgn gaap royaltymemberamgn otherrevenuesmemberamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc gaap royaltymemberamgn otherrevenuesmemberamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc gaap royaltymemberamgn otherrevenuesmemberamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc otherrevenuesmemberamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc memberamgn otherrevenuesmemberamgn collaborativearrangementswithbayerhealthcarepharmaceuticalsinc memberamgn gaap gaap gaap gaap gaap gaap gaap gaap gaap fairvaluemeasuredatnetassetvaluepersharemembersrt gaap fairvaluemeasuredatnetassetvaluepersharemembersrt gaap fairvaluemeasuredatnetassetvaluepersharemembersrt gaap fairvaluemeasuredatnetassetvaluepersharemembersrt gaap fairvaluemeasuredatnetassetvaluepersharemembersrt minimummemberamgn beigenemembersrt minimummemberus gaap gaap buildingandbuildingimprovementsmembersrt minimummemberamgn manufacturingequipmentmembersrt minimummemberamgn maximummemberamgn gaap softwareandsoftwaredevelopmentcostsmembersrt gaap softwareandsoftwaredevelopmentcostsmembersrt minimummemberus gaap gaap propertyplantandequipmentothertypesmembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap gaap gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn onepointeightfivepercentnotesduetwozerotwoonememberus gaap onepointeightfivepercentnotesduetwozerotwoonememberus gaap gaap gaap onepointtwofivepercenteuronotesduetwozerotwotwomemberus gaap onepointtwofivepercenteuronotesduetwozerotwotwomemberus gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap notespayabletobanksmemberamgn threepointonetwofivepercentnotesduetwozerotwofivememberus gaap threepointonetwofivepercentnotesduetwozerotwofivememberus gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn twopointtwozeropercentnotesduetwozerotwosevenmemberus gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn fourpointfivesixthreepercentnotesduetwozerofoureightmemberus gaap fourpointfivesixthreepercentnotesduetwozerofoureightmemberus gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn twopointsevensevenpercentnotesduetwozerofivethreememberus gaap twopointsevensevenpercentnotesduetwozerofivethreememberus gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn fourpointfivesixthreepercentnotesduetwozerofoureightmemberus gaap gaap notespayabletobanksmemberamgn onepointeightfivepercentnotesduetwozerotwoonememberus gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap notespayabletobanksmemberamgn gaap gaap notespayabletobanksmemberamgn gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn threepointonetwofivepercentnotesduetwozerotwofivememberus gaap gaap notespayabletobanksmemberamgn gaap gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn onepointtwofivepercenteuronotesduetwozerotwotwomemberus gaap gaap twopointsevensevenpercentnotesduetwozerofivethreememberus gaap gaap notespayabletobanksmemberamgn gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn twopointtwozeropercentnotesduetwozerotwosevenmemberus gaap minimummemberus gaap gaap debtsecuritiespayablemembersrt gaap gaap notespayabletobanksmemberamgn twopointtwozeropercentnotesduetwozerotwosevenmemberus gaap gaap notespayabletobanksmemberamgn gaap gaap gaap twopointtwozeropercentnotesduetwozerotwosevenmemberus gaap gaap gaap gaap notespayabletobanksmemberamgn gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap gaap gaap gaap gaap gaap gaap notespayabletobanksmemberamgn gaap notespayabletobanksmemberamgn gaap gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberamgn interestrateswaptwomemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberamgn interestrateswapthreememberus gaap gaap gaap notespayableotherpayablesmemberus gaap gaap gaap notespayableotherpayablesmemberus gaap gaap notespayableotherpayablesmemberamgn gaap notespayableotherpayablesmemberus gaap londoninterbankofferedratelibormemberamgn gaap notespayableotherpayablesmemberamgn gaap notespayableotherpayablesmemberus gaap londoninterbankofferedratelibormemberamgn gaap gaap notespayableotherpayablesmemberus gaap gaap gaap notespayableotherpayablesmemberus gaap gaap gaap notespayableotherpayablesmemberus gaap gaap gaap notespayableotherpayablesmemberus gaap gaap gaap notespayableotherpayablesmemberus gaap gaap gaap notespayableotherpayablesmemberus gaap threepointonetwofivepercentnotesduetwozerotwofivememberus gaap threepointonetwofivepercentnotesduetwozerotwofivememberus gaap notespayableotherpayablesmemberus gaap threepointonetwofivepercentnotesduetwozerotwofivememberus gaap threepointonetwofivepercentnotesduetwozerotwofivememberus gaap notespayableotherpayablesmemberus gaap gaap notespayableotherpayablesmemberamgn gaap notespayableotherpayablesmemberus gaap londoninterbankofferedratelibormemberamgn gaap notespayableotherpayablesmemberamgn gaap notespayableotherpayablesmemberus gaap londoninterbankofferedratelibormemberamgn gaap notespayableotherpayablesmemberamgn gaap notespayableotherpayablesmemberamgn fourpointsixsixthreepercentnotesduetwozerofiveonememberus gaap gaap notespayableotherpayablesmemberamgn gaap notespayableotherpayablesmemberamgn fourpointsixsixthreepercentnotesduetwozerofiveonememberus gaap gaap gaap onepointtwofivepercenteuronotesduetwozerotwotwomemberus gaap gaap notespayableotherpayablesmemberamgn gaap notespayableotherpayablesmemberamgn gaap gaap gaap londoninterbankofferedratelibormemberus gaap gaap federalfundseffectiveswapratememberus gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberus gaap foreignexchangecontractmemberus gaap cashflowhedgingmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberus gaap foreignexchangecontractmemberus gaap cashflowhedgingmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberus gaap foreignexchangecontractmemberus gaap cashflowhedgingmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberamgn crosscurrencyswapcontractsmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberamgn crosscurrencyswapcontractsmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberamgn crosscurrencyswapcontractsmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap gaap gaap ustreasurysecuritiesmemberus gaap gaap ustreasurysecuritiesmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap corporatedebtsecuritiesindustrialmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap othershortterminterestbearingsecuritiesmemberus gaap othershortterminterestbearingsecuritiesmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap ustreasurysecuritiesmemberus gaap gaap ustreasurysecuritiesmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap corporatedebtsecuritiesindustrialmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap othershortterminterestbearingsecuritiesmemberus gaap othershortterminterestbearingsecuritiesmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap inprocessresearchanddevelopmentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap crosscurrencyswapcontractsmemberamgn onepointtwentyfivepercenteuronotesduetwothousandtwentytwomemberus gaap crosscurrencyswapcontractsmemberamgn onepointtwentyfivepercenteuronotesduetwothousandtwentytwomemberus gaap cashflowhedgingmembercurrency usdamgn crosscurrencyswapcontractsmemberamgn onepointtwentyfivepercenteuronotesduetwothousandtwentytwomemberus gaap crosscurrencyswapcontractsmemberus gaap cashflowhedgingmemberamgn chfamgn crosscurrencyswapcontractsmemberus gaap cashflowhedgingmemberamgn usdamgn crosscurrencyswapcontractsmemberus gaap cashflowhedgingmemberamgn crosscurrencyswapcontractsmemberamgn twopercenteuronotesduetwothousandtwentysixmemberus gaap crosscurrencyswapcontractsmemberamgn twopercenteuronotesduetwothousandtwentysixmemberus gaap cashflowhedgingmembercurrency usdamgn crosscurrencyswapcontractsmemberamgn twopercenteuronotesduetwothousandtwentysixmemberus gaap crosscurrencyswapcontractsmemberus gaap cashflowhedgingmemberamgn crosscurrencyswapcontractsmemberus gaap cashflowhedgingmemberamgn usdamgn crosscurrencyswapcontractsmemberus gaap cashflowhedgingmemberamgn crosscurrencyswapcontractsmemberamgn gaap crosscurrencyswapcontractsmemberamgn gaap cashflowhedgingmembercurrency usdamgn crosscurrencyswapcontractsmemberamgn gaap gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap crosscurrencyswapcontractsmemberus gaap crosscurrencyswapcontractsmemberus gaap crosscurrencyswapcontractsmemberus gaap forwardinterestratecontractmemberus gaap forwardinterestratecontractmemberus gaap forwardinterestratecontractmemberus gaap gaap gaap gaap gaap designatedashedginginstrumentmemberus gaap gaap interestexpensememberus gaap gaap longtermdebtmemberamgn gaap gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberus gaap foreignexchangecontractmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberamgn gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberus gaap foreignexchangecontractmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberamgn gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberus gaap foreignexchangecontractmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlossnetcashflowhedgeparentmemberamgn gaap gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangecontractmemberamgn gaap designatedashedginginstrumentmemberus gaap foreignexchangecontractmemberamgn gaap designatedashedginginstrumentmemberamgn crosscurrencyswapcontractsmemberamgn gaap designatedashedginginstrumentmemberamgn crosscurrencyswapcontractsmemberamgn gaap designatedashedginginstrumentmemberamgn othercurrentnoncurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberamgn accruedliabilitiesothernoncurrentliabilitiesmemberus gaap gaap gaap othercurrentassetsmemberus gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangecontractmemberamgn gaap designatedashedginginstrumentmemberus gaap foreignexchangecontractmemberamgn gaap designatedashedginginstrumentmemberamgn crosscurrencyswapcontractsmemberamgn gaap designatedashedginginstrumentmemberamgn crosscurrencyswapcontractsmemberamgn gaap designatedashedginginstrumentmemberamgn othercurrentnoncurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberamgn accruedliabilitiesothernoncurrentliabilitiesmemberus gaap gaap gaap othercurrentassetsmemberus gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap kyproliscarfilzomibpatentlitigationmembersrt gaap gaap gaap gaap gaap gaap gaap gaap statessecurities exchange commissionwashington mark one annual report pursuant section security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of file number amgen inc exact name of registrant specified charter state or jurisdiction ofincorporation or organization employeridentification one amgen center oakscalifornia address of principal executive office zip code registrant telephone number including area code security registered pursuant to section of the act title of classtrading symbol name of each exchange registeredcommon stock par valueamgnthe nasdaq stock market senior note due nasdaq stock market senior note due nasdaq stock market llcsecurities registered pursuant to section of the act noneindicate check mark the registrant well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is required to file report pursuant to section or section of the act yes no ýindicate by check mark whether the registrant filed report required to filed by section or section of the security exchange act of the preceding month or shorter period the registrant required to file such report and ha subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated fileraccelerated filernon accelerated filersmaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report indicate by check mark whether the registrant is shell company defined in rule of the act yes no ýthe approximate aggregate market value of voting and non voting stock held by non affiliate of the registrant wa of june excludes share of common stock held by director and executive officer and any stockholder whose ownership exceeds ten percent of the share outstanding june exclusion of share held by any person not be construed to indicate that such person posse the power directly or indirectly to direct or cause the direction of the management or policy of the registrant or that such person is controlled by or under common control with the registrant number of share of common stock outstanding of february document incorporated by referencespecified portion of the registrant proxy statement with respect to the annual meeting of stockholder to be held may incorporated by reference part iii of this annual report index page no part distribution and selected marketed distribution and raw and development and selected product capital executive area financial risk unresolved staff legal mine safety market for registrant common equity related stockholder matter and issuer purchase of equity selected financial management discussion and analysis of financial condition and result of quantitative and qualitative disclosure about market financial statement and supplementary change in and disagreement with accountant on accounting and financial control and other director executive officer and corporate governance executive security ownership of certain beneficial owner and management and related stockholder certain relationship and related transaction and director principal accounting fee and exhibit financial statement form iitem businessamgen inc including it subsidiary referred to amgen the company our or is committed to unlocking the potential of biology for patient suffering serious illness by discovering developing manufacturing and delivering innovative human therapeutic this approach begin by using tool like advanced human genetics to unravel the complexity of disease and understand the fundamental of human biology amgen focus on area of high unmet medical need and leverage it expertise to strive for solution that improve health outcome and dramatically improve people life biotechnology pioneer amgen ha grown to be one of the world leading independent biotechnology company ha reached million of patient around the world and is developing pipeline of medicine with breakaway potential amgen wa incorporated in california in and became delaware corporation in we presence in approximately country worldwide amgen operates in one business segment human therapeutic significant development following is summary of significant development affecting our business that have occurred and that we have reported since the filing of our annual report on form for the year ended december covid pandemica novel strain of coronavirus sars cov or severe acute respiratory syndrome coronavirus causing coronavirus disease or covid wa declared global pandemic by the world health organization on march since the first quarter of and continuing into we have seen impact of the pandemic to our operation we continue to monitor and respond the pandemic evolves to ensure the continued development manufacture and distribution of our medicine for discussion see item management discussion and analysis of financial condition and result of operation overview selected financial information and result of operation for discussion of the risk presented by the covid pandemic to our result see risk factor in item also see the remainder of item business for discussion of pandemic related impact to our overall business product pipeline oncology hematologykyprolis carfilzomib in august we announced that the food and drug administration fda approved the expansion of the kyprolis prescribing information to include it use in combination with darzalex daratumumab plus dexamethasone in two dosing regimen weekly and twice weekly for the treatment of patient with relapsed or refractory multiple myeloma who have received one to three previous line of therapy sotorasib formerly amg in september we announced updated phase data evaluating sotorasib in patient across multiple advanced solid tumor with kirsten rat sarcoma viral oncogene homolog kras mutation which published in the new england journal of medicine data from patient with advanced non small cell lung cancer nsclc were also featured in an oral presentation at september medical conference in the patient with advanced nsclc who were treated with the mg daily dose the confirmed objective response rate orr wa across all dose level the confirmed orr wa with median duration of response of month and median progression free survival pfs of month of responder were still in response of the data cutoff in october we announced top line phase result in patient with kras mutant advanced nsclc sotorasib demonstrated an orr primary endpoint consistent with previously reported phase data in patient taking the mg daily dose other measure of efficacy including duration of response were promising and half of the responder were still on treatment and continuing to respond of the data cutoff date the result of this phase study are potentially registrational and phase confirmatory study comparing sotorasib to docetaxel is currently recruiting patient with kras mutant advanced nsclc in december we announced that the fda had granted breakthrough therapy designation for our investigational inhibitor sotorasib for the treatment of patient with locally advanced or metastatic nsclc with kras mutation determined by an fda approved test following at least one prior systemic therapy following this announcement we submitted new drug application nda to the fda the sotorasib nda is reviewed by the fda real time oncology review rtor pilot program which aim to explore more efficient review process that ensures safe and effective treatment are made available to patient early possible later in december we also submitted marketing authorization application maa to the european medicine agency ema in january we announced result from the phase cohort of the clinical study evaluating sotorasib in patient with kras mutant advanced nsclc sotorasib demonstrated confirmed orr and disease control rate of and respectively median duration of response of month and median progression free survival of month in addition sotorasib wa granted breakthrough therapy designation by the center for drug evaluation of the national medical product administration in china riabnitm rituximab arrx formerly abp in december we announced that the fda had approved riabnitm biosimilar to rituxan rituximab for the treatment of adult patient with non hodgkin lymphoma chronic lymphocytic leukemia granulomatosis with polyangiitis wegener granulomatosis and microscopic polyangiitis riabnitm launched in the united state in january inflammationotezla apremilast in may we announced positive top line result from phase study to ass the efficacy of otezla in adult with mild to moderate plaque psoriasis the study showed that oral otezla mg twice daily achieved statistically significant improvement compared with placebo in the primary endpoint of the static physician global assessment spga response defined an spga score of clear or almost clear with at least point reduction from baseline at week enbrel etanercept in july the court of appeal for the federal circuit affirmed the judgment by the district court for the district of new jersey upholding the validity of the two patent that describe and claim enbrel and method for making see note contingency and commitment to the consolidated financial statement tezepelumab in november we and astrazeneca plc astrazeneca announced positive top line result from the registrational phase navigator trial in adult and adolescent with severe uncontrolled asthma the trial met the primary endpoint with tezepelumab added to standard of care soc demonstrating statistically significant and clinically meaningful reduction compared with placebo plus soc in the annualized asthma exacerbation rate aaer over week in the overall patient population soc consisted of medium or high dose inhaled corticosteroid ic plus at least one additional controller medication with or without oral corticosteroid ocs we expect to submit result of this study to regulator in in december we and astrazeneca announced that the source trial had not met the primary endpoint of statistically significant reduction in the daily ocs dose without loss of asthma control with tezepelumab compared to placebo the result of this trial have no impact on our submission plan cardiovascularomecamtiv mecarbil in november based on result of the omecamtiv mecarbil phase trial we provided notice to cytokinetics incorporated cytokinetics of termination of our collaboration and our intention to transition to the development and commercialization right for omecamtiv mecarbil and amg of wholly owned affiliate in japan in april we completed our purchase from astellas of the remaining share of amgen astellas biopharma aabp joint venture amgen and astellas established in aabp wholly owned amgen affiliate in japan and renamed amgen ha enabled to build strong presence in japan we continue to advance treatment for serious illness the purchase not have material impact to our consolidated financial statement marketing distribution and selected marketed productsthe largest concentration of our sale and marketing force is based in the united state and europe in addition we continue to expand the commercialization and marketing of our product into other geographic territory including part of asia the middle east canada and latin america this expansion is occurring by establishing our affiliate by acquiring existing third party business or product right or by collaborating with third party see business relationship for our significant alliance whether we use our own sale and marketing force or third party varies across market such use typically depends on several factor including the nature of entry into the new market the size of an opportunity and operational capability together with our collaborator we market our product to healthcare provider including physician or clinic dialysis center hospital and pharmacy in the united state substantially all of our sale are to pharmaceutical wholesale distributor which are the principal mean of distributing our product to healthcare provider we also market certain product direct to consumer channel including print television and online medium for further discussion see government regulation regulation in the united state regulation of product marketing and promotion outside the united state we sell principally to healthcare provider and or pharmaceutical wholesale distributor depending on the distribution practice in each country our product sale to three large wholesaler amerisourcebergen corporation mckesson corporation and cardinal health inc each individually accounted for more than of total revenue for each of the year and on combined basis these wholesaler accounted for and of worldwide gross revenue for and respectively we monitor the financial condition of our larger customer and limit our credit exposure by setting credit limit and in certain circumstance by requiring letter of credit or obtaining credit insurance product are marketed around the world with the united state being our largest market the following chart show our product sale by principal product and the table dollar amount in million show product sale by geography for the year and sale by geography ex total market enbrel tumor necrosis factor blocker primarily in the united state enbrel wa launched in and is used primarily in indication for the treatment of adult patient with moderately to severely active rheumatoid arthritis patient with chronic moderate to severe plaque psoriasis who are candidate for systemic therapy or phototherapy and patient with active psoriatic arthritis prolia denosumab we market prolia primarily in the united state europe and the asia pacific region prolia contains the active ingredient xgeva denosumab is approved for different indication patient population dos and frequency of administration prolia wa launched in the united state and europe in in the united state it is used primarily in the indication for the treatment of postmenopausal woman with osteoporosis at high risk of fracture defined history of osteoporotic fracture or multiple risk factor for fracture or in patient who have failed or are intolerant to other available osteoporosis therapy in europe prolia is used primarily for the treatment of osteoporosis in postmenopausal woman at increased risk of fracture neulasta pegfilgrastim we market neulasta pegylated protein based on the filgrastim molecule primarily in the united state and europe neulasta wa launched in and is used primarily in the indication to help reduce the chance of infection due to low white blood cell count in patient with certain type of cancer nonmyeloid who receive anticancer medicine chemotherapy that cause fever and low blood cell count in the neulasta onpro kit became available in the united state the neulasta onpro kit provides physician the opportunity to initiate the administration of neulasta on the same day chemotherapy with drug delivery of the recommended dose of neulasta at home the day chemotherapy thereby saving patient trip back to the doctor otezla we market otezla small molecule that inhibits phosphodiesterase primarily in the united state and europe otezla wa acquired from bristol myers squibb company bm in november post their acquisition of celgene corporation celgene otezla is an oral therapy approved for the treatment of adult patient with moderate to severe plaque psoriasis for phototherapy or systemic therapy is appropriate patient with active psoriatic arthritis and patient with oral ulcer associated with behçet disease in europe otezla is approved for second line use in the treatment of psoriatic arthritis and psoriasis xgeva we market xgeva primarily in the united state and europe xgeva wa launched in and is used primarily in the indication for prevention of skeletal related event sres pathological fracture radiation to bone spinal cord compression or surgery to bone in patient with bone metastasis from solid tumor and multiple myeloma aranesp darbepoetin alfa we market aranesp primarily in the united state and europe it wa launched in and is indicated to treat lower than normal number of red blood cell anemia caused by chronic kidney disease ckd in patient on dialysis and patient not on dialysis aranesp is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in certain patient with nonmyeloid malignancy and chemotherapy be used for at least two month after starting aranesp kyprolis we market kyprolis primarily in the united state and europe kyprolis wa launched in and is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patient with relapsed or refractory multiple myeloma who have received one to three prior line of therapy it is also approved single agent for patient with relapsed or refractory multiple myeloma who have received one or more previous therapy in september the candor phase study of kyprolis in combination with dexamethasone and darzalex daratumumab met it primary endpoint of pfs in patient with relapsed or refractory multiple myeloma in august the fda approved the expansion of the kyprolis prescribing information to include it use in combination with dexamethasone and darzalex evolocumab we market repatha proprotein convertase subtilisin kexin type primarily in the united state and europe repatha wa launched in and is indicated to reduce the risk of myocardial infarction stroke and coronary revascularization in adult with established cardiovascular cv disease other marketed productswe also market number of other product in various market worldwide including nplate romiplostim vectibix panitumumab mvasi bevacizumab awwb parsabiv etelcalcetide epogen epoetin alfa kanjinti trastuzumab anns blincyto blinatumomab aimovig erenumab aooe evenity romosozumab aqqg amgevitatm adalimumab sensipar mimpara cinacalcet neupogen filgrastim imlygic talimogene laherparepvec corlanor ivabradine and avsola infliximab axxq patentsthe following table list our outstanding material patent for the indicated product by territory general subject matter and latest expiry date certain of the european patent are the subject of supplemental protection certificate that provide additional protection for the product in certain european country beyond the date listed in the table see footnote to the patent table below one or more patent with the same or earlier expiry date may fall under the same general subject matter and are not listed separately subject matterexpirationenbrel etanercept method of treatment using aqueous fusion protein and pharmaceutical dna encoding fusion protein and method of making fusion xgeva denosumab rankl method of nucleic acid encoding rankl antibody and method of producing rankl rankl antibody including antibody including epitope antibody including sequence apremilast composition and crystalline method of compound and method of treatment darbepoetin alfa glycosylation analog of erythropoietin carfilzomib composition and method of method of compound and method of treatment evolocumab antibody method of of romiplostim thrombopoietic compound panitumumab europehuman monoclonal antibody to epidermal growth factor receptor etelcalcetide compound and pharmaceutical method of and pharmaceutical composition blinatumomab pharmaceutical composition and bifunctional method of polypeptide of erenumab aooe cgrp receptor antibody method of receptor antibody of romosozumab aqqg antibody method of treatment formulation and method of using of and method of using talimogene laherparepvec method of and us calcitonin gene related peptide rankl receptor activator of nuclear factor kappa ligand european patent with this subject matter may also be entitled to supplemental protection in one or more country in europe and the length of any such extension will vary by country for example supplementary protection certificate have been issued related to the indicated product for patent in at least the following country denosumab france germany italy spain and the united kingdom expiring in carfilzomib france germany italy and spain expiring in romiplostim france germany italy spain and the united kingdom expiring in panitumumab france germany italy spain and the united kingdom expiring in evolocumab france and spain expiring in etelcalcetide france and italy expiring in blinatumomab france italy and spain expiring in erenumab france italy and spain expiring in talimogene laherparepvec spain expiring in france germany italy and the united kingdom expiring in romosozumab italy expiring in apremilast italy and spain expiring in patent with this subject matter may be entitled to patent term extension in the united state competitionwe operate in highly competitive environment number of our marketed product are indicated for disease area in which other product or treatment are currently available or are being pursued by our competitor through research and development activity additionally some competitor marketed product target the same genetic pathway our recently launched marketed product or are currently in development this competition could impact the pricing and market share of our product we continue to pursue way of increasing the value of our medicine through innovation during their life cycle which can include expanding the disease area for which our product are indicated and finding new method to make the delivery of our medicine easier and le costly such activity can offer important opportunity for differentiation for example we market the neulasta onpro kit which provides physician the opportunity to initiate the administration of the recommended dose of neulasta on the same day chemotherapy with drug delivery at home the day after chemotherapy thereby saving patient trip back to the doctor we plan to continue pursuing innovation effort to strengthen our competitive position such position may be based on among other thing safety efficacy reliability availability patient convenience delivery device price reimbursement access to and timing of market entry and patent position and expiration certain of the existing patent on our principal product have expired and we face new and increasing competition including from biosimilars and generic biosimilar is another version of biological product for which marketing approval is sought or ha been obtained based on demonstration that it is highly similar to the original reference product we expect that the adverse impact on our originator product sale from biosimilar competition will reflect current trend and actual result given similar condition we also believe that when multiple biosimilar version of one of our originator product get approved and launched competition could intensify more rapidly leading to net price decline for both reference and biosimilar product resulting in greater impact on our product sale in the united state company have now launched biosimilar version of epogen neupogen and neulasta and have approved biosimilars for enbrel see also government regulation regulation in the united state approval of biosimilars although we expect competitor biosimilars to compete on price we believe many patient provider and payer will continue to place high value on the reputation reliability and safety of our product additional biosimilar competitor come to market we will leverage our global experience versus both branded and biosimilar competition we also have our own biosimilar product both in the united state and outside of market that are competing branded and biosimilar version of our competitor product in amgen launched mvasi biosimilar to avastin bevacizumab and kanjinti biosimilar to herceptin trastuzumab in the united state and amgevitatm biosimilar to humira adalimumab in europe we have also received fda approval for amjevitatm adalimumab atto biosimilar to humira in we launched avsola biosimilar to remicade infliximab and in january we launched riabnitm biosimilar for rituxan rituximab we expect additional biosimilar competition against both our branded and biosimilar product in the future across all market addition although of our product are biologics some are small molecule product the fda approval process permit generic manufacturer to rely on the safety and efficacy data of the innovator product rather than to conduct their own costly and time consuming clinical trial generic manufacturer can often develop and market their competing version of our small molecule product at much lower price for example following loss of exclusivity of patent directed to cinacalcet the active ingredient in our small molecule calcimimetic sensipar we lost significant share of the market and corresponding revenue in short period of time see part iv note contingency and commitment to the consolidated financial statement the introduction of new product the development of new process or technology by competitor or the emergence of new information about existing product may result in increased competition for our marketed product even for protected by patent and or ii in reduction in the price we receive from selling our product in addition the development of new treatment option or standard of care may reduce the use of our product or may limit the utility and application of ongoing clinical trial for our product candidate used in this document the term clinical trial may include prospective clinical trial observational study registry and other study see item risk factor our product face substantial competition and item risk factor we currently face competition from biosimilars and expect to face increasing competition from biosimilars and generic in the future following table reflects our significant competitor and is not exhaustive productterritorycompetitor marketed productcompetitorsenbrelu canadaremicade janssen biotech inc janssen canadahumira abbvie inc abbvie europexeljanz pfizer inc canadarinvoq abbvieprolia europealendronate raloxifene and zoledronate genericsvariousneulasta udenyca coherus bioscience inc fulphila mylan institutional inc europefilgrastim biosimilarsvariousotezla europehumira abbvieu europecosentyx novartis pharma ag novartis europetaltz eli lilly and company lilly europetremfya janssenu europeskyrizi abbvieu europemethotrexate generic variousxgeva europezoledronate genericsvariousaranesp procrit janssen europeepoetin alfa biosimilarsvariouskyprolis velcade millennium pharmaceutical inc europerevlimid celgene pomalyst celgene darzalex janssen repatha europepraluent regeneron pharmaceutical inc sanofi approved biosimilars available approved biosimilars available in europe subsidiary of johnson johnson other biosimilars under regulatory review in the united state and europe dermatology procrit competes with aranesp in supportive cancer care and predialysis setting kyprolis is facing increased competition from several recently approved product subsidiary of takeda pharmaceutical company limited subsidiary of bm reimbursement sale of our principal product are dependent on the availability and extent of coverage and reimbursement from third party payer in many market around the world these payer including government health system private health insurer and other organization remain focused on reducing the cost of healthcare and their effort have intensified result of rising healthcare cost economic pressure and broader challenge generated by the covid pandemic drug remain heavily scrutinized for cost containment result payer are becoming more restrictive regarding the use of biopharmaceutical product and are scrutinizing the price of these product requiring higher level of clinical evidence to support the benefit such product bring to patient and the broader healthcare system these pressure are intensified when our product are subject to competition including from biosimilars the united state healthcare provider and other entity such pharmacy and pharmacy benefit manager pbms are reimbursed for covered service and product deliver through both private payer and government healthcare program such medicare and medicaid we provide negotiated rebate to healthcare provider private payer government payer and pbms in addition we are required to provide rebate or discount on our product that are reimbursed through certain government program including medicare and medicaid and ii provide discount to qualifying healthcare provider under the federal drug pricing program both private and government payer use formulary to manage access and utilization of drug drug inclusion and favorable positioning on formulary are essential to ensure patient have access to particular drug even when access is available some patient abandon their prescription for economic reason payer continue to institute cost reduction and containment measure that lower drug utilization and or spending altogether and or shift greater portion of the cost to patient such measure include but are not limited to more limited benefit plan design higher patient co pay or coinsurance obligation limitation on patient use of commercial manufacturer co pay payment assistance program including through co pay accumulator adjustment or maximization program stricter utilization management criterion patient may get access to drug higher tier formulary placement that increase the level of patient of pocket cost and formulary exclusion which effectively encourages patient and provider to seek alternative treatment or pay of the cost of drug the use of such measure by pbms and insurer ha continued to intensify and ha thereby limited amgen product usage and sale furthermore during the past year many pbms and insurer have consolidated resulting in smaller number of pbms and insurer overseeing large portion of total covered life in the united state result pbms and insurer have greater market power and negotiating leverage to mandate stricter utilization criterion and or exclude drug from their formulary in favor of competitor drug or alternative treatment in highly competitive treatment market such the market for enbrel otezla repatha and aimovig pbms are also able to exert negotiating leverage by requiring incremental rebate from manufacturer in order for them to gain and or maintain their formulary position in addition to market action taken by private and government payer in the united state policy maker from both of the major political party are pursuing policy to lower drug cost potential policy cover wide range of area including allowing the importation of drug from other country instituting international reference pricing irp scheme which would set the price of certain drug based on those available in other country establishing cap on price increase based on inflation metric increasing transparency on drug pricing and using third party value assessment to determine drug price example of such policy include the previous administration november interim final rule which attempt to institute most favored nation mfn irp in medicare part and final rule instituting rebate reform in medicare part both of these rule are being challenged in court and therefore have not yet been implemented the direction of drug pricing policy reform remains unclear at this time in many country outside the united state government sponsored healthcare system are the primary payer for drug and biologics with increasing budgetary constraint and or difficulty in understanding the value of medicine government and payer in many country are applying variety of measure to exert downward price pressure these measure can include mandatory price control price referencing therapeutic reference pricing increase in mandate incentive for generic substitution and biosimilar usage and government mandated price cut in this regard many country have health technology assessment organization that use formal economic metric such cost effectiveness to determine price coverage and reimbursement of new therapy and these organization are expanding in both established and emerging market many country also limit coverage to population narrower than those specified on our product label or impose volume cap to limit utilization we expect that country will continue taking aggressive action to seek to reduce expenditure on drug and biologics similarly fiscal constraint may also affect the extent to which country are willing to approve new and innovative therapy and or allow access to new technology dynamic and development discussed serve to create pressure on the pricing and potential usage of our product and the industry given the diverse interest in play between payer biopharmaceutical manufacturer policy maker healthcare provider and independent organization if and whether the party involved can achieve alignment on the matter discussed above remain unclear and the outcome of any such alignment is difficult to predict we remain focused on pricing our product responsibly and delivering breakthrough treatment for unmet medical need amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicine we this by investing billion of dollar annually in developing more affordable therapeutic choice in the form of high quality and reliably supplied biosimilars pricing our medicine to reflect the value they provide partnering with payer to share risk and accountability for health outcome providing patient support and education program helping patient in financial need access our medicine and working with policy maker patient and other stakeholder to establish sustainable healthcare system with access to affordable care and patient and their healthcare professional are the primary decision maker see item risk factor our sale depend on coverage and reimbursement from government and commercial third party payer and pricing and reimbursement pressure may affect our profitability and item risk factor guideline and recommendation published by various organization can reduce the use of our product manufacturing distribution and raw materialsmanufacturingwe believe we are leader in the manufacture of biologics and that our manufacturing capability represent competitive advantage the product we manufacture consist of both biologics and small molecule drug the majority of our product are biologics that are produced in living cell and that are inherently complex due to naturally occurring molecular variation highly specialized knowledge and extensive process and product characterization are required to transform laboratory scale process into reproducible commercial manufacturing process further our expertise in the manufacture of biologics position well for leadership in the global biosimilars market for additional information regarding manufacturing facility see item property our internal manufacturing network ha commercial production capability for bulk manufacturing formulation fill finish tableting and device assembly these activity are performed within the united state and it territory in our puerto rico rhode island and california facility well internationally in our ireland netherlands and singapore facility in addition we use third party contract manufacturer to supplement the capacity or capability of our commercial manufacturing network to support our clinical trial we manufacture product candidate primarily at our california facility we also use third party contract manufacturer to supplement the capacity or capability of our overall clinical manufacturing network see item risk factor for discussion of the factor that could adversely impact our manufacturing operation and the global supply of our product distributionwe operate distribution center in puerto rico kentucky california and the netherlands for worldwide distribution of the majority of our commercial and clinical product we also use third party distributor to supplement distribution of our product worldwide otherin addition to the manufacturing and distribution activity noted above each of our manufacturing location includes key manufacturing support function such quality control process development engineering procurement production scheduling and warehousing certain of those manufacturing and distribution activity are highly regulated by the fda well international regulatory agency see government regulation regulation in the united state regulation of manufacturing standard initiativeswe have multiple ongoing initiative that are designed to extend our manufacturing advantage by optimizing our manufacturing network and or by mitigating risk while continuing to ensure adequate supply of our product for example our licensed next generation biomanufacturing plant operating in singapore incorporates multiple innovative technology into single facility and wa built in half the construction time and at approximately half the operating cost of traditional plant next generation biomanufacturing plant require smaller manufacturing footprint and offer greater environmental benefit including reduced consumption of water and energy and lower level of carbon emission within such plant the equipment is portable and smaller and some component are disposable which provides greater flexibility and speed when manufacturing different medicine simultaneously this eliminates the otherwise costly and complex retrofitting inherent in standard plant and enables amgen to respond to changing demand for it medicine with increased agility ultimately increasing the speed at which medicine can become available for patient the singapore site also ha plant that ha been approved to produce small molecule drug for commercial manufacturing in july we broke ground for our newest next generation biomanufacturing plant at our west greenwich rhode island campus construction on this new plant the first of it kind in the united state is complete upon approval by the fda and global regulatory authority this plant will expand our capacity to manufacture certain product for and global market in we initiated project to expand our manufacturing capability in thousand oak california well at contract manufacturer these investment will initially support clinical manufacturing but in the future may also be leveraged for commercial manufacturing in september we entered into an arrangement with lilly to manufacture lilly potential covid therapy for and potentially through we expect to allocate portion of our manufacturing capacity to support this production additionally starting in we will initiate project that will expand our manufacturing capacity to enable supply of product and product candidate these project will employ new technology that are being developed by amgen that are anticipated to allow further optimization of our manufacturing network and process see item risk factor manufacturing difficulty disruption or delay could limit supply of our product and limit our product sale raw material and medical devicescertain raw material medical device including companion diagnostics and component necessary for the commercial and or clinical manufacturing of our product are provided by and are the proprietary product of unaffiliated third party supplier certain of which may be our only source for such material we currently attempt to manage the risk associated with such supplier by mean of inventory management relationship management and evaluation of alternative source when feasible we also monitor the financial condition of certain supplier and their ability to supply our need see item risk factor we rely on third party supplier for certain of our raw material medical device and component we perform various procedure to help authenticate the source of raw material including intermediary material used in the manufacture of our product which include verification of the country of origin the procedure are incorporated into the manufacturing process we and our third party contract manufacturer perform to better ensure supply amgen ha risk mitigation strategy that us combination of method including multiple source or backup inventory of critical raw material in response to covid we continue to closely monitor our inventory level and have taken additional measure to mitigate against raw material supply interruption part of our ongoing business continuity effort see item risk factor for discussion of the factor that could adversely impact our manufacturing operation and the global supply of our product government regulationregulation by government authority in the united state and other country is significant factor in the production and marketing of our product and our ongoing activity to clinically test manufacture and market product for therapeutic use we must satisfy mandatory procedure and safety and effectiveness standard established by various regulatory body compliance with these standard is complex and failure to comply with any of these standard can result in significant implication see item risk factor for discussion of factor including global regulatory implication that can adversely impact our development and marketing of commercial product in the united statesin the united state the public health service act the federal food drug and cosmetic act fdca and the regulation promulgated thereunder well other federal and state statute and regulation govern among other thing the production research development testing manufacture quality control labeling storage record keeping approval advertising promotion and distribution of our product in addition to the reporting of certain payment and other transfer of value to healthcare professional and teaching hospital clinical development and product approval drug development in our industry is complex challenging and risky and failure rate are high product development cycle are typically very long approximately to year from discovery to market potential new medicine must undergo many year of preclinical and clinical testing to establish it safety and efficacy for use in human at appropriate dosing level and with an acceptable risk benefit profile we continue to work toward reducing cycle time by applying our expertise in human genetics and innovation in technology clinical trial and real world evidence after laboratory analysis and preclinical testing in animal we file an investigational new drug application ind with the fda to begin human testing typically we undertake an fda designated three phase human clinical testing program in phase we conduct small clinical trial to investigate the safety and proper dose range of our product candidate in small number of human subject in phase we conduct clinical trial to investigate side effect profile and the efficacy of our product candidate in patient population larger than phase but still relatively small who have the disease or condition under study in phase we conduct clinical trial to investigate the short and long term safety and efficacy of our product candidate compared to commonly used treatment in large number of patient who have the disease or condition under study the fda monitor the progress of each trial conducted under an ind and may at it discretion reevaluate alter suspend or terminate the testing based on the data accumulated to that point and the fda risk benefit assessment with regard to the patient enrolled in the trial the result of preclinical and clinical trial are submitted to the fda in the form of either biologics license application for biologic product or nda for small molecule product we are not permitted to market or promote new product the fda ha approved our marketing application approval of biosimilars the affordable care act aca authorized the fda to approve biosimilars via separate abbreviated pathway the pathway allows sponsor of biosimilar to seek and obtain regulatory approval based in part on the nonclinical trial and clinical trial data of an originator product to which the biosimilar ha been demonstrated to be highly similar and to have no clinically meaningful difference in term of safety purity and potency the relevance of demonstrating similarity is that in many case biosimilars can be brought to market without conducting the full suite of clinical trial typically required of originator because risk benefit ha previously been established to preserve incentive for future innovation the law establishes period of exclusivity for originator product which in general prohibits biosimilars from gaining fda approval based in part on reliance on or reference to the originator data in their application to the fda for year after initial fda approval of the originator product the law not change the duration of patent granted on biologic product part of the implementation of the abbreviated approval pathway for biosimilars the fda released number of guidance document some of which remain in draft form regulation of product marketing and promotion the fda regulates the marketing and promotion of drug product our product promotion for approved product indication must comply with the statutory standard of the fdca and the fda implemented regulation and guidance the fda review of marketing and promotional activity encompasses but is not limited to direct to consumer advertising healthcare provider directed advertising and promotion sale representative communication to healthcare professional promotional programming and promotional activity involving electronic medium the fda may also review industry sponsored scientific and educational activity that make representation regarding product safety or efficacy in promotional context the fda may take enforcement action against company for promoting unapproved us of product or for other violation of the fda advertising and labeling law and regulation enforcement action may include product seizure injunction civil or criminal penalty or regulatory letter which may require corrective advertising or other corrective communication to healthcare professional failure to comply with the fda regulation also can result in adverse publicity or increased scrutiny of company activity by the congress or other legislator additionally described below such failure may lead to additional liability under healthcare fraud and abuse law of manufacturing standard the fda regulates and inspects the equipment facility laboratory and process used in the manufacturing and testing of product prior to granting approval to market product if after receiving approval from the fda we make material change in manufacturing equipment location or process additional regulatory review may be required we also must adhere to current good manufacturing practice regulation and product specific regulation enforced by the fda through it facility inspection program the fda conduct regular periodic visit to reinspect our equipment facility laboratory and process following an initial approval regulation of combination product combination product are defined by the fda product composed of two or more regulated component biologic and or drug and device biologics drug and device each have their own regulatory requirement and combination product may have additional requirement number of our marketed product meet this definition and are regulated under this framework and we expect that number of our pipeline product candidate will be evaluated for regulatory approval under this framework well regulation outside the united statesin european union eu country well in switzerland canada australia and japan regulatory requirement and approval process are similar in principle to those in the united state in the eu are currently two potential track for seeking marketing approval for product not authorized in any eu member state decentralized procedure and centralized procedure in the decentralized procedure identical application for marketing authorization are submitted simultaneously to the national regulatory agency regulatory review is led by one member state the reference member state and it assessment based on safety quality and efficacy is reviewed and approved assuming there are no concern that the product pose serious risk to public health by the other member state from which the applicant is seeking approval the concerned member state the decentralized procedure lead to series of single national approval in all relevant country in the centralized procedure which is required of all product derived from biotechnology company submits single maa to the ema which conduct an evaluation of the dossier drawing upon it scientific resource across europe if the drug product is proven to fulfill requirement for quality safety and efficacy the ema committee for medicinal product of human use chmp adopts positive opinion which is transmitted to the european commission ec for final decision on granting of the marketing authorization even though the ec generally follows the chmp opinion it is not bound to do subsequent commercialization is enabled by country by country reimbursement approval in the eu biosimilars are approved under specialized pathway of the centralized procedure with the pathway an applicant seek and obtains regulatory approval for biosimilar once the data exclusivity period for the original reference product ha expired relying in part on the data submitted for the originator product together with data evidencing that the biosimilar is highly similar in term of quality safety and efficacy to the original reference product authorized in the european economic area result of the united kingdom decision to leave the eu the ema in march relocated to amsterdam the united kingdom officially left the eu in january and in december new trade deal wa agreed that start to clarify medicine will be independently supervised and where continued collaboration and recognition can be expected amgen continues to monitor future negotiation to ensure no interruption in the supervision regulation or supply of medicine in the united kingdom and europe other country such russia turkey and those in latin america and the middle east have review process and data requirement similar to those of the eu and in some case can rely on prior marketing approval from or eu regulatory authority the regulatory process in these country may include manufacturing testing facility inspection testing of drug product upon importation and other domestic requirement in asia pacific number of country such china japan south korea and taiwan may require local clinical trial data for bridging purpose part of the drug registration process in addition to global clinical trial which can add to overall drug development and registration timeline in most of the asian market registration timeline depend on marketing approval in the united state or the eu in some market in asia such china indonesia and thailand the regulatory timeline can be le predictable the regulatory process may also include manufacturing testing facility inspection testing of drug product upon importation and other domestic requirement country such australia and japan have more mature system that would allow for submission under more competitive time frame regarding biosimilars several of these country have pathway to register biosimilars australia india singapore south korea and taiwan and biosimilar product are already present on the market australia and south korea some country such japan and those in the eu medical device may be subject to regulatory regime whereby manufacturer must establish that their medical device conform to essential requirement set out in the law for the particular device category for example in the eu with limited exception medical device placed on the market must bear the conformité européenne marking to indicate their conformity with legal requirement postapproval phaseafter approval we continue to monitor adverse event and product complaint reported following the use of our product through routine postmarketing surveillance and study when applicable we report such event to the appropriate regulatory agency required by local regulation for individual case and aggregate report we proactively monitor according to good pharmacovigilance practice and ensure the implementation of signal detection assessment and the communication of adverse event that may be associated with the use of our product we also proactively monitor product complaint through our quality system which includes assessing our drug delivery device for device complaint adverse event and malfunction we may also be required by regulatory agency to conduct further clinical trial on our marketed product condition of their approval or to provide additional information on safety and efficacy health regulator including the fda have authority to mandate labeling change to product at any point in product life cycle based on new safety information or part of an evolving label change to particular class of product health regulator including the fda also have authority before or after approval to require company to implement risk management program for product to ensure that the benefit of the drug outweigh the risk each risk management program is unique and varies depending on the specific factor required in the united state risk management program is known risk evaluation and mitigation strategy rem and we currently have rem for prolia nplate and blincyto other regulationwe are also subject to various law pertaining to healthcare fraud and abuse including antikickback law and false claim law antikickback law make it illegal to solicit offer receive or pay any remuneration in exchange for or to induce the referral of business including the purchase or prescribing of particular drug that is reimbursed by state or federal program false claim law prohibit knowingly and willingly presenting or causing to be presented for payment to third party payer including medicare and medicaid any claim for reimbursed drug or service that are false or fraudulent claim for item or service not provided claimed or claim for medically unnecessary item or service violation of fraud and abuse law may be punishable by criminal and or civil sanction including fine and civil monetary penalty well by the possibility of exclusion from federal healthcare program including medicare and medicaid liability under the false claim law may also arise when violation of certain law or regulation related to the underlying product violation regarding improper promotional activity or unlawful payment contributes to the submission of false claim in amgen entered into corporate integrity agreement with the office of inspector general oig of the department of health human service hhs which wa formally closed out in august on april we entered into settlement agreement with the department of justice doj and the oig of the hhs to settle certain allegation related to our support of independent charitable organization that provide patient with financial assistance to access their medicine additionally we entered into corporate integrity agreement that requires to maintain corporate compliance program and to undertake set of defined corporate integrity obligation for period of five year due to the breadth of the statutory provision and the absence of guidance in the form of regulation or court decision addressing some of our practice it is possible that in the future our practice might be further challenged under antikickback or similar law the foreign corrupt practice act fcpa prohibits corporation and their representative from offering promising authorizing or making payment to any foreign government official government staff member political party or political candidate in an attempt to obtain or retain business abroad the scope of the fcpa arguably includes interaction with certain healthcare professional in many country other country have enacted similar anticorruption law and or regulation failure by our employee agent contractor vendor licensee partner or collaborator to comply with the fcpa and other anticorruption law and or regulation could result in significant civil or criminal penalty we are subject to various law and regulation globally regarding privacy and data protection these law and regulation involve the collection storage handling use disclosure transfer and security of personal data the legislative and regulatory environment regarding privacy and data protection are continually evolving and developing these issue are the subject of increasing amount of attention in country globally for example we are subject to the eu general data protection regulation gdpr which became effective on may and the california consumer privacy act of which became effective on january other jurisdiction where we operate have enacted or proposed similar legislation and or regulation failure to comply with these law could result in significant penalty business ha been and will continue to be subject to various other and foreign law rule and regulation see reimbursement section above research and development and selected product candidateswe focus our on novel human therapeutic for the treatment of serious illness we capitalize on our strength in human genetics novel biology and protein engineering we leverage our biologic expertise and take modality independent approach to and we use cutting edge science and technology to study subtle biological mechanism in search of therapy that will improve the life of those who suffer from disease our discovery research program may therefore yield target that lead to the development of human therapeutic delivered large molecule small molecule other combination modality or new modality we have reshaped our portfolio and have increasingly focused our effort on human genetics when possible to enhance the likelihood of success in response to the covid pandemic we managed our clinical development on case by case basis patient who were already enrolled in study continued to receive study drug including through direct to patient shipment for study that had the potential for significant benefit in serious or life threatening condition and when site resource enabled new patient to be enrolled safely and monitored closely we continued enrollment for clinical trial experiencing uncertainty with regard to the trial site ability to ensure subject safety or data integrity at that time we temporarily paused enrollment we remain focused on supporting our active clinical site in providing care for these patient and providing investigational drug supply to date the majority of clinical trial that were paused at the onset of the pandemic to ensure subject safety or data integrity have resumed study enrollment were affected the most in the second quarter of and by the end of the year resumed to prepandemic level although covid infection rate and related vaccination activity may impact future patient enrollment we continuously monitor and reevaluate the status of study pausing when uncertainty arises with regard to the trial site ability to ensure safety or data integrity we remain focused on supporting our active clinical site in providing care for these patient and in providing investigational drug supply in addition our organization is supporting effort to combat the covid pandemic in number of way including by working to support production of therapeutic antibody that could diminish the impact of covid on patient ii joining public private partnership between leading company in our industry and government health agency to develop strategy for coordinated research response and iii participating in platform study to investigate treatment in adult patient hospitalized with severe covid infection for the year ended december and our expense were billion billion and billion respectively we have major center in thousand oak and san francisco california iceland and the united kingdom well smaller research center and development facility globally see item property our clinical trial activity are conducted by both our internal staff and third party contract clinical trial service provider to increase the number of patient available for enrollment in our clinical trial we have opened clinical site and will continue opening clinical site and enrolling patient in number of geographic location see government regulation regulation in the united state clinical development and product approval for discussion of government regulation over clinical development also see item risk factor we must conduct clinical trial in human before we commercialize and sell any of our product candidate or existing product for new indication some of our competitor are actively engaged in in area in which we have product or in which we are developing product candidate or new indication for existing product for example we compete with other clinical trial for eligible patient which may limit the number of available patient who meet the criterion for certain clinical trial the competitive marketplace for our product candidate is greatly dependent on the timing of entry into the market early entry may have important advantage in gaining product acceptance thereby contributing to product eventual success and profitability accordingly we expect that in some case the relative speed with which we can develop product complete clinical testing receive regulatory approval and supply commercial quantity of product to the market will be important to our competitive position in addition to product candidate and marketed product generated from our internal effort we acquire company acquire and license certain product and technology right and establish arrangement with third party to enhance our strategic position within our industry by strengthening and diversifying our capability product pipeline and marketed product base in pursuing these arrangement and licensing or acquisition activity we face competition from other pharmaceutical and biotechnology company that also seek to license or acquire technology product candidate or marketed product from those entity performing the following table show selection of certain of our product candidate by phase of development in our therapeutic area of focus of february unless otherwise indicated additional product candidate information can be found on our website at www amgen com the website address is not intended to function hyperlink and the information contained on our website is not intended to be part of this filing the information in this section doe not include other nonregistrational clinical trial that we may conduct for purpose other than for submission to regulatory agency for their approval of new product indication we may conduct nonregistrational clinical trial for various reason including to evaluate real world outcome or to collect additional safety information with regard to the use of our product conditionphase programsevenity male osteoporosiskyprolis weekly dosing for relapsed multiple myelomanplate chemotherapy induced thrombocytopeniaotezla covid psoriasismild to moderate psoriasisrepatha cardiovascular diseaseriabnitmrheumatoid arthritissotorasibnsclc with kras mutationstezepelumabsevere asthmaabp psoriatic arthritis and crohn diseaseabp wet age related macular degeneration macular edema following retinal vein occlusion diabetic macular edema and diabetic retinopathyabp nocturnal hemoglobinuria pnh phase programsolpasiran formerly amg cardiovascular diseaserozibafusp alfa formerly amg systemic lupus erythematosussotorasibadvanced colorectal cancerother solid tumor with kras mutationstezepelumabchronic obstructive pulmonary diseaseamg prv diseasephase programsefavaleukin alfa formerly amg inflammatory diseasesamg cell lung canceramg canceramg malignanciesamg gastric and gastroesophageal junction canceramg tumorsamg myeloid leukemiaamg malignanciesamg tumorsamg myeloid leukemiaamg tumorsamg canceramg cardiovascular diseaseamg tumorsamg myeloid leukemiaamg myelomaamg cell lung canceramg and gastroesophageal junction cancer in november we provided notice to cytokinetics of termination of our collaboration effective may and of our intention to transition to them the development and commercialization right for omecamtiv mecarbil and amg phase trial investigate the short and long term safety and efficacy of our product candidate compared to commonly used treatment in large number of patient who have the disease or condition under study phase trial investigate side effect profile and efficacy of product candidate in larger patient population than phase but still relatively small who have the disease or condition under study phase trial investigate the safety and proper dose range of product candidate in small number of human subject product candidate program changesas of february we had phase program of february we had phase program regulatory approval were received for three program two program initiated phase study two program initiated biosimilarity study one concluded and one termination and transition of program to cytokinetics these change are set forth in the following table moleculedisease conditionprogram changekyprolis multiple myelomaapproved by the fdaotezla behçet diseaseapproved by the fdacovid phase studyriabnitmnon hodgkin lymphomaapproved by the fdasotorasibnsclcinitiated phase studyabp psoriatic arthritis and crohn diseaseinitiated biosimilarity studyabp wet age related macular degeneration macular edema following retinal vein occlusion diabetic macular edema and diabetic retinopathyinitiated biosimilarity studyimlygic metastatic melanomaconcludedomecamtiv mecarbilchronic heart failureconcluded no longer pursuing our marketing application with the fda and ec in november we provided notice to cytokinetics of termination of our collaboration effective may and of our intention to transition to them the development and commercialization right for omecamtiv mecarbil and amg based on our approval pathway that did not require phase study in january nplate wa approved by the fda for treatment of hematopoietic syndrome of acute radiation syndrome phase product candidate patent informationthe following table describes our composition of matter patent that have been issued thus far for our product candidate in phase development that have yet to be approved for any indication in the united state or the eu patent for product already approved for one or more indication in the united state or the eu but that are currently undergoing phase clinical trial for additional indication have been previously described see marketing distribution and selected marketed product patent moleculeterritorygeneral subject matterestimated expiration sotorasibu patent expiration estimate are based on issued patent which may be challenged invalidated or circumvented by competitor the patent expiration estimate do not include any term adjustment extension or supplemental protection certificate that may be obtained in the future and thereby extend these date corresponding patent application are pending in other jurisdiction additional patent may be filed or issued and may provide additional exclusivity for the product candidate or it use phase and program descriptionsthe following provides additional information about selected product candidate that have advanced into human clinical trial evenity evenity is humanized monoclonal antibody that inhibits the action of sclerostin it is being evaluated treatment for male osteoporosis evenity is being developed in collaboration with ucb imlygic is an oncolytic immunotherapy derived from herpes simplex virus type hsv phase study evaluating imlygic in combination with pembrolizumab keytruda versus pembrolizumab alone for treatment of unresectable stage iiib to melanoma wa stopped for futility after an interim analysis by the data monitoring committee no new safety signal were observed kyprolis kyprolis is small molecule proteasome inhibitor it is being investigated for weekly dosing in combination with lenalidomide and dexamethasone for relapsed multiple myeloma in august the fda approved the expansion of the kyprolis prescribing information to include it use in combination with darzalex plus dexamethasone in two dosing regimen once weekly and twice weekly for the treatment of patient with relapsed or refractory multiple myeloma who have received one to three previous line of therapy nplate nplate is thrombopoietin receptor agonist it is being investigated in phase study for chemotherapy induced thrombocytopenia in december the european commission approved an expanded indication for use in adult patient who have had immune thrombocytopenia for month or le and who have had an insufficient response to corticosteroid or immunoglobulin noted above the fda ha approved nplate for the treatment of hematopoietic syndrome of acute radiation syndrome is small interfering rna sirna that lower lipoprotein also known lp it is being investigated in phase for the treatment of atherosclerotic cv disease otezla otezla is small molecule that inhibits it is being investigated in phase study for the treatment of patient with mild to moderate plaque psoriasis patient with moderate to severe genital psoriasis and in collaboration with some of the member of the covid alliance adult patient hospitalized with covid in may we announced positive result from the advance trial phase multicenter randomized placebo controlled double blind study to ass the efficacy of otezla in adult with mild to moderate plaque psoriasis the study showed that oral otezla mg twice daily achieved statistically significant improvement compared with placebo in the primary endpoint of the spga response at week in addition the week secondary endpoint of achieving at least improvement from baseline in the percent of affected body surface area bsa change in bsa total score from baseline and change in psoriasis area and severity index pasi total score from baseline were each also statistically significant for the treatment effect of otezla compared with placebo repatha repatha is human monoclonal antibody that inhibits it is being investigated treatment for atherosclerotic cv disease in high risk patient with high low density lipoprotein cholesterol ldl without prior heart attack or stroke in march we announced positive result from the beijerinck study evaluating the efficacy and safety of repatha in patient who are human immunodeficiency virus positive hiv and have high ldl despite stable background lipid lowering therapy the study demonstrated that treatment with repatha significantly reduced ldl riabnitmriabnitm biosimilar candidate to rituxan mabthera rituximab is an anti monoclonal antibody it is being investigated in phase study for treatment of rheumatoid arthritis the reference product primary condition are non hodgkin lymphoma chronic lymphocytic leukemia and rheumatoid arthritis funding and execution of the pivotal study wa provided by the national institute of allergy and infectious disease niaid and the priority review regulatory submission wa conducted in partnership with the biomedical advanced research and development authority barda december we announced that the fda had approved riabnitm for the treatment of adult patient with non hodgkin lymphoma chronic lymphocytic leukemia granulomatosis with polyangiitis wegener granulomatosis and microscopic polyangiitis riabnitm launched in the united state in january rozibafusp alfa rozibafusp alfa is novel bispecific antibody peptide conjugate that simultaneously block the lymphocyte stimulator baff and inducible costimulatory ligand icosl activity it is being investigated treatment for systemic lupus erythematosus sotorasibsotorasib is kras small molecule inhibitor it is being investigated treatment for variety of solid tumor including nsclc colorectal cancer and other solid tumor cancer in december we announced that the fda had granted breakthrough therapy designation for sotorasib for the treatment of patient with locally advanced or metastatic nsclc with kras mutation determined by an fda approved test following at least one prior systemic therapy the sotorasib application is being reviewed under the fda rtor pilot program which aim to explore more efficient review process that ensures safe and effective treatment are made available to patient early possible in january we announced phase result from the codebreak clinical study evaluating sotorasib in patient with kras mutant advanced nsclc who had failed median of two prior line of anticancer therapy immunotherapy and or chemotherapy sotorasib demonstrated confirmed orr primary end point and disease control rate of and respectively median duration of response of month and median progression free survival of month patient were treated with sotorasib mg once daily orally tezepelumab tezepelumab is human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin it is being evaluated in phase treatment for severe asthma it is also being investigated in phase for chronic obstructive pulmonary disease tezepelumab is being developed jointly in collaboration with astrazeneca in november we announced positive result from the registrational phase navigator trial in which the investigational medicine tezepelumab demonstrated statistically significant reduction in exacerbation compared to placebo in patient with severe asthma the navigator trial met the primary endpoint with tezepelumab added to soc demonstrating statistically significant and clinically meaningful reduction compared to placebo plus soc in the aaer over week in the overall patient population soc consisted of medium or high dose ic plus at least one additional controller medication with or without ocs in december we announced that the source trial had not met the primary endpoint of statistically significant reduction in the daily ocs dose without loss of asthma control with tezepelumab compared to placebo the result of this trial have no impact on our submission plan amg prv prv is human monoclonal antibody that bind to interleukin it is being investigated for the treatment of celiac disease and is being developed in collaboration with provention bio abp biosimilar candidate to stelara ustekinumab is monoclonal antibody that inhibits interleukin and interleukin it is being investigated in phase study for biosimilarity to stelara the reference product primary condition are psoriasis psoriatic arthritis and crohn disease abp biosimilar candidate to eylea aflibercept is vascular endothelial growth factor receptor vegfr fc fusion protein it is being investigated in phase study for neovascular wet age related macular degeneration amd the reference product primary condition are wet amd macular edema following retinal vein occlusion diabetic macular edema and diabetic retinopathy biosimilar candidate to soliris eculizumab is monoclonal antibody that specifically bind to the complement protein it is being investigated in phase study for pnh the reference product primary condition are pnh and atypical hemolytic uremic syndrome ahus business relationshipsfrom time to time we enter into business relationship including joint venture and collaborative arrangement for the manufacture and or commercialization of product and or product candidate in addition we acquire product and technology right and establish collaboration with third party to enhance our strategic position within our industry by strengthening and diversifying our capability product pipeline and marketed product base these arrangement generally provide for nonrefundable upfront license fee development and commercial performance milestone payment cost sharing royalty payment and or profit sharing the activity under these collaboration agreement are performed with no guarantee of either technological or commercial success and each is unique in nature trade secret protection for our unpatented confidential and proprietary information is important to to protect our trade secret we generally require counterparties to execute confidentiality agreement upon commencement of business relationship with however others could either develop independently the same or similar information or unlawfully obtain access to our information beigene ltd on january we acquired stake in beigene ltd beigene for approximately billion in cash part of collaboration to expand our oncology presence in china under the collaboration beigene commenced selling xgeva and will commercialize kyprolis and blincyto in china and amgen will share profit and loss equally during the initial product specific commercialization period thereafter product right may revert to amgen and amgen will pay royalty to beigene on sale in china of such product for specified period in addition we will jointly develop portion of our oncology portfolio with beigene sharing in global cost by providing cash and development service to billion upon regulatory approval beigene will assume commercialization right in china for specified period and amgen and beigene will share profit equally until certain of these product right revert to amgen upon return of the product right amgen will pay royalty to beigene on sale in china for specified period for product sale outside of china amgen will also pay beigene royalty novartiswe are in collaboration with novartis to jointly develop and commercialize aimovig in the united state amgen and novartis jointly develop and collaborate on the commercialization of aimovig amgen the principal recognizes product sale of aimovig in the united state share commercialization cost with novartis and pay novartis significant royalty on net sale in the united state novartis hold global co development right and exclusive commercial right outside the united state and japan for aimovig novartis pay amgen double digit royalty on net sale of the product in the novartis exclusive territory and fund portion of global expense in addition novartis will make payment to amgen of up to million if certain commercial and expenditure threshold are achieved with respect to aimovig in the united state amgen manufacture and supply aimovig worldwide we are currently involved in litigation with novartis over our collaboration agreement for the development and commercialization of aimovig see part iv note contingency and commitment to the consolidated financial statement bayer healthcare llcwe are in licensing arrangement with bayer healthcare llc bayer for nexavar in february we amended the term of our agreement with bayer which transferred all of our operational responsibility outside the united state to bayer including commercial and medical affair activity prior to the amendment of the agreement we shared equally in the profit outside the united state excluding japan in lieu of this profit share bayer now pay royalty on sale of nexavar at percentage rate in the low the right to develop and market nexavar in japan are reserved to bayer in the united state bayer pay royalty on sale of nexavar at percentage rate in the high inc in january we entered into six year supply agreement with davita inc davita which superseded the previously existing seven year supply agreement that commenced in pursuant to the agreement we supply epogen and aranesp in amount necessary to meet specified annual percentage of davita and it affiliate requirement for erythropoiesis stimulating agent esas used in providing dialysis service in the united state and puerto rico such percentage vary during the term of the agreement but in each year are at least the agreement expires in the agreement may be terminated by either party before expiration of it term in the event of certain breach of the agreement by the other party for financial information concerning our significant collaborative arrangement see part iv note collaboration to the consolidated financial statement human capital resourcesamgen approach to human capital resource management start with our mission to serve patient our industry exists in complex regulatory and reimbursement environment the unique demand of our industry together with the challenge of running an enterprise focused on the discovery development manufacture and commercialization of innovative medicine require talent that is highly educated and or ha significant industry experience additionally for certain key function we require specific scientific expertise to oversee and conduct activity and the complex manufacturing requirement for biopharmaceutical product of december amgen had approximately staff member and we have had relatively low global turnover rate we consider our staff relation to be good supported by our regular staff engagement assessment with survey on wide range of topic including engagement in the covid environment diversity inclusion and belonging and ethic we discus the result of these survey with our board of director compensation benefit and developmentour approach to employee compensation and benefit is designed to deliver cash equity and benefit program that are competitive with those offered by leading company in the biotechnology and pharmaceutical industry to attract motivate and retain talent with focus on encouraging performance promoting accountability and adherence to company value and alignment with the interest of the company shareholder our base pay program aim to compensate staff member relative to the value of the contribution of their role which take into account the skill knowledge and ability required to perform each position well the experience brought to the job we also provide annual incentive program to reward our staff in alignment with achievement of company wide goal that are established annually and designed to drive aspect of our strategic priority that support and advance our strategy across our company the majority of our staff member are also eligible for the grant of equity award under our long term incentive program that are designed to align the experience of these staff with that of our shareholder all staff also participate in regular performance measurement process that aligns pay to performance and through which staff receive performance and development feedback to support the development of our staff we provide variety of program including leadership development program virtual instructor led course and self paced learning option our benefit program are also generally broad based promote health and overall well being and emphasize saving for retirement all regular staff member are eligible to participate in the same core health and welfare and retirement saving plan other employee benefit include medical plan dental plan access to childcare employee assistance program employee stock purchase plan flexible spending account life long term care and business travel accident insurance short and long term disability benefit wellness benefit and work life resource and referral comparable program and benefit are available globally with the same health and well being intent consistent with statutory requirement our compensation and management development committee provides oversight of our compensation plan policy and program and wellness and our response to covid safe and healthy workplace for our staff is priority at amgen our goal is to have world class safety record through safety leadership risk management practice and integrating safety throughout our business process to foster our safety culture we implement comprehensive safety program driving to understand and mitigate the root cause of safety incident and manage and control variability we use leading indicator to ass the effectiveness of our safety program and make course correction needed additionally we perform formal executive management review of functional safety performance for operation global commercial operation and on quarterly basis with focus on identifying early signal and taking action to drive continuous improvement based on our performance compared to benchmark of twelve company in the pharmaceutical industry amgen wa in the quartile with the lowest injury rate in response to the covid pandemic and part of our commitment to work to ensure the safety and well being of our employee we have activated our applicable business continuity plan including having those of our employee who are able to work from home to do so since mid march for employee returning to the workplace and the field we have also taken additional safety measure including implementing occupancy limit restricting business travel providing and requiring the use of personal protective equipment temperature screening and covid testing to access our workplace our corporate responsibility and compliance committee provides general oversight of our safety program and initiative while our board of director whole ha overseen our specific response to the covid pandemic diversity inclusion and belongingwe believe that diverse and inclusive culture foster innovation which support our ability to serve patient further we also believe our global presence is strengthened by having workforce that reflects the diversity of the patient we serve it is with these belief in mind that we have continued to strengthen and grow our culture of diversity inclusion and belonging our internal effort include in establishing diversity inclusion and belonging council chaired by our chief executive officer in we implemented global unconscious bias training program and launched portal devoted to diversity inclusion and belonging that includes learning and resource further we are leveraging our employee resource group listed below to represent and support the diversity of amgen staff employee resource groupsamgen asian association aaa amgen black employee network aben ability bettered through leadership and education able resource group for the physically or cognitively disabledamgen early career professional aecp amgen indian subcontinent network aisn amgen latin employee network alen amgen lgbtq and ally network pride amgen veteran employee network aven woman empowered to be exceptional woman in information system enrichment wise in area of underrepresentation we develop plan with goal of bringing our representation in line with availability and we also engage in outreach effort to attract retain and advance more woman and minority in our workforce for example we have worked to enhance our diverse candidate recruiting pool by developing relationship with organization that can serve source of diverse candidate such the national black mba association and national sale network well historically black college and university additionally at the end of we became founding member of oneten coalition of of the world largest best known company that aim to hire one million black american with specific focus on those without four year college degree into good paying family sustaining job over the next ten year other example of action that we are taking in this area include investment and participation in healthcare businesswoman association global organization focused on development and business networking for woman in healthcare and the university of california los angeles ucla anderson school of management woman leadership program an effort to provide additional transparency into the makeup of our workforce we intend to disclose our consolidated eeo report after our submission of the report to the equal employment opportunity commission our corporate responsibility and compliance committee provides oversight of our policy program and initiative focusing on workforce diversity and inclusion information about our executive officersthe executive officer of the company of february are set forth below mr robert bradway age ha served director of the company since and chairman of the board of director since mr bradway ha been the company president since and chief executive officer since from to mr bradway served the company president and chief operating officer mr bradway joined the company in vice president operation strategy and served executive vice president and chief financial officer from to prior to joining the company mr bradway wa managing director at morgan stanley in london where beginning in had responsibility for the firm banking department and corporate finance activity in europe mr bradway ha been director of the boeing company an aerospace company and manufacturer of commercial airplane defense space and security system since he ha served on the board of trustee of the university of southern california since from to mr bradway wa director of norfolk southern corporation transportation company mr murdo gordon age became executive vice president global commercial operation in prior to joining the company mr gordon wa chief commercial officer at bm from to mr gordon served head of worldwide market at bm from to prior to this mr gordon served in variety of leadership role at bm for more than year mr jonathan graham age became executive vice president general counsel and secretary in mr graham joined the company in from to mr graham wa senior vice president general counsel and secretary prior to joining amgen from to mr graham wa senior vice president and general counsel at danaher corporation from to mr graham wa vice president litigation and legal policy at general electric company ge prior to ge mr graham wa partner at williams connolly llp mr peter griffith age became executive vice president and chief financial officer in mr griffith joined the company in executive vice president finance prior to joining amgen mr griffith wa president of sherwood canyon group llc from to mr griffith wa partner at ey and served in variety of senior leadership role with last position being global vice chair corporate development prior to ey mr griffith wa managing director and head of the investment banking division of wedbush security inc nancy grygiel age became senior vice president and chief compliance officer in grygiel joined the company in from to grygiel wa vice president compliance prior to joining amgen from to grygiel served vice president compliance corporate international at allergan inc allergan prior to allergan grygiel held several management position at mylan pharmaceutical inc lori johnston age became executive vice president human resource in from to johnston served the company senior vice president human resource from to johnston wa executive vice president and chief administrative officer of celanese corporation celanese prior to celanese johnston served in series of progressive leadership role at amgen from to with last position being vice president human resource prior to joining the company johnston held human resource and other position at dell inc mr david piacquad age became senior vice president business development in mr piacquad joined the company in and served vice president strategy and corporate development until his appointment to the role of vice president business development in prior to joining the company from to mr piacquad wa principal of david piacquad consulting llc from to mr piacquad served senior vice president business development and licensing at schering plough corporation schering plough prior to schering plough mr piacquad served in series of leadership role in finance and business development at with his last position being vice president venture and business development david reese age became executive vice president in dr reese joined the company in and ha held leadership role in development medical science and discovery research dr reese wa senior vice president translational science and oncology from to and senior vice president translational science from to prior to joining amgen dr reese wa director of clinical research at the breast cancer international research group from to and cofounder president and chief medical officer of translational oncology research international not for profit academic clinical research organization from to dr reese previously served on the faculty at ucla and the university of california san francisco mr esteban santos age became executive vice president operation in mr santos joined the company in executive director manufacturing technology from to mr santos held number of vice president role at the company in engineering manufacturing site operation and drug product from to mr santos wa senior vice president manufacturing prior to joining the company mr santos served site general manager of cordis operation in puerto rico prior to mr santos held several management position in ge industrial and transportation business geographic area financial informationfor financial information concerning the geographic area in which we operate see part iv note revenue and note property plant and equipment to the consolidated financial statement investor informationfinancial and other information about is available on our website at www amgen com we make available on our website free of charge copy of our annual report on form quarterly report on form current report on form and amendment to those report filed or furnished pursuant to section or of the exchange act soon reasonably practicable after we electronically file such material with or furnish it to the security and exchange commission sec in addition we have previously filed registration statement and other document with the sec any document we file may be inspected without charge at the sec website at www sec gov these website address are not intended to function hyperlink and the information contained in our website and in the sec website is not intended to be part of this filing item risk factorsthis report and other document we file with the sec contain forward looking statement that are based on current expectation estimate forecast and projection about our future performance our business our belief and our management assumption these statement are not guarantee of future performance and involve certain risk uncertainty and assumption that are difficult to predict should carefully consider the risk and uncertainty our business face the risk described below are not the only one we face our business is also subject to the risk that affect many other company such employment relation general economic condition geopolitical event and international operation further additional risk not currently known to or that we currently believe are immaterial may in the future materially and adversely affect our business operation liquidity and stock price summaryrisks related to economic condition and operating global business including during the covid pandemic the covid pandemic and the public and governmental effort to mitigate against the spread of the disease have had and are expected to continue to have an adverse effect and may have material adverse effect on our clinical trial operation supply chain distribution system product development product sale business and result of operation breakdown cyberattack or information security breach could compromise the confidentiality integrity and availability of our information technology system network connected control system and or our data interrupt the operation of our business and or affect our reputation our sale and operation are subject to the risk of business internationally including in emerging market related to government regulation and third party policy our sale depend on coverage and reimbursement from government and commercial third party payer and pricing and reimbursement pressure have affected and are likely to continue to affect our profitability guideline and recommendation published by various organization can reduce the use of our product the adoption and interpretation of new tax legislation or exposure to additional tax liability could affect our profitability our business may be affected by litigation and government investigation risk related to competition our product face substantial competition and our product candidate are also likely to face substantial competition our intellectual property position may be challenged invalidated or circumvented or we may fail to prevail in current and future intellectual property litigation we currently face competition from biosimilars and generic and expect to face increasing competition from biosimilars and generic in the future concentration of sale at certain of our wholesaler distributor and at one free standing dialysis clinic business and consolidation of private payer may negatively affect our business risk related to research and development we may not be able to develop commercial product despite significant investment in we must conduct clinical trial in human before we commercialize and sell any of our product candidate or existing product for new indication our current product and product in development can not be sold without regulatory approval some of our product are used with drug delivery or companion diagnostic device that have their own regulatory manufacturing and other risk some of our pharmaceutical pipeline and our commercial product sale rely on collaboration with third party which may adversely affect the development and sale of our product our effort to collaborate with or acquire other company product or technology and to integrate the operation of company or to support the product or technology we have acquired may not be successful and may result in unanticipated cost delay or failure to realize the benefit of the transaction risk related to operation we perform substantial majority of our commercial manufacturing activity at our facility in the territory of puerto rico and substantial majority of our clinical manufacturing activity at our facility in thousand oak california significant disruption or production failure at these facility could significantly impair our ability to supply our product or continue our clinical trial we rely on third party supplier for certain of our raw material medical device and component manufacturing difficulty disruption or delay could limit supply of our product and limit our product sale general risk factor global economic condition may negatively affect and may magnify certain risk that affect our business our stock price is volatile we may not be able to access the capital and credit market on term that are favorable to or at all related to economic condition and operating global business including during the covid pandemicthe covid pandemic and the public and governmental effort to mitigate against the spread of the disease have had and are expected to continue to have an adverse effect and may have material adverse effect on our clinical trial operation supply chain distribution system product development product sale business and result of operation the novel coronavirus identified in late sars cov which cause the disease known covid is an ongoing global pandemic that ha resulted in public and governmental effort to contain or slow the spread of the disease including widespread shelter in place order social distancing intervention quarantine travel restriction and various form of operational shutdown the covid pandemic and the resulting measure implemented in response to the pandemic are adversely affecting and is expected to continue to adversely affect our business including our clinical trial operation supply chain distribution system product development and sale activity the business activity of our supplier customer third party payer and our patient see our current product and product in development can not be sold without regulatory approval and see also we must conduct clinical trial in human before we commercialize and sell any of our product candidate or existing product for new indication due to the pandemic and these measure and their effect we have experienced and expect to continue to experience unpredictable reduction in demand for certain of our product and in some case have experienced and could continue to experience unpredictable increase in demand for certain of our product our clinical trial have been and are expected to continue to be adversely affected by the covid pandemic we have clinical work ongoing at investigational site across the globe number of clinical trial site including those in region experiencing new or resurgent outbreak of covid have restricted site visit and imposed restriction on the initiation of new clinical trial and or patient visit to protect both site staff and patient from possible covid exposure that ha stopped or slowed clinical trial activity in response to the safety concern related to covid we have suspended and will continue to suspend enrollment and screening in clinical trial where site are unable to perform clinical trial work due to covid or there is uncertainty around the ability of site to ensure subject safety or data integrity further the covid pandemic ha adversely affected and may continue to adversely affect our ability to enroll or to continue to enroll certain required post marketing study including pediatric study while many of our clinical trial activity have recommenced over the course of the initial disruption caused by the covid pandemic to our clinical trial and our clinical trial plan and timeline and any similar future disruption including result of the current surge and lockdown in numerous region may have significant adverse effect on our product development and launch and in turn on future product sale business and result of operation for example to ensure patient safety we initially paused enrollment of our sotorasib phase combination cohort with keytruda and phase lung cancer study and such interruption in enrollment may ultimately affect the timeline of these or other study additionally while we are investing in research collaboration and operational support to potentially develop and or produce treatment for covid such activity may not result in therapeutic candidate product approval successful production and or significant commercial value being derived from potential covid related medicine result of the covid pandemic we have experienced and expect to continue to experience regulatory delay including delay in receiving regulatory advice review of application or performance of inspection required for approval the pandemic may also result in greater regulatory uncertainty for example the fda and the ema have issued guidance to provide biopharmaceutical manufacturer greater flexibility in certain regulatory area including protocol deviation and adverse event reporting however such flexibility may result in greater uncertainty regarding the expectation of such health authority in relation to this guidance additionally there may be delay in ongoing or new patent office or patent proceeding in the united state or internationally that may delay the outcome of such proceeding such delay and disruption could have significant adverse effect on our product development and launch product sale business and result of operation response to covid we have activated our applicable business continuity plan including suspending in person meeting and interaction with the healthcare community and professional in substantial number of state suspending general matter all international business travel and the majority of domestic travel within the united state and employee who are able to work from home have been doing so since mid march our ability to perform critical function and maintain operation have been adversely affected and could continue to be adversely affected result of such workforce restriction and the covid related support program we have put into place for our staff supplier and customer have increased and are expected to continue to increase our operating expense and reduce the efficiency of our operation notwithstanding such support program the covid pandemic effect on the health and availability of our workforce well those of the third party on which we rely could have an adverse effect on our business if member of our management and other key personnel in critical function across our organization are unable to perform their duty or have limited availability due to covid we may not be able to execute on our business strategy and our operation may be adversely affected additionally disruption in public and private infrastructure including transportation and supply chain have adversely affected and continue to adversely affect the efficiency of our business operation also the transition of the majority of our workforce to remote work environment in response to covid well that of our third party service provider have exacerbated certain risk to our business including but not limited to those associated with an increased demand for information technology resource increased risk of cybersecurity attack including social engineering attack and increased risk of unauthorized dissemination of sensitive personal information or our proprietary or confidential information the pandemic continues to progress we have observed an increase in cybersecurity incident predominantly ransomware and social engineering attack experienced by our third party service provider further government entity have also been the subject of cyberattacks the ema disclosed in december that it had been the subject of cyberattack that targeted and accessed third party document relating to regulatory submission and that such document were published on the internet some of which were manipulated prior to publication such third party and governmental incident have created the risk of the loss of availability and or control of information including information related to our clinical trial important to the operation of our business see breakdown cyberattack or information security breach could compromise the confidentiality integrity and availability of our information technology system network connected control system and or our data interrupt the operation of our business and or affect our reputation in the future the pandemic progress and afterwards we may experience significant adverse effect on our commercial and clinical manufacturing activity our operation and our cybersecurity and our supplier and vendor may also experience significant disruption to their activity and operation on which we depend result of these cybersecurity incident federal state and local and international governmental policy and initiative designed to reduce the transmission of covid also have resulted in the cancellation or delay of diagnostic elective specialty and other procedure and appointment to avoid non essential patient exposure to medical environment and potential infection with covid and to focus limited resource and personnel capacity toward the treatment of covid these measure and challenge will likely continue to varying degree for the duration of the pandemic and have significantly reduced patient access to and administration of certain of our drug for example prolia is product requiring administration by healthcare provider in doctor office or other healthcare setting that are affected by covid the label for prolia instructs healthcare professional who discontinue prolia to transition the patient to an alternative antiresorptive including oral treatment that do not require administration by healthcare provider further result of covid oncology patient in consultation with their doctor may be selecting le immunosuppressive therapy or therapy that do not require administration in hospital setting potentially adversely affecting certain of our product also new patient are le likely to be diagnosed and or to start therapeutic during the pandemic once the pandemic subsides we anticipate there will be substantial backlog of patient seeking appointment with physician relating to variety of medical condition and result patient seeking treatment with certain of our product may have to navigate limited provider capacity and this limited provider capacity could have continued adverse effect on our sale following the opening up of various geography and or the end of the pandemic further the effect of the covid pandemic may result in long term shift in preference among healthcare professional and patient toward treatment that do not require administration by healthcare professional or visit to medical facility legislative and regulatory environment governing our business is dynamic and changing frequently in response to covid for example the covid pandemic ha resulted in increased interest in compulsory license march in right or other governmental intervention both in the united state and internationally related to the procurement of drug such the who covid technology access pool initiative which provides an approach for sharing all intellectual property information and clinical trial data necessary to enable generic drug manufacturing see our intellectual property position may be challenged invalidated or circumvented or we may fail to prevail in current and future intellectual property litigation further the challenge of the pandemic have resulted in the exploration of signification legislation to address the need to supply medicine to address covid pursuant to the declaration of national emergency in the united state in march under the stafford act state and local government may request access to discounted pricing for certain item related to the covid response the coronavirus aid relief and economic security care act implement initiative to provide advanced payment from medicare to healthcare provider clinic and physician and to require medicare plan to provide up to day supply of part drug however despite such initiative and government support there may be adverse effect on the timing and collectability of our customer receivables result of the covid pandemic see concentration of sale at certain of our wholesaler distributor and at one free standing dialysis clinic business and consolidation of private payer may negatively affect our business the covid pandemic ha also resulted in significant increase in unemployment and underemployment which may continue after the pandemic such significant increase in unemployment or other disruption in the labor market have led to substantial reduction in disposable income and in the access to healthcare insurance including reduction in the commercially insured population that ha led to growth and is expected to continue to lead to growth in medicaid enrollment which ha adversely affected our product sale see global economic condition may negatively affect and may magnify certain risk that affect our business such reduction in healthcare insurance could be compounded by any full or partial repeal of the aca by the supreme court further globally the substantial pressure placed on governmental and payor budget result of the covid pandemic and the projected governmental budget shortfall caused by significantly reduced economic activity during and potentially after the covid pandemic together with the long term impact from the pressure on healthcare system may result in greater and continued downward price pressure on biopharmaceutical product and increased intensity of stakeholder negotiation across the biopharmaceutical value chain see our sale depend on coverage and reimbursement from third party payer and pricing and reimbursement pressure may affect our profitability the pandemic continues and if condition worsen or if the duration of the pandemic extends significantly we expect to experience additional adverse effect on our operational and commercial activity customer purchase and our collection of account receivable it is unclear which adverse effect may be material and it remains uncertain the degree to which these adverse effect would impact our future operational and commercial activity customer purchase and our collection even if condition begin to improve there wa resurgence in covid infection in numerous jurisdiction in the autumn of and winter of resulting in the reinstatement of stricter restriction and shutdown in number of jurisdiction it is expected that the pandemic will continue to ebb and flow with different jurisdiction having higher level of infection than others over the course of the pandemic in addition to existing travel restriction jurisdiction may continue or reinstate border closure impose or reimpose prolonged quarantine and further restrict travel and business activity which could significantly affect our ability to support our operation and customer and the ability of our employee to get to their workplace to discover study develop and produce our product candidate and product disrupt the movement of our product through the supply chain and prevent or discourage patient from seeking healthcare service and the administration of certain of our product further in connection with the global outbreak and spread of covid and in an effort to increase the wider availability of needed medical product we or our supplier may elect to or government may require or our supplier to allocate manufacturing capacity for example pursuant to the defense production act in way that adversely affect our regular operation customer relationship and financial result in the on january president biden issued an executive order instructing federal agency to use all available legal authority including the defense production act to improve current and future pandemic response and biological threat preparedness the rapid reallocation of resource for the treatment and prevention of covid including the production of covid vaccination or related therapy such our agreement to contribute to the production of one of lilly potential covid antibody therapy could also result in increased competition for or reduced availability of material used in the manufacturing or distribution of our product in addition unpredictable increase in demand for certain of our product could exceed our capacity to meet such demand which could adversely affect our financial result and customer relationship covid pandemic and the volatile global economic condition stemming from it may precipitate or amplify the other risk described in this risk factor section which could materially adversely affect our business operation and financial condition and result for example if natural disaster or other potentially disruptive event occurs concurrently with the covid pandemic such disaster or event could deplete our inventory level and we could experience disruption to our manufacturing or ability to supply our product further the global pandemic ha exacerbated geopolitical tension and some country such china may be especially vulnerable to such dynamic if relation between the united state and china or other government deteriorates our business and investment in china or other such market may also be adversely affected see our sale and operation are subject to the risk of doing business internationally including in emerging market the rapid development and fluidity of the pandemic preclude any prediction to the ultimate effect of covid on the duration of the measure being taken by the authority to mitigate against the spread of covid including the distribution of vaccine and the extent to which such measure are effective if at all remain highly uncertain the magnitude and degree of covid adverse effect on our business including our product development product sale operating result and resulting cash flow and financial condition will be driven by the severity and duration of the pandemic the pandemic effect on the united state and global economy and the timing scope and effectiveness of federal state local and international governmental response to the pandemic if the spread continues at or near it current trajectory or mitigation continues to require similar level of shelter in place and shut order any adverse effect of covid will likely grow and could be enduring and our business and financial position could be materially adversely affected breakdown cyberattack or information security breach could compromise the confidentiality integrity and availability of our information technology system network connected control system and or our data interrupt the operation of our business and or affect our reputation to achieve our business objective we rely on sophisticated information technology system including software mobile application cloud service and network connected control system some of which are managed hosted provided or serviced by third party internal or external event that compromise the confidentiality integrity and availability of our system and data may significantly interrupt the operation of our business result in significant cost and or adversely affect our reputation our information technology system are highly integrated into our business including our effort our clinical and commercial manufacturing process and our product sale and distribution process further the majority of our employee are working remotely our reliance on our and third party information technology system ha increased substantially and is expected to continue to increase the complexity and interconnected nature of our system make them potentially vulnerable to breakdown or other service interruption our system are also subject to frequent cyberattacks the cyber threat landscape evolves these attack are growing in frequency sophistication and intensity and are becoming increasingly difficult to detect such attack could include the use of harmful and virulent malware including ransomware or other denial of service that can be deployed through various mean including the software supply chain mail malicious website and or the use of social engineering attack such those experienced by governmental entity including those that approve and or regulate our product such the ema and other multi national company including some of our peer could leave unable to utilize key business system or access or protect important data and could have material adverse effect on our ability to operate our business including developing gaining regulatory approval for manufacturing selling and or distributing our product for example in pharmaceutical company experienced cyberattack involving virulent malware that significantly disrupted it operation including it research and sale operation and the production of some of it medicine and vaccine result of the cyberattack it order and sale for certain product in certain market were negatively affected in december solarwinds corporation leading provider of software for monitoring and managing information technology infrastructure disclosed that it had suffered cybersecurity incident whereby attacker had inserted malicious code into legitimate software update for it product that were installed by myriad private and government customer enabling the attacker to access backdoor to such system see the covid pandemic and the public and governmental effort to mitigate against the spread of the disease have had and are expected to continue to have an adverse effect and may have material adverse effect on our clinical trial operation supply chain distribution system product development product sale business and result of operation for discussion of the cyberattack on the ema our system also contain and utilize high volume of sensitive data including intellectual property trade secret financial information regulatory information strategic plan sale trend and forecast litigation material and or personal information belonging to our staff our patient customer and or other party in some case we utilize third party service provider to process store manage or transmit such data which may increase our risk intentional or inadvertent data privacy or security breach including cyberattacks or lapse by employee service provider including provider of information technology specific service nation state including group associated with or supported by foreign intelligence agency organized crime organization hacktivists or others create risk that our sensitive data may be exposed to unauthorized person our competitor or the public and global government regulator our business partner supplier with whom we do business company that provide or our partner with business service and company we may acquire may face similar risk and security breach of their system could adversely affect our security leave without access to important system product raw material component service or information or expose our confidential data for example in two vendor that perform testing and analytical service that we use in developing and manufacturing our product have experienced cyberattacks and in april and september of vendor that provide with information technology service and clinical data service respectively each experienced ransomware attack each of these incident required to disconnect our system from those vendor system while we were able to reconnect our system following restoration of these vendor capability without significantly affecting product availability more extended service outage affecting these or other vendor particularly where such vendor is the single source from which we obtain the service could have material adverse effect on our business or result of operation in addition we distribute our product in the united state primarily through three pharmaceutical wholesaler and security breach that impairs the distribution operation of our wholesaler could significantly impair our ability to deliver our product to healthcare provider and patient although we have experienced system breakdown attack and information security breach we do not believe such breakdown attack and breach have had material adverse effect on our business or result of operation we continue to invest in the monitoring protection and resilience of our critical and or sensitive data and system however there can be no assurance that our effort will detect prevent or fully recover system or data from all breakdown service interruption attack and or breach of our system that could adversely affect our business and operation and or result in the loss or exposure of critical proprietary private confidential or otherwise sensitive data which could result in material financial legal business or reputational harm to or negatively affect our stock price while we maintain cyber liability insurance our insurance is not sufficient to cover against all loss that could potentially result from service interruption breach of our system or loss of our critical or sensitive data we are also subject to various law and regulation globally regarding privacy and data protection including law and regulation relating to the collection storage handling use disclosure transfer and security of personal data the legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally for example we are subject to the eu gdpr which became effective in may and the california consumer privacy act of which became effective in january both of which provide for substantial penalty for non compliance other jurisdiction where we operate have enacted or proposed similar legislation and or regulation failure to comply with these current and future law could result in significant penalty and could have material adverse effect on our business and result of operation our sale and operation are subject to the risk of doing business internationally including in emerging market we continue our expansion effort in emerging market around the world through acquisition and licensing transaction well through the development and introduction both independently and through collaboration such our collaboration with beigene of our product in new market we face numerous risk to our business there is no guarantee that our effort and strategy to expand sale in emerging market will succeed our international business including in china and emerging market country may be especially vulnerable to period of global and local political legal regulatory and financial instability including issue of geopolitical relation the imposition of international sanction in response to certain state action and or sovereign debt issue we may also be required to increase our reliance on third party agent and unfamiliar operation and arrangement including those previously utilized by company we partner with or acquire in emerging market see we must conduct clinical trial in human before we commercialize and sell any of our product candidate or existing product for new indication our expansion effort in china and emerging market around the world is dependent upon the establishment of an environment that is predictable navigable and supportive of biopharmaceutical innovation sustained access for our product and limited pricing control for example china continues to strengthen regulation on the collection use and transmission of chinese human genetic resource and ha expanded regulation on the conduct of biotechnology activity in china our application to the human genetic resource administration of china hgrac seeking approval to conduct clinical trial in china are delayed pending further guidance from hgrac our international operation and business may also be subject to le protective intellectual property or other applicable law diverse data privacy and protection requirement changing tax law and tariff trade restriction or other barrier designed to protect industry in the home country against foreign competition far reaching antibribery and anticorruption law and regulation and or evolving legal and regulatory environment we expand internationally we are subject to fluctuation in foreign currency exchange rate relative to the dollar while we have program in place that is designed to reduce our exposure to foreign currency exchange rate fluctuation through foreign currency hedging arrangement our hedging effort do not completely offset the effect of these fluctuation on our revenue and earnings in addition we have number of financial instrument referencing the london interbank offered rate libor on july the financial conduct authority which regulates libor announced that it will no longer require bank to submit rate for the calculation of libor to the libor administrator after and it is anticipated that libor will be phased out and replaced by in march the financial accounting standard board issued new accounting standard to ease the financial burden of the expected market transition from libor and other interbank offered rate to alternative reference rate while various replacement reference rate have been proposed an alternative reference rate to libor ha not yet been widely adopted and the specific mechanism to replace libor in our existing libor linked financial instrument have not been finalized such the replacement of libor could have an adverse effect on the market for or value of our libor linked financial instrument see part iv note summary of significant accounting policy recent accounting pronouncement we are also subject to the economic and political uncertainty stemming from the united kingdom exit from the eu commonly referred to brexit which occurred on january while our manufacturing and packaging activity take place largely outside the united kingdom minimizing the need to make costly and significant change to those operation we have nevertheless been working to put in place contingency plan to attempt to mitigate the effect of brexit on overall the legal and operational challenge of our international business operation along with government control the challenge of attracting and retaining qualified personnel and obtaining and or maintaining necessary regulatory or pricing approval of our product may result in material adverse effect on our international product sale business and result of operation risk related to government regulation and third party policiesour sale depend on coverage and reimbursement from government and commercial third party payer and pricing and reimbursement pressure have affected and are likely to continue to affect our profitability sale of our product depend on the availability and extent of coverage and reimbursement from third party payer including government healthcare program and private insurance plan government and private payer continue to pursue initiative to manage drug utilization and contain cost these payer are increasingly focused on the effectiveness benefit and cost of similar treatment which could result in lower reimbursement rate for our product or narrower population for whom payer will reimburse continued intense public scrutiny of the price of drug and other healthcare cost together with payer dynamic have limited and are likely to continue to limit our ability to set or adjust the price of our product based on their value which could have material adverse effect on our business in the united state particularly over the past few year number of legislative and regulatory proposal have been introduced in an attempt to lower drug price these include proposal that would allow the government to negotiate drug price directly limit drug reimbursement based on price abroad or permit importation of drug from canada proposal focused on drug pricing are likely to continue to be proposed and may be adopted and implemented in some form changing federal coverage and reimbursement policy and practice have affected and may continue to affect access to pricing and sale of our productsa substantial portion of our business relies on reimbursement from federal government healthcare program and commercial insurance plan regulated by federal and state government see item business reimbursement our business ha been and will continue to be affected by legislative action changing federal reimbursement policy since late congressional focus on drug pricing ha increased placing our industry under greater congressional scrutiny for example in early the chair of the house oversight and reform committee sent letter to twelve different biopharmaceutical manufacturer including amgen seeking document and detailed information about such company drug pricing practice subsequently in the fall of the house oversight and reform committee released staff report and held hearing with executive from six biopharmaceutical manufacturer including amgen about their company drug pricing practice also between and number of other congressional committee held hearing and evaluated proposed legislation on drug pricing and payment policy for example in the senate finance committee advanced bill that would among other thing penalize pharmaceutical manufacturer for raising price on drug covered by medicare part and or faster than the rate of inflation cap out of pocket expense for medicare part beneficiary and require higher additional manufacturer discount in medicare part additionally in late drug pricing bill passed the house of representative which would among other thing enable direct price negotiation by the federal government on certain drug with the maximum price paid by medicare capped by price derived from an international index includes penalty for failing to reach agreement with the government and requires that manufacturer offer these negotiated price to other payer we expect or some similar proposed legislation to be debated by congress this year additional legislative or regulatory proposal have been introduced by member of congress and the prior administration that if enacted and implemented in whole or in part could also affect access to and sale of our product including but not limited to proposal to allow importation of prescription medication from canada or other country and to set medicare payment rate using international price referencing further in mid the prior administration announced number of executive order intended to reduce the cost of biopharmaceuticals for patient including mfn policy for medicare part and under which the hhs wa directed to take step to implement payment model that set medicare purchase price based on the lowest price available in economically comparable country for certain part and part medicine in september in response to the corresponding executive order hhs released final rule to allow state or other nonfederal government entity to submit proposal to the fda allowing for the importation of certain nonbiologic prescription drug from canada currently the rule is being challenged by litigation however should such litigation be unsuccessful and should the secretary of hhs authorize state proposal for importation this rule could allow the importation of canadian version of certain of amgen product including otezla that could have material adverse effect on amgen business further in november also in response to the corresponding executive order hhs released an interim final rule to implement the mfn pricing approach if implemented the mfn rule would set the reimbursement rate for medicare part drug including our product such prolia xgeva kyprolis neulasta nplate epogen and aranesp equal to the lowest adjusted price for such product of the organization for economic co operation and development oecd nation lawsuit have been filed by certain trade group challenging the implementation of this mfn rule based on among other thing procedural defect late in in the case filed by the biotechnology industry organization and others the district court for the northern district of california issued preliminary injunction preventing the rule from taking effect nationwide pending the government completion of required administrative procedure the case wa subsequently stayed by the court and the party were ordered to file joint status report by april another case filed by the pharmaceutical research and manufacturer of america and others in the district court for the district of maryland wa also stayed notwithstanding these stay the mfn rule approach to drug pricing and other similar approach remain of interest further despite the change in administration we expect continued significant focus on healthcare and similar drug pricing proposal including proposal similar to the mfn rule for the foreseeable future our business ha been and is expected to continue to be affected by change in federal reimbursement policy resulting from federal regulation and federal demonstration project for example the previous administration released drug pricing blueprint in which introduced an array of policy idea intended to increase competition improve the negotiating power of the federal government reduce drug price and lower patient out of pocket cost with the potential to significantly affect whether individually or collectively our industry such policy idea included but were not limited to moving coverage and reimbursement for medicare part drug into medicare part and instituting competitive acquisition program for part drug in which competing third party vendor take on the financial risk of acquiring drug and billing medicare over the past three year federal agency including the center for medicare medicaid service cm announced number of recommendation policy proposal and demonstration project to implement various element of the drug pricing blueprint cm is the federal agency responsible for administering medicare and overseeing state medicaid program and health insurance marketplace and ha substantial power to implement policy change or demonstration project that can quickly and significantly affect how drug including our product are covered and reimbursed cm issued guidance to allow certain medicare plan offered by private insurance company to require that patient receiving medicare part drug first try drug preferred by the plan before covering another therapy step therapy and lowered reimbursement rate for new medicare part drug further hhs issued final rule under medicare part revising the regulation under the federal antikickback statute to encourage pbms to use rebate received from biopharmaceutical manufacturer to reduce patient cost sharing at the point of sale change to the regulation will be phased in beginning on march with all change effective of january however there are numerous logistical hurdle to overcome before such rule can be effectively implemented and it is unclear how pbms will change their business practice in response furthermore trade association representing pbms recently filed litigation challenging this hhs final rule given these uncertainty it remains unclear when any anticipated benefit to patient will materialize the incoming administration also could develop and seek to advance range of policy proposal that could impact federal reimbursement policy for drug and biologics cm policy change and demonstration project to test new care delivery and payment model can significantly affect how drug including our product are covered and reimbursed in end stage renal disease esrd cm us bundled payment rate between and sensipar and parsabiv our calcimimetics that are used in dialysis clinic were eligible for temporary drug add on payment adjustment tdapa to the bundled rate in november cm released it final rule ending the tdapa for calcimimetics and adjusting esrd prospective payment system bundled rate on january by per dialysis treatment for calcimimetics and we expect the sale of our calcimimetics to be materially adversely affected by this rule change additionally cm created new mandatory payment model effective january focused on encouraging greater use of home dialysis and kidney transplant for esrd patient that could result in change to treatment of dialysis patient including reduction of the use of our esas further back in november cm announced additional voluntary payment model for nephrologists and dialysis facility partner that also seek to encourage home dialysis and preemptive transplantation through increased risk sharing but due to covid the start date of such program ha been pushed back to april cm ha also solicited suggestion regarding other potential care model in cm initiated the oncology care model demonstration which provides participating physician practice with performance based financial incentive that aim to manage or reduce medicare cost without negatively affecting the efficacy of care that ha been extended by one year to due to covid we believe the oncology care model ha reduced utilization of certain of our oncology product by participating physician practice and expect it to continue to do so in the future additionally in late cm announced request for information on the oncology care first model new voluntary model that build on the oncology care model cm recently finalized rule that starting january unless manufacturer can ensure that the full amount of manufacturer patient assistance program is passed on to the patient such amount will be treated price reduction that will be taken into account when reporting our best price and or average manufacturer price amp given the use by pbms and insurer of copay accumulator adjustment program to apply such patient assistance for the benefit of such company and not to defray cost to patient it could be difficult to impossible for manufacturer to ensure that the full value of such amount is being passed on to the patient this new policy if implemented would have significant implication for our ability to offer copay assistance program in this dynamic environment we are unable to predict which or how many federal policy legislative regulatory executive or administrative change may ultimately be or effectively estimate the consequence to our business if enacted and implemented however to the extent that these or other federal government initiative further decrease or modify the coverage or reimbursement available for our product require that we pay increased rebate or shift other cost to limit or affect our decision regarding the pricing of or otherwise reduce the use of our product or limit our ability to offer co pay payment assistance to commercial patient such action could have material adverse effect on our business and result of operation we also face risk relating to the reporting of pricing data that affect the reimbursement of and discount provided for our product government price reporting regulation are complex and may require biopharmaceutical manufacturer to update certain previously submitted data if our submitted pricing data are incorrect we may become subject to substantial fine and penalty or other government enforcement action which could have material adverse effect on our business and result of operation in addition result of restating previously reported price data we also may be required to pay additional rebate and provide additional discount changing reimbursement and pricing action in various state have negatively affected and may continue to negatively affect access to and have affected and may continue to affect sale of our productsat the state level government action or ballot initiative can also affect how our product are covered and reimbursed and or create additional pressure on our pricing decision number of state have adopted and many other state are considering drug importation program or other new pricing action including proposal designed to require biopharmaceutical manufacturer publicly to report proprietary pricing information limit price increase or place maximum price ceiling or cap on biopharmaceutical product existing and proposed state pricing law have added complexity to the pricing of drug and may already be affecting industry pricing decision for example california law the constitutionality of which is currently being challenged purport to require biopharmaceutical manufacturer to notify health insurer and government health plan at least day before scheduled prescription drug price increase that exceed certain threshold similar law exist in oregon and washington state are also seeking to change the way they pay for drug for patient covered by state program california adopted budget that incorporates international pricing into medicaid supplemental rebate negotiation and allows it medicaid program to seek federal approval to extend supplemental rebate to non medicaid population new york massachusetts and ohio have established medicaid drug spending cap and additional state may consider doing so they face budget deficit from the effect of covid additionally colorado florida maine new hampshire new mexico and vermont have enacted law and several other state have proposed law to facilitate the importation of drug from canada other state could adopt similar approach or could pursue different policy change in continuing effort to reduce their cost ultimately with federal government action existing or future state government action or ballot initiative may also have material adverse effect on our product sale business and result of operation commercial payer action have affected and may continue to affect access to and sale of our productspayers including healthcare insurer pbms integrated healthcare delivery system vertically integrated organization built from the consolidation of healthcare insurer and pbms and group purchasing organization increasingly seek way to reduce their cost with increasing frequency payer are adopting benefit plan change that shift greater proportion of drug cost to patient such measure include more limited benefit plan design high deductible plan higher patient copay or coinsurance obligation and more significant limitation on patient use of manufacturer commercial copay assistance program further government regulation of payer may affect these trend for example cm recently finalized policy that could cause commercial payer to adopt copay accumulator adjustment program more widely payer have sought and will likely continue to seek price discount or rebate in connection with the placement of our product on their formulary or those they manage particularly in treatment area where the payer ha taken the position that multiple branded product are therapeutically comparable payer also control cost by imposing restriction on access to or usage of our product such step therapy or requiring that patient receive the payer prior authorization before covering the product or that patient use mail order pharmacy or limited network of payer fully owned mail order or specialty pharmacy payer may also choose to exclude certain indication for which our product are approved or even choose to exclude coverage entirely for example some payer require physician to demonstrate or document that the patient for whom repatha ha been prescribed meet payer utilization management criterion and these requirement have limited and may continue to limit patient access to repatha treatment in an effort to reduce barrier to access we reduced the net price of repatha by providing greater discount and rebate to payer including pbms that administer medicare part prescription drug plan however affordability of patient out of pocket co pay cost ha limited and may continue to limit patient use for example in late and early in response to very high percentage of medicare patient abandoning their repatha prescription rather than pay their co pay payment we introduced set of new national drug code to make repatha available at lower list price to attempt to address affordability for patient particularly those on medicare and on december we discontinued the higher list price option for repatha despite these net and list price reduction some payer have restricted and may continue to restrict patient access and may change formulary coverage for repatha seek further discount or rebate or take other action that could reduce our sale of repatha these factor have limited and may continue to limit patient affordability and use and negatively affect repatha sale significant consolidation in the health insurance industry ha resulted in few large insurer and pbms which place greater pressure on pricing and usage negotiation with biopharmaceutical manufacturer significantly increasing discount and rebate requirement and limiting patient access and usage for example in the united state in the top five integrated health plan and pbms controlled about of all pharmacy prescription the consolidation among insurer pbms and other payer including through integrated healthcare delivery system and or with specialty or mail order pharmacy and pharmacy retailer ha increased the negotiating leverage such entity have over and other biopharmaceutical manufacturer and ha resulted in greater price discount rebate and service fee realized by those payer in and cv and express script created rebate management organization that further increase their respective leverage to negotiate deeper discount ultimately additional discount rebate fee coverage or plan change restriction or exclusion imposed by these commercial payer could have material adverse effect on our product sale business and result of operation policy reform advanced by congress or the administration that refine the role of pbms in the marketplace could have downstream implication or consequence for our business and how we interact with these entity government and commercial payer action outside the united state have affected and will continue to affect access to and sale of our productsoutside the united state we expect country will also continue to take action to reduce their drug expenditure see item business reimbursement irp ha been widely used by many country outside the united state to control cost based on an external benchmark of product price in other country irp policy can change quickly and frequently and may not reflect difference in the burden of disease indication market structure or affordability difference across country or region in addition country may refuse to reimburse or may restrict the reimbursed population for product when their national health technology assessment do not consider medicine to demonstrate sufficient clinical benefit beyond existing therapy or to meet certain cost effectiveness threshold for example despite the ema approval of repatha for the treatment of patient with established atherosclerotic disease the reimbursement for repatha in france is limited to narrower patient population such those with homozygous familial hypercholesterolemia following national health technology assessment while the pricing and reimbursement process in that country remains ongoing the assessment currently limit our effort in france to expand repatha access to the broader patient population covered by the approved label some country decide on reimbursement between potentially competing product through national or regional tender that often result in one product receiving most or all of the sale in that country or region failure to obtain coverage and reimbursement for our product deterioration in their existing coverage and reimbursement or decline in the timeliness or certainty of payment by payer to physician and other provider ha negatively affected and may further negatively affect the ability or willingness of healthcare provider to prescribe our product for their patient and otherwise negatively affect the use of our product or the price we realize for them such change have had and could in the future have material adverse effect on our product sale business and result of operation guideline and recommendation published by various organization can reduce the use of our product government agency promulgate regulation and guideline directly applicable to and to our product professional society practice management group insurance carrier physician group private health and science foundation and organization involved in various disease also publish guideline and recommendation to healthcare provider administrator and payer well patient community recommendation by government agency or other group and organization may relate to such matter usage dosage route of administration and use of related therapy in addition growing number of organization are providing assessment of the value and pricing of biopharmaceutical product and even organization whose guideline have historically been focused on clinical matter have begun to incorporate analysis of the cost effectiveness of various treatment into their treatment guideline and recommendation value assessment may come from private organization that publish their finding and offer recommendation relating to the product reimbursement by government and private payer some company and payer have announced pricing and payment decision based in part on the assessment of private organization in addition government health technology assessment organization in many country make reimbursement recommendation to payer in their jurisdiction based on the clinical effectiveness cost effectiveness and service effect of new emerging and existing medicine and treatment such health technology assessment organization have recommended and may in the future recommend reimbursement for certain of our product for narrower indication than wa approved by applicable regulatory agency or may recommend against reimbursement entirely see our sale depend on coverage and reimbursement from government and commercial third party payer and pricing and reimbursement pressure have affected and are likely to continue to affect our profitability such recommendation or guideline may affect our reputation and any recommendation or guideline that result in decreased use dosage or reimbursement of our product could have material adverse effect on our product sale business and result of operation in addition the perception by the investment community or stockholder that such recommendation or guideline will result in decreased use and dosage of our product could adversely affect the market price of our common stock adoption and interpretation of new tax legislation or exposure to additional tax liability could affect our profitability we are subject to income and other tax in the united state and other jurisdiction in which we do business result our provision for income tax is derived from combination of applicable tax rate in the various place we operate significant judgment is required for determining our provision for income tax our tax return are routinely examined by tax authority in the united state and other jurisdiction in which we do business and number of audit are currently underway tax authority including the internal revenue service irs are becoming more aggressive in their audit and are particularly focused on the allocation of income and expense among tax jurisdiction in we received revenue agent report rar and modified rar from the irs for the year and proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico we disagree with the proposed adjustment and calculation and have been pursuing resolution with the irs administrative appeal office however we have been unable to reach resolution at the administrative appeal level and we anticipate that we will receive notice of deficiency which we would expect to vigorously contest through the judicial process in addition in we received an rar and modified rar from the irs for the year and also proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico similar to those proposed for the year and we disagree with the and proposed adjustment and calculation and are pursuing resolution with the irs administrative appeal office the irs audit for year and is expected to start in the near term we are also currently under examination by number of other state and foreign tax jurisdiction final resolution of these complex matter is not likely within the next month we believe our accrual for income tax liability is appropriate based on past experience interpretation of tax law application of the tax law to our fact and judgment about potential action by tax authority however due to the complexity of the provision for income tax and uncertain resolution of these matter the ultimate outcome of any tax matter may result in payment substantially greater than amount accrued and could have material adverse effect on the result of our operation our provision for income tax and result of operation in the future could be adversely affected by change to our operating structure change in the mix of income and expense in country with differing tax rate change in the valuation of deferred tax asset and liability and change in applicable tax law regulation or administrative interpretation thereof the tax cut and job act the tax act is complex and large volume of regulation and guidance ha been issued and could be subject to different interpretation we could face audit challenge to our application of the tax act the new administration and congress could make change to existing tax law including an increase in the corporate tax rate and the tax rate on foreign earnings change to existing tax law in the the territory of puerto rico or other jurisdiction including effort by the oecd to align country on corporate tax matter that would likely result in tax increase where we do business could have material adverse effect on the result of our operation our business may be affected by litigation and government investigation we and certain of our subsidiary are involved in legal proceeding see part iv note contingency and commitment to the consolidated financial statement civil and criminal litigation is inherently unpredictable and the outcome can result in costly verdict fine and penalty exclusion from federal healthcare program and or injunctive relief that affect how we operate our business defense of litigation claim can be expensive time consuming and distracting and it is possible that we could incur judgment or enter into settlement of claim for monetary damage or change the way we operate our business which could have material adverse effect on our product sale business and result of operation in addition product liability is major risk in testing and marketing biotechnology and pharmaceutical product we may face substantial product liability exposure in human clinical trial and for product we sell after regulatory approval product liability claim regardless of their merit could be costly and divert management attention and could adversely affect our reputation and the demand for our product we and certain of our subsidiary have previously been named defendant in product liability action for certain of our product are also involved in government investigation that arise in the ordinary course of our business in recent year there ha been trend of increasing government investigation and litigation against company operating in our industry both in the united state and around the world see our sale depend on coverage and reimbursement from third party payer and pricing and reimbursement pressure may affect our profitability our business activity outside of the united state are subject to the fcpa and similar antibribery or anticorruption law regulation or rule of other country in which we operate including the uk bribery act we can not ensure that all our employee agent contractor vendor licensee partner or collaborator will comply with all applicable law and regulation on april we entered into settlement agreement with the doj and the oig of the hhs to settle certain allegation relating to our support of independent charitable organization that provide patient with financial assistance to access their medicine result we entered into corporate integrity agreement with the oig that requires to maintain corporate compliance program and to undertake set of defined corporate integrity obligation for period of five year while we expect to fully comply with all of our obligation under the corporate integrity agreement failure to do so could result in substantial penalty and potential exclusion from government healthcare program we may also see new government investigation of or action against citing novel theory of recovery for example prosecutor are placing greater scrutiny on patient support program including commercial copay assistance program and further enforcement action and investigation regarding such program could limit our ability to provide co pay assistance to commercial patient greater scrutiny ha also been placed on sponsorship speaker program and other arrangement where healthcare professional receive remuneration travel or other value to participate in certain event and further enforcement action could limit our ability to participate in such arrangement any of these result could have material adverse effect on our business and result of operation risk related to competitionour product face substantial competition and our product candidate are also likely to face substantial competition we operate in highly competitive environment see item business marketing distribution and selected marketed product competition we expect that our product and product candidate will compete with existing drug new drug currently in development drug currently approved for other indication that may later be approved for the same indication those of our product and drug approved for other indication that are used label large pharmaceutical company and generic manufacturer of pharmaceutical product are expanding into the biotechnology field and some pharmaceutical company and generic manufacturer have formed partnership to pursue biosimilars with the proliferation of company pursuing biopharmaceuticals number of our product candidate may enter market with one or more competitor or with competitor soon to arrive in addition some of our competitor may have technical competitive or other advantage over for the development of technology and process or greater experience in particular therapeutic area and consolidation among pharmaceutical and biotechnology company can enhance such advantage these advantage may make it difficult for to compete with them successfully to discover develop and market new product and for our current product to compete with new product or new product indication they may bring to market result our product have been competing and may continue to compete and our product candidate may compete against product or product candidate that offer higher rebate or discount lower price equivalent or superior efficacy better safety profile easier administration earlier market availability or other competitive feature if we are unable to compete effectively this could reduce sale which could have material adverse effect on our business and result of operation intellectual property position may be challenged invalidated or circumvented or we may fail to prevail in current and future intellectual property litigation our success depends in part on our ability to obtain and defend patent right and other intellectual property right that are important to the commercialization of our product and product candidate the patent position of pharmaceutical and biotechnology company can be highly uncertain and often involve complex legal scientific and factual question driven by cost pressure effort to limit or weaken patent protection for our industry are increasing for example the covid pandemic ha resulted in increased interest in compulsory license march in right or other governmental intervention both in the united state and internationally related to the procurement of drug see the covid pandemic and the public and governmental effort to mitigate against the spread of the disease have had and are expected to continue to have an adverse effect and may have material adverse effect on our clinical trial operation supply chain distribution system product development product sale business and result of operation third party have challenged and may continue to challenge invalidate or circumvent our patent and patent application relating to our product product candidate and technology challenge to patent may come from potential competitor or from party other than those who seek to market potentially infringing product in addition our patent position might not protect against competitor with similar product or technology because competing product or technology may not infringe our patent for certain of our product candidate there are third party who have patent or pending patent application that they may claim necessitate payment of royalty or prevent from commercializing these product candidate in certain territory patent dispute are frequent costly and can preclude delay or increase the cost of commercialization of product we have been in the past are currently and expect to be in the future involved in patent litigation these matter have included and may in the future include litigation with manufacturer of product that purport to be biosimilars of certain of our product for patent infringement and for failure to comply with certain provision of the biologics price competition and innovation act of bpcia determination made by court agency or tribunal concerning infringement validity enforceability injunctive or economic remedy or the right to patent protection for example are typically subject to appellate or administrative review upon review such initial determination may be afforded little or no deference by the reviewing tribunal and may be affirmed reversed or made the subject of reconsideration through further proceeding patent dispute or litigation ha not discouraged and may not in the future discourage potential violator from bringing the allegedly infringing product to market prior to final resolution of the dispute or litigation the period from inception until resolution of patent dispute or litigation is subject to the availability and schedule of the court agency or tribunal before which the dispute or litigation is pending we have been and may in the future be subject to competition during this period and may not be able to recover fully from the loss damage and harm we incur from infringement by the competitor product even if we prevail moreover if we lose or settle current or future litigation at certain stage or entirely we could be subject to competition and or significant liability be required to enter into third party license for the infringed product or technology or be required to cease using the technology or product in dispute in addition we can not guarantee that such license will be available on term acceptable to or at all further under the hatch waxman act our product approved by the fda under the fdca have been and may in the future be the subject of patent litigation with generic competitor before expiry of the five year period of data exclusivity provided for under the hatch waxman act and prior to the expiration of the patent listed for the product likewise our innovative biologic product have been and may in the future be the subject of patent litigation prior to the expiration of our patent and with respect to competitor seeking approval biosimilar or interchangeable version of our product prior to the year exclusivity period provided under the bpcia in addition we may face patent litigation involving claim that the biosimilar product candidate we are working to develop infringe the patent of other company including those that manufacture market or sell the applicable reference product or who are developing or have developed other biosimilar version of such product due to the covid pandemic there may be delay in ongoing or new patent office or court proceeding in the or abroad that may delay the outcome of such proceeding while we have attempted and expect to continue to attempt to challenge the patent held by other company our effort may be unsuccessful alternatively such patent have contributed and may in the future contribute to decision by to not pursue all of the same labeled indication are held by these company for example of and information related to our patent litigation see part iv note contingency and commitment to the consolidated financial statement certain of the existing patent on our product have expired see item business marketing distribution and selected marketed product patent our patent expire competitor are able to legally produce and market similar product or technology including biosimilars which ha had and may continue to have material adverse effect on our product sale business and result of operation in addition competitor have been and may continue to be able to invalidate design around or otherwise circumvent our patent and sell competing product currently face competition from biosimilars and generic and expect to face increasing competition from biosimilars and generic in the future we currently face competition from biosimilars and generic in most of the territory in which we operate including europe and the united state and we expect to face increasing biosimilar and or generic competition this year and beyond expiration or successful challenge of applicable patent right or expiration of an applicable exclusivity period ha accelerated such competition and we expect to face more litigation regarding the validity and or scope of our patent our product have also experienced greater competition from lower cost biosimilars or generic that come to market when branded product that compete with our product lose their own patent protection to the extent that government adopt more permissive regulatory approval standard and competitor are able to obtain broader or expedited marketing approval for biosimilars and generic the rate of increased competition for our product could accelerate in the eu biosimilars are evaluated for marketing authorization pursuant to set of general and product class specific guideline in addition in an effort to spur biosimilar utilization and or increase potential healthcare saving some eu country and some canadian province have adopted or are considering the adoption of biosimilar uptake measure such physician prescribing quota or automatic pharmacy substitution of biosimilars for the corresponding reference product some eu country impose automatic price reduction upon market entry of one or more biosimilar competitor while the degree of competitive effect of biosimilar competition differs between eu country and between product in the eu the overall use of biosimilars and the rate at which product sale of innovative product are being affected by biosimilar competition is increasing in the united state the bpcia authorizes the fda to approve biosimilars via separate abbreviated pathway see item business government regulation regulation in the united state approval of biosimilars the first biosimilar entrant into the market wa sandoz zarxio filgrastim sndz biosimilar version of neupogen in since the fda ha approved additional biosimilars including biosimilar version of neulasta epogen and enbrel and growing number of company have announced that they are also developing biosimilar version of our product four biosimilar version of neulasta are now marketed in the united state and we expect other biosimilar version of neulasta to receive approval in and beyond impact to our neulasta sale ha accelerated additional competitor have launched see item business marketing distribution and selected marketed product competition an approved biosimilar version of epogen ha also launched in the united state and we are currently involved in patent litigation with the manufacturer of the approved biosimilar version of enbrel manufacturer of biosimilars have attempted and may in the future attempt to compete with our product by offering lower list price greater discount or rebate or contract that offer longer term pricing or broader portfolio of other product company pursuing development of biosimilar version of our product have challenged and may continue to challenge our patent well in advance of the expiration of our material patent for example we recently successfully defended our enbrel patent against litigation challenge for example of and information related to our biosimilars and generic patent litigation see part iv note contingency and commitment to the consolidated financial statement see our intellectual property position may be challenged invalidated or circumvented or we may fail to prevail in current and future intellectual property litigation the pathway includes the option for biosimilar product that meet certain criterion to be approved interchangeable with their reference product some company currently developing or already marketing biosimilars may seek to obtain interchangeable status from the fda which could potentially allow pharmacist to substitute those biosimilars for our reference product without prior approval from the prescriber in most state in november the fda issued draft guidance that provides that comparative immunogenicity study will not generally be expected for biosimilar and interchangeable insulin product this may open the door for other product specific guidance development and the removal of the expectation for certain study which may contribute to increased biosimilar competition for our innovative product in addition critic of the year exclusivity period in the biosimilar pathway law will likely continue to seek to shorten the data exclusivity period and or to encourage the fda to interpret narrowly the law provision regarding which new product receive data exclusivity in late the previous administration agreed to remove from the united state mexico canada agreement requirement for at least year of data exclusivity for biologic product also the fda is considering whether subsequent change to licensed biologic would be protected by the remainder of the reference product original year exclusivity period concept known in the generic drug context umbrella exclusivity if the fda were to decide that umbrella exclusivity doe not apply to biological reference product or were to make other change to the exclusivity period this could expose to biosimilar competition at an earlier time there also have been and may continue to be legislative and regulatory effort to promote competition through policy enabling easier generic and biosimilar approval and commercialization including effort to lower standard for demonstrating biosimilarity or interchangeability limit patent that may be litigated and or patent settlement implement preferential reimbursement policy for biosimilars and passage of new law requiring more disclosure in the fda orange and purple book the expiration or loss of patent protection and or applicable exclusivity for one of our small molecule product we can lose the majority of revenue for that product in very short period of time see item business marketing distribution and selected marketed product competition additionally if one of our small molecule product is the subject of an fda written request for pediatric study and we are unable to adequately complete these study we may not obtain the pediatric exclusivity award that extends existing patent for the product by an additional six month for example result of the product already introduced and or that could further be introduced into the market our product sale for sensipar have been adversely affected and could be further materially and adversely affected by competing generic california is the first state to have passed legislation effective on january against pay for delay settlement of patent infringement claim filed by manufacturer of generic or biosimilars where anything of value is given in exchange for settlement under this law such settlement agreement are presumptively anticompetitive the law may result in prolonged litigation and fewer settlement other state including connecticut new york illinois and minnesota may adopt similar law or similar law could be adopted at the federal level while we are unable to predict the precise effect of biosimilars and generic on our product we are currently facing and expect to face greater competition in the united state europe and elsewhere in and beyond result of biosimilar and generic competition and in turn downward pressure on our product price and sale this competition ha had and could increasingly have material adverse effect on our product sale business and result of operation concentration of sale at certain of our wholesaler distributor and at one free standing dialysis clinic business and consolidation of private payer may negatively affect our business certain of our distributor customer and payer have substantial purchasing leverage due to the volume of our product they purchase or the number of patient life for which they provide coverage the substantial majority of our product sale is made to three pharmaceutical product wholesaler distributor amerisourcebergen mckesson and cardinal health these distributor in turn sell our product to their customer which include physician or their clinic dialysis center hospital and pharmacy one of our product epogen is sold primarily to free standing dialysis clinic davita owns or manages large number of the outpatient dialysis facility located in the united state and account for approximately of all epogen sale similarly discussed above there ha been significant consolidation in the health insurance industry including that small number of pbms now oversee substantial percentage of total covered life in the united state see our sale depend on coverage and reimbursement from third party payer and pricing and reimbursement pressure may affect our profitability the three largest pbms in the united state are now part of major health insurance provider the growing concentration of purchasing and negotiating power by these entity may put pressure on our pricing due to their ability to extract price discount on our product fee for other service or rebate negatively affecting our bargaining position sale and or profit margin in addition decision by these entity to purchase or cover le or none of our product in favor of competitive product could have material adverse effect on our product sale business and result of operation due to their purchasing volume further if one of our significant wholesale distributor encounter financial or other difficulty and becomes unable or unwilling to pay all amount that such distributor owes on timely basis or at all it could negatively affect our business and result of operation in addition if one of our significant wholesale distributor becomes insolvent or otherwise unable to continue it commercial relationship with in it present form it could significantly disrupt our business and adversely affect our product sale our business and result of operation unless suitable alternative are timely found or lost sale are absorbed by another distributor risk related to research and developmentwe may not be able to develop commercial product despite significant investment in amgen invests heavily in successful product development in the biotechnology industry is highly uncertain and very few project produce commercial product product candidate including biosimilar product candidate or new indication for existing product collectively product candidate that appear promising in the early phase of development may fail to reach the market for number of reason such the product candidate did not demonstrate acceptable clinical trial result even though it achieved it primary endpoint and or demonstrated positive preclinical or early clinical trial result for reason that could include change in the standard of care of medicine or expectation of health authority the product candidate wa not effective or not more effective than currently available therapy in treating specified condition or illness the product candidate wa not cost effective in light of existing therapeutic the product candidate had harmful side effect in animal or human the necessary regulatory body such the fda or ema did not approve the product candidate for an intended use the product candidate wa not economical for to manufacture and commercialize other party had or may have had proprietary right relating to our product candidate such patent right and did not let sell it on reasonable term or at all we and certain of our licensee partner contracted organization or independent investigator may have failed to effectively conduct clinical development or clinical manufacturing activity the pathway to regulatory approval or reimbursement for product candidate wa uncertain or not well defined the biosimilar product candidate failed to demonstrate the requisite biosimilarity to the applicable reference product or wa otherwise determined by regulatory authority to not meet applicable standard for approval and companion diagnostic device that is required with the use of product candidate is not approved by the necessary regulatory authority we have spent considerable time energy and resource developing our expertise in human genetics and acquiring access to library of genetic information with the belief that genetics could meaningfully aid our search for new medicine and help guide our decision and investment we have focused our strategy on drug target validated by genetic or other compelling human evidence however product candidate based on genetically validated target remain subject to the uncertainty of the drug development process and may not reach the market for number of reason including the factor listed above number of our product candidate have failed or been discontinued at various stage in the product development process for example in we terminated our participation in the co development and commercialization of brodalumab product candidate that wa in phase with astrazeneca the decision wa based on event of suicidal ideation and behavior in the brodalumab program that occurred late in the development program which we believed likely would necessitate restrictive labeling that would limit the appropriate patient population inability to bring product to market or significant delay in the expected approval and related launch date of new product for any of the reason discussed could potentially have negative effect on our product sale and earnings and could result in significant impairment of in process research and development ipr or other intangible asset we must conduct clinical trial in human before we commercialize and sell any of our product candidate or existing product for new indication before we sell any product we must conduct clinical trial to demonstrate that our product candidate are safe and effective for use in human the result of those clinical trial are used the basis to obtain approval from regulatory authority such the fda and ema see our current product and product in development can not be sold without regulatory approval we are required to conduct clinical trial using an appropriate number of trial site and patient to support the product label claim the length of time number of trial site and number of patient required for clinical trial vary substantially and we may spend several year and incur substantial expense in completing certain clinical trial in addition we may have difficulty finding sufficient number of clinical trial site and patient to participate in our clinical trial particularly if competitor are conducting clinical trial in similar patient population see the covid pandemic and the public and governmental effort to mitigate against the spread of the disease have had and are expected to continue to have an adverse effect and may have material adverse effect on our clinical trial operation supply chain distribution system product development product sale business and result of operation patient may withdraw from clinical trial at any time and privacy law and or other restriction in certain country may restrict the ability of clinical trial investigator to conduct further follow up on such patient which may adversely affect the interpretation of study result delay and complication in planned clinical trial can result in increased development cost associated delay in regulatory approval and in product candidate reaching the market and revision to existing product label to increase the number of patient available for enrollment in our clinical trial we have opened and will continue to open clinical site and enroll patient in number of location where our experience conducting clinical trial is more limited including russia india china south korea the philippine singapore and some central and south american country either through utilization of third party contract clinical trial provider entirely or in combination with local staff conducting clinical trial in location where we have limited experience requires substantial time and resource to understand the unique regulatory environment of individual country for other example of the risk of conducting clinical trial in china see also our sale and operation are subject to the risk of doing business internationally including in emerging market further we must ensure the timely production distribution and delivery of the clinical supply of our product candidate to numerous and varied clinical trial site additionally regional disruption including natural and man made disaster or health emergency such novel virus or pandemic such the one we are currently experiencing with covid could significantly disrupt the timing of clinical trial if we fail to adequately manage the design execution and diverse regulatory aspect of our large and or complex clinical trial or to manage the production or distribution of our clinical supply or such site experience disruption result of natural man made disaster or health emergency corresponding regulatory approval may be delayed or we may fail to gain approval for our product candidate or could lose our ability to market existing product in certain therapeutic area or altogether for example our clinical trial have been adversely affected by the covid pandemic see the covid pandemic and the public and governmental effort to mitigate against the spread of the disease have had and are expected to continue to have an adverse effect and may have material adverse effect on our clinical trial operation supply chain distribution system product development product sale business and result of operation if we are unable to market and sell our product or product candidate or to obtain approval in the timeframe needed to execute our product strategy our business and result of operation could be materially and adversely affected we rely on independent third party clinical investigator to recruit patient and conduct clinical trial on our behalf in accordance with applicable study protocol law and regulation further we rely on unaffiliated third party vendor to perform certain aspect of our clinical trial operation in some circumstance we enter into co development arrangement with other pharmaceutical and medical device company that provide for the other company to conduct certain clinical trial for the product we are co developing or to develop diagnostic test used in screening or monitoring patient in our clinical trial see some of our pharmaceutical pipeline and of our commercial product sale rely on collaboration with third party which may adversely affect the development and sale of our product we also may acquire company that have past or ongoing clinical trial or right to product or product candidate for which clinical trial have been or are being conducted these trial may not have been conducted to the same standard however once an acquisition ha been completed we assume responsibility for the conduct of these trial including any potential risk and liability associated with the past and prospective conduct of those trial if regulatory authority determine that we or others including our licensee or co development partner or the independent investigator or vendor selected by our co development partner or by company we have acquired or from which we have acquired right to product or product candidate have not complied with regulation applicable to the clinical trial those authority may refuse or reject some or all of the clinical trial data or take other action that could delay or otherwise negatively affect our ability to obtain or maintain marketing approval of the product or indication in addition delay or failure to develop diagnostic test for our clinical trial can affect the timely enrollment of such trial and lead to delay or inability to obtain marketing approval if we were unable to market and sell our product or product candidate our business and result of operation could be materially and adversely affected in addition some of our clinical trial utilize drug manufactured and marketed by other pharmaceutical company these drug may be administered in clinical trial in combination with one of our product or product candidate or in head to head study comparing the product or product candidate relative efficacy and safety in the event that any of these vendor or pharmaceutical company have unforeseen issue that negatively affect the quality of their work product or create shortage of supply or if we are otherwise unable to obtain an adequate supply of these other drug our ability to complete our applicable clinical trial and or evaluate clinical result may also be negatively affected result such quality or supply problem could adversely affect our ability to timely file for gain or maintain regulatory approval worldwide clinical trial must generally be designed based on the current standard of medical care however in certain disease such cancer the standard of care is evolving rapidly in some case we may design clinical trial based on the standard of care we anticipate will exist at the time our study is completed the duration of time needed to complete certain clinical trial may result in the design of such clinical trial being based on standard of medical care that are no longer or that have not become the current standard by the time such trial are completed limiting the utility and application of such trial additionally the view of regulatory agency relating to the requirement for accelerated approval may change over time and trial design that were sufficient to support accelerated approval for some oncology product may not be considered sufficient for later candidate we may not obtain favorable clinical trial result and therefore may not be able to obtain regulatory approval for new product candidate or new indication for existing product and or maintain our current product label participant in clinical trial of our product and product candidate may also suffer adverse medical event or side effect that could among other factor delay or terminate clinical trial program and or require additional or longer trial to gain approval after product is on the market safety concern may require additional or more extensive clinical trial part of risk management plan for our product or for approval of new indication for example in connection with the june esa label change we agreed to and conducted additional clinical trial examining the use of esas in ckd additional clinical trial we initiate including those required by the fda could result in substantial additional expense and the outcome could result in further label restriction or the loss of regulatory approval for an approved indication each of which could have material adverse effect on our product sale business and result of operation additionally any negative result from such trial could materially affect the extent of approval the use reimbursement and sale of our product our business and result of operation our current product and product in development can not be sold without regulatory approval our business is subject to extensive regulation by numerous state and federal government authority in the united state including the fda and by foreign regulatory authority including the ema we are required in the united state and in foreign country to obtain approval from regulatory authority before we manufacture market and sell our product once our product are approved the fda and other and foreign regulatory agency have substantial authority to require additional testing and reporting perform inspection change product labeling or mandate withdrawal of our product failure to comply with applicable regulatory requirement may subject to administrative and or judicially imposed sanction or monetary penalty well reputational and other harm the sanction could include the fda or foreign regulatory authority refusal to approve pending application delay in obtaining or withdrawal of approval delay or suspension of clinical trial warning letter product recall or seizure total or partial suspension of our operation injunction fine civil penalty and or criminal prosecution obtaining and maintaining regulatory approval have been and will continue to be increasingly difficult time consuming and costly legislative body or regulatory agency could enact new law or regulation change existing law or regulation or change their interpretation of law or regulation at any time which could affect our ability to obtain or maintain approval of our product or product candidate the rate and degree of change in existing law and regulation and regulatory expectation have accelerated in established market and regulatory expectation continue to evolve in emerging market we are unable to predict whether and when any further change to law or regulatory policy affecting our business could occur such change to law or regulation governing manufacturer communication concerning drug product and drug product candidate and whether such change could have material adverse effect on our product sale business and result of operation in the united state partial federal government shutdown halted the work of many federal agency and their employee from late december through late january subsequent extended shutdown could result in reduction or delay of fda activity including with respect to our ongoing clinical program our manufacturing of our product and product candidate and our product approval regulatory authority have questioned and may in the future question the sufficiency for approval of the endpoint we select for our clinical trial number of our product and product candidate have been evaluated in clinical trial using surrogate endpoint that measure an effect that is known to correlate with an ultimate clinical benefit for example therapeutic oncology product candidate may be evaluated for it ability to reduce or eliminate minimal residual disease mrd or to extend the length of time during and after the treatment that patient life without the disease worsening measured by pfs demonstrating that the product candidate induces mrd negative response or produce statistically significant improvement in pfs doe not necessarily mean that the product candidate will show statistically significant improvement in overall survival or the time that the patient remain alive in the cv setting heart disease therapeutic candidate may be evaluated for it ability to reduce ldl level an elevated ldl level ha been surrogate endpoint for cv event such death heart attack and stroke the use of surrogate endpoint such pfs and ldl reduction in the absence of other measure of clinical benefit may not be sufficient for broad usage or approval even when such result are statistically significant regulatory authority could also add new requirement such the completion of enrollment in confirmatory study or the completion of an outcome study or meaningful portion of an outcome study condition for obtaining approval or obtaining an indication for example despite demonstrating that repatha reduced ldl level in broad patient population only after our large phase outcome study evaluating the ability of repatha to prevent cv event met certain of it primary composite endpoint and key secondary composite endpoint did the fda grant broader approval of repatha to reduce the risk of certain cv event and also to be used alone or in combination with other lipid lowering therapy for the treatment of adult with primary hyperlipidemia to reduce ldl there may also be situation in which demonstrating the efficacy and safety of product candidate may not be sufficient to gain regulatory approval unless superiority to other existing treatment option can be shown the imposition of additional requirement or our inability to meet them in timely fashion or at all ha delayed and may in the future delay our clinical development and regulatory filing effort delay or prevent from obtaining regulatory approval for new product candidate or new indication for existing product or prevent from maintaining our current product label of our product have been approved by and foreign regulatory authority on an accelerated or conditional basis with full approval conditioned upon fulfilling the requirement of regulator for example in march we announced that the fda approved blincyto under accelerated approval for the treatment of adult and child with cell precursor acute lymphoblastic leukemia all in first or second complete remission with mrd greater than or equal to percent continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial regulatory authority are placing greater focus on monitoring product originally approved on an accelerated or conditional basis and on whether the sponsor of such product have met the condition of the accelerated or conditional approval if we are unable to fulfill the regulator requirement that were condition of product accelerated or conditional approval and or if regulator reevaluate the data or risk benefit profile of our product the conditional approval may not result in full approval or may be revoked or not renewed alternatively we may be required to change the product labeled indication or even withdraw the product from the market regulatory authority can also impose post marketing pediatric study requirement failure to fulfill such requirement may result in regulatory or enforcement action including financial penalty or the invalidation of product marketing authorization safety problem or signal can arise our product and product candidate are evaluated in clinical trial including investigator sponsored study or our marketed product are used in clinical practice we are required continuously to collect and ass adverse event reported to and to communicate to regulatory agency these adverse event and safety signal regarding our product regulatory agency periodically perform inspection of our pharmacovigilance process including our adverse event reporting in the united state for our product with approved rem see item business government regulation postapproval phase we are required to submit periodic assessment report to the fda to demonstrate that the goal of the rem are being met rem and other risk management program are designed to ensure that drug benefit outweigh the risk and vary in the element they contain if the fda is not satisfied with the result of the periodic assessment report we submit for any of our rem the fda may also modify our rem or take other regulatory action such implementing revised or restrictive labeling the drug delivery device approved for use in combination with our product are also subject to regulatory oversight and review for safety and malfunction see some of our product are used with drug delivery or companion diagnostic device that have their own regulatory manufacturing and other risk if regulatory agency determine that we or other party including our clinical trial investigator those operating our patient support program or licensee of our product have not complied with the applicable reporting other pharmacovigilance or other safety or quality assessment requirement we may become subject to additional inspection warning letter or other enforcement action including fine marketing authorization withdrawal and other penalty our product candidate and marketed product can also be affected by safety problem or signal occurring with respect to product that are similar to ours or that implicate an entire class of product further result of clinical trial including sub analysis or meta analysis of earlier clinical trial meta analysis involves the use of various statistical method to combine result from previous separate but related study performed by or others concern may arise about the sufficiency of the data or study underlying product approved label such actual or perceived safety problem or concern can lead to revised or restrictive labeling for our product or the potential for restrictive labeling that ha resulted and may in the future result in our decision not to commercialize product candidate requirement of risk management or minimization activity or other regulatory agency compliance action related to the promotion and sale of our product post marketing commitment mandated post marketing requirement or pharmacovigilance program for our approved product product recall of our approved product required change to the process used in the manufacture of our product which could increase our manufacturing cost and affect the availability of contract manufacturer we may utilize to assist in such manufacturing revocation of approval for our product from the market completely or within particular therapeutic area or patient type increased timeline or delay in being approved by the fda or other regulatory body and or treatment or product candidate not being approved by regulatory body example after an imbalance in positively adjudicated cv serious adverse event wa observed in one of the phase clinical trial for evenity but not in another larger phase study in april the fda approved evenity for the treatment of osteoporosis in postmenopausal woman at high risk for fracture along with post marketing requirement the requirement includes five year observational feasibility study that could be followed by comparative safety study or trial in addition to our innovative product we are working to develop and commercialize biosimilar version of number of product currently manufactured marketed and sold by other pharmaceutical company in some market there is not yet legislative or regulatory pathway for the approval of biosimilars in the united state the bpcia provided for such pathway while the fda continues to implement it discussion continue to the evidence needed to demonstrate biosimilarity or interchangeability for specific product see we currently face competition from biosimilars and generic and expect to face increasing competition from biosimilars and generic in the future delay or uncertainty in the development or implementation of such pathway could result in delay or difficulty in getting our biosimilar product approved by regulatory authority subject to unanticipated development cost or otherwise reduce the value of the investment we have made in the biosimilars area further we can not predict whether any repeal or reform of the aca or other legislation or policy initiative would affect the biosimilar pathway or have material adverse effect on our development of biosimilars or on our marketed biosimilars in addition if we are unable to bring our biosimilar product to market on timely basis and secure first to market or other advantageous position our future biosimilar sale business and result of operation could be materially and adversely affected some of our product are used with drug delivery or companion diagnostic device that have their own regulatory manufacturing and other risk many of our product and product candidate may be used in combination with drug delivery device such an injector or other delivery system for example neulasta is available part of the neulasta onpro kit and our autotouch reusable autoinjector is used with enbrel mini single dose prefilled cartridge in addition some of our product or product candidate including many of our oncology product candidate including sotorasib may also require the use of companion or other diagnostic device such device that determines whether the patient is eligible to use our drug or that help ensure it safe and effective use in some region including the united state regulatory authority may require contemporaneous approval of the companion diagnostic device and the therapeutic product in others the regulatory authority may require separate study of the companion diagnostic device our product candidate or expanded indication of our product used with such device may not be approved or may be substantially delayed in receiving regulatory approval if development or approval of such device is delayed such device do not also gain or maintain regulatory approval or clearance or if such device do not remain commercially available when approval of the product and device is sought under single marketing drug application the increased complexity of the review process may delay receipt of regulatory approval in addition some of these device may be provided by single source unaffiliated third party company we are dependent on the sustained cooperation and effort of those third party company to supply and or market the device and in some case to conduct the study required for approval or clearance by the applicable regulatory agency we are also dependent on those third party company continuing to meet applicable regulatory or other requirement failure to successfully develop modify or supply the device delay in or failure of the amgen or third party study or failure of or the third party company to obtain or maintain regulatory approval or clearance of the device could result in increased development cost delay in or failure to obtain or maintain regulatory approval and or associated delay in product candidate reaching the market or in the addition of new indication for existing product we are also required to collect and ass user complaint adverse event and malfunction regarding our device and actual or perceived safety problem or concern with device used with our product can lead to regulatory action and adverse effect on our product see our current product and product in development can not be sold without regulatory approval additionally regulatory agency conduct routine monitoring and inspection to identify and evaluate potential issue with our device for example in the fda reported on it adverse event reporting system that it wa evaluating our neulasta onpro kit subsequently we implemented device and labeling enhancement to address product complaint received on this device we continuously monitor complaint and adverse event and implement additional enhancement needed loss of regulatory approval or clearance of device that is used with our product may also result in the removal of our product from the market further failure to successfully develop supply or gain or maintain approval for these device could adversely affect sale of the related approved product of our pharmaceutical pipeline and our commercial product sale rely on collaboration with third party which may adversely affect the development and sale of our product we depend on alliance with other company including pharmaceutical and biotechnology company vendor and service provider for the development of portion of the product in our pharmaceutical pipeline and for the commercialization and sale of certain of our commercial product for example we have collaboration with third party under which we share development right obligation and cost and or commercial right and obligation see item business business relationship failure by these party to meet their contractual regulatory or other obligation to or any disruption in the relationship between and these third party could have material adverse effect on our pharmaceutical pipeline and business in addition our collaborative relationship for and or commercialization and sale often extend for many year and have given and may in the future give rise to dispute regarding the relative right obligation and revenue of and our collaboration partner including the ownership or prosecution of intellectual property and associated right and obligation this could result in the loss of intellectual property right or protection delay the development and sale of potential pharmaceutical product affect the effective sale and delivery of our commercialized product and lead to lengthy and expensive litigation administrative proceeding or arbitration for example we are currently involved in litigation with novartis over our collaboration agreement for the development and commercialization of aimovig see part iv note contingency and commitment to the consolidated financial statement while our collaboration remains in place until the litigation is resolved and we remain committed to continuing to work with novartis to sell and deliver aimovig it is possible that the dispute may nevertheless affect the efficiency of operation and future growth of the collaboration the litigation may also affect or delay or lead to termination of other project with novartis our effort to collaborate with or acquire other company product or technology and to integrate the operation of company or to support the product or technology we have acquired may not be successful and may result in unanticipated cost delay or failure to realize the benefit of the transaction we seek innovation through significant investment in both internal and external transaction including collaboration partnering alliance license joint venture merger and acquisition collectively acquisition activity acquisition activity may be subject to regulatory approval or other requirement that are not within our control there can be no assurance that such regulatory or other approval will be obtained or that all closing condition required in connection with our acquisition activity will be satisfied or waived which could result in being unable to complete the planned acquisition activity acquisition activity are complex time consuming and expensive and may result in unanticipated cost delay or other operational or financial problem related to integrating the acquired company and business with our company which may divert our management attention from other business issue and opportunity and restrict the full realization of the anticipated benefit of such transaction within the expected timeframe or at all we may pay substantial amount of cash incur debt or issue equity security to pay for acquisition activity which could adversely affect our liquidity or result in dilution to our stockholder respectively further failure or difficulty in integrating or retaining new personnel or in integrating the operation of the business product or asset we acquire including related technology commercial operation compliance program manufacturing distribution and general business operation and procedure may affect our ability to realize the benefit of the transaction and grow our business and may result in incurring asset impairment or restructuring charge these and other challenge may arise in connection with our recent acquisition of otezla and or collaboration with beigene or with other acquisition activity which could have material adverse effect on our business result of operation and stock price risk related to operationswe perform substantial majority of our commercial manufacturing activity at our facility in the territory of puerto rico and substantial majority of our clinical manufacturing activity at our facility in thousand oak california significant disruption or production failure at these facility could significantly impair our ability to supply our product or continue our clinical trial the global supply of our product and product candidate for commercial sale and for use in our clinical trial is significantly dependent on the uninterrupted and efficient operation of our manufacturing facility in particular those in the territory of puerto rico and thousand oak california see manufacturing difficulty disruption or delay could limit supply of our product and limit our product sale currently perform substantial majority of our clinical manufacturing that support our product candidate at our facility in thousand oak california substantial disruption in our ability to operate our thousand oak manufacturing facility could materially and adversely affect our ability to supply our product candidate for use in our clinical trial leading to delay in development of our product candidate in addition we currently perform substantial majority of our commercial manufacturing activity at our facility in the territory of puerto rico in recent year puerto rico ha been affected by natural disaster including drought in mid earthquake in early and hurricane maria in these natural disaster have affected and may continue to affect public and private property and puerto rico electric grid and communication network in the future while the critical manufacturing area of our commercial manufacturing facility were not significantly affected by these natural disaster the restoration of electrical service on the island after hurricane maria wa slow process and our facility operated with electrical power from backup diesel powered generator for some time we also operated on backup generator for few week after the early earthquake in puerto rico further instability of the electric grid could require to increase the use of our generator or to continue using them exclusively in addition future storm earthquake or other natural disaster or event could cause more significant effect on our manufacturing operation puerto rico and the rest of the world are facing the effect of the covid pandemic and the associated health and economic implication since the governor of puerto rico issued executive order requiring the lockdown of business and government facility imposing restriction on business operation and curfew on resident our operation and employee have been exempted from the lockdown and curfew but we can not predict how long these order will continue in effect and impact these order and the covid pandemic will have on our future operation and whether the governor will issue future executive order imposing stricter lockdown and curfew measure should covid case rise in puerto rico although our ability to manufacture and supply our product ha not to date been significantly affected by these natural disaster or the covid pandemic combination of these challenge or other issue that could give rise to any substantial disruption to our ability to operate our puerto rico manufacturing facility or get supply and manufactured product transported to and from that location could materially and adversely affect our ability to supply our product and affect our product sale see manufacturing difficulty disruption or delay could limit supply of our product and limit our product sale hurricane maria the earthquake of early and the covid pandemic have placed greater stress on the island already challenged economy beginning in the government of puerto rico defaulted on it roughly billion in debt in response the congress passed the puerto rico oversight management and economic stability act promesa which established financial oversight and management board oversight board to provide fiscal oversight title iii of promesa provides puerto rico with judicial process for restructuring it debt similar to but not identical to chapter of the bankruptcy code including stay of debtholder litigation in the oversight board approved and certified the filing in the district court for the district of puerto rico of voluntary petition under title iii of promesa for the government of puerto rico and certain of it governmental entity including the puerto rico electric power authority which is currently undergoing privatization process of it transmission and distribution infrastructure under promesa other title iii filing for additional government entity may occur further complicating puerto rico already uncertain fiscal stability in june in response to legal challenge the supreme court ruled in favor of promesa and confirmed the constitutionality of the appointment process each year since the oversight board ha updated puerto rico fiscal plan imposing significant expense reduction each plan ha stressed the need for fiscal and structural reform to address puerto rico challenging economic and demographic trend there is pending litigation between the government of puerto rico and the oversight board with regard to the oversight board power under promesa and authority to review and prevent the enforcement of government approved legislation this litigation currently underway in the title iii court may impact how and when puerto rico will eventually restructure it debt and achieve fiscal and economic stability while the government and the oversight board have authorized emergency relief package due to the covid pandemic it is uncertain how or the degree to which the pandemic will impact puerto rico fiscal and structural reform and it economy in addition the tax act no longer permit deferral of taxation on puerto rico earnings although these earnings generally will be taxed in the united state at reduced rate given puerto rico challenged economy disaster recovery need and impact from the covid pandemic it may be difficult for puerto rico to sustain or grow it manufacturing base which contributes significantly to puerto rico economy due to competition from other location subject to similar level of taxation promesa and the action above continue to be important factor in moving puerto rico toward economic stability puerto rico ongoing economic and demographic trend challenge and political situation the effect of natural disaster the covid pandemic and the effect of the tax act or other potential tax law change have negatively affected and may in the future negatively affect the territorial government provision of utility or other service in puerto rico that we use in the operation of our business and could create the potential for increased tax or fee to operate in puerto rico result in migration of worker from puerto rico to the mainland united state or make it more expensive or difficult for to operate in puerto rico these factor could have material adverse effect on our ability to supply our product on our business and on our product sale we rely on third party supplier for certain of our raw material medical device and component we rely on unaffiliated third party supplier for certain raw material medical device and component necessary for the manufacturing of our commercial and clinical product certain of those raw material medical device and component are proprietary product of those unaffiliated third party supplier and are specifically cited in our drug application with regulatory agency so that they must be obtained from that specific sole source or source and could not be obtained from another supplier unless and until the regulatory agency approved such supplier for example scandinavian health limited group is our single source of sureclick autoinjector for repatha enbrel aimovig amgevitatm and aranesp also certain of the raw material required in the commercial and clinical manufacturing of our product are sourced from other country and or derived from biological source including mammalian tissue bovine serum and human serum albumin among the reason we may be unable to obtain these raw material medical device and component include regulatory requirement or action by regulatory agency or others adverse financial or other strategic development at or affecting the supplier including bankruptcy unexpected demand for or shortage of raw material medical device or component failure to comply with our quality standard which result in quality and product failure product contamination and or recall material shortage contamination recall and or restriction on the use of certain biologically derived substance or other raw material discovery of previously unknown or undetected imperfection in raw material medical device or component cyberattacks on supplier system and labor dispute or shortage including from the effect of health emergency such novel virus or pandemic such the one we are currently experiencing with covid and natural disaster for example in prior year we have experienced shortage in certain component necessary for the formulation fill and finish of certain of our product in our puerto rico facility further quality issue that result in unexpected additional demand for certain component may lead to shortage of required raw material or component such we have experienced with epogen glass vial we may experience similar or other shortage in the future resulting in delayed shipment supply constraint clinical trial delay contract dispute and or stock out of our product these or other similar event could negatively affect our ability to satisfy demand for our product or conduct clinical trial which could have material adverse effect on our product sale business and result of operation manufacturing difficulty disruption or delay could limit supply of our product and limit our product sale manufacturing biologic and small molecule human therapeutic product is difficult complex and highly regulated we manufacture many of our commercial product and product candidate internally in addition we currently use third party contract manufacturer to produce or assist in the production of number of our product and we currently use contract manufacturer to produce or assist in the production of number of our late stage product candidate and drug delivery device see item business manufacturing distribution and raw material manufacturing our ability to adequately and timely manufacture and supply our product and product candidate to support our clinical trial is dependent on the uninterrupted and efficient operation of our facility and those of our third party contract manufacturer which may be affected by capacity of manufacturing facility contamination by microorganism or virus or foreign particle from the manufacturing process natural or other disaster including hurricane earthquake volcano or fire labor dispute or shortage including the effect of health emergency such novel virus or pandemic such the one we are currently experiencing with covid or natural disaster compliance with regulatory requirement change in forecast of future demand timing and actual number of production run and production success rate and yield update of manufacturing specification contractual dispute with our supplier and contract manufacturer timing and outcome of product quality testing power failure and or other utility failure cyberattacks on supplier system breakdown failure substandard performance or improper installation or operation of equipment including our information technology system and network connected control system or those of our contract manufacturer or third party service provider and or delay in the ability of the fda or foreign regulatory agency to provide necessary review inspection and approval including result of subsequent extended federal or other government shutdown if any of these or other problem affect production in one or more of our facility or those of our third party contract manufacturer or if we do not accurately forecast demand for our product or the amount of our product candidate required in clinical trial we may be unable to start or increase production in our unaffected facility to meet demand if the efficient manufacture and supply of our product or product candidate is interrupted we may experience delayed shipment delay in our clinical trial supply constraint stock out adverse event trend contract dispute and or recall of our product from time to time we have initiated recall of certain lot of our product for example in july we initiated voluntary recall of an aranesp lot distributed in the eu after particle were detected in quality control sample following distribution of that lot and in april we initiated precautionary recall of two batch of vectibix distributed in switzerland after potential crimping defect were discovered in the metal seal on some product vial if we are at any time unable to provide an uninterrupted supply of our product to patient we may lose patient and physician may elect to prescribe competing therapeutic instead of our product which could have material adverse effect on our product sale business and result of operation our manufacturing process those of our third party contract manufacturer and those of certain of our third party service provider must undergo regulatory approval process and are subject to continued review by the fda and other regulatory authority it can take longer than five year to build validate and license another manufacturing plant and it can take longer than three year to qualify and license new contract manufacturer or service provider if we elect or are required to make change to our manufacturing process because of new regulatory requirement new interpretation of existing requirement or other reason this could increase our manufacturing cost and result in delayed shipment delay in our clinical trial supply constraint stock out adverse event trend or contract negotiation or dispute such manufacturing challenge may also occur if our existing contract manufacturer are unable or unwilling to timely implement such change or at all addition regulatory agency conduct routine monitoring and conduct inspection of our manufacturing facility and process well those of our third party contract manufacturer and service provider if regulatory authority determine that we or our third party contract manufacturer or certain of our third party service provider have violated regulation they may mandate corrective action and or issue warning letter or even restrict suspend or revoke our prior approval prohibiting from manufacturing our product or conducting clinical trial or selling our marketed product until we or the affected third party contract manufacturer or third party service provider comply or indefinitely see also our current product and product in development can not be sold without regulatory approval such issue may also delay the approval of product candidate we have submitted for regulatory review even if such product candidate are not directly related to the product device or process at issue with regulator because our third party contract manufacturer and certain of our third party service provider are subject to the fda and foreign regulatory authority alternative qualified third party contract manufacturer and third party service provider may not be available on timely basis or at all if we or our third party contract manufacturer or third party service provider cease or interrupt production or if our third party contract manufacturer and third party service provider fail to supply material product or service to we may experience delayed shipment delay in our clinical trial supply constraint contract dispute stock out and or recall of our product additionally we distribute substantial volume of our commercial product through our primary distribution center in louisville kentucky for the united state and in breda netherlands for europe and much of the rest of the world we also conduct most of the labeling and packaging of our product distributed in europe and much of the rest of the world in breda our ability to timely supply product is dependent on the uninterrupted and efficient operation of our distribution and logistics center our third party logistics provider and our labeling and packaging facility in breda further we rely on commercial transportation including air and sea freight for the distribution of our product to our customer which may be negatively affected by natural disaster security threat and or the ongoing covid pandemic there have also been legislative and administrative proposal seeking to incentivize greater drug manufacturing in the united state with the stated goal of improving supply reliability in the united state for example on august the previous administration issued an executive order aimed at boosting domestic production of essential medicine medical countermeasure and critical input titled executive order on ensuring essential medicine medical countermeasure and critical input are made in the united state additionally one legislative proposal would prohibit the department of veteran affair from purchasing certain drug that have active pharmaceutical ingredient manufactured outside the united state while we perform substantial majority of our commercial manufacturing activity in the united state including in the territory of puerto rico and substantial majority of our clinical manufacturing activity at our facility in thousand oak california the passage of such legislation could result in foreign government enacting retaliatory legislation or regulatory action which may have an adverse effect on our product sale business and result of operation general risk factorsglobal economic condition may negatively affect and may magnify certain risk that affect our business our operation and performance have been and may continue to be affected by global economic condition the economic downturn resulting from the covid pandemic ha precipitated global recession which may be of an extended duration additionally financial pressure may cause government or other third party payer to more aggressively seek cost containment measure see our sale depend on coverage and reimbursement from third party payer and pricing and reimbursement pressure may affect our profitability result of global economic condition some third party payer may delay or be unable to satisfy their reimbursement obligation job loss or other economic hardship may also affect patient ability to afford health care result of increased co pay or deductible obligation greater cost sensitivity to existing co pay or deductible obligation lost healthcare insurance coverage or for other reason we believe such condition have led and could continue to lead to reduced demand for our product which could have material adverse effect on our product sale business and result of operation economic condition may also adversely affect the ability of our distributor customer and supplier to obtain the liquidity required to buy inventory or raw material and to perform their obligation under agreement with which could disrupt our operation although we monitor our distributor customer and supplier financial condition and their liquidity to mitigate our business risk some of our distributor customer and supplier may become insolvent which could have material adverse effect on our product sale business and result of operation significant worsening of global economic condition could materially increase these risk facing we maintain significant portfolio of investment disclosed cash equivalent and marketable security on our consolidated balance sheet the global spread of covid ha also led to disruption and volatility in the global capital market we have certain asset including equity investment that are exposed to market fluctuation that could in sustained or recurrent series of market disruption result in impairment the value of our investment may also be adversely affected by interest rate fluctuation downgrade in credit rating illiquidity in the capital market and other factor that may result in other than temporary decline in the value of our investment any of those event could cause to record impairment charge with respect to our investment portfolio or to realize loss on sale of investment stock price is volatile our stock price like that of our peer in the biotechnology and pharmaceutical industry is volatile our revenue and operating result may fluctuate from period to period for number of reason event such delay in product development change to our expectation or strategy or even relatively small revenue shortfall may cause financial result for period to be below our expectation or projection result our revenue and operating result and in turn our stock price may be subject to significant fluctuation announcement or discussion including via social medium channel of possible restrictive action by government or private payer that would negatively affect our business or industry if ultimately enacted or adopted may also cause our stock price to fluctuate whether or not such restrictive action ever actually occur similarly actual or perceived safety issue with our product or similar product or unexpected clinical trial result can have an immediate and rapid effect on our stock price whether or not our operating result are materially affected we may not be able to access the capital and credit market on term that are favorable to or at all the capital and credit market may experience extreme volatility and disruption which may lead to uncertainty and liquidity issue for both borrower and investor for example early in there were significant disruption in the commercial paper market and several borrower were unable to obtain funding at normal rate or maturity which resulted in significant increase in draw of corporate credit line with bank similarly the bond market experienced extreme volatility in term of interest rate and credit spread with several day without new issuance of corporate bond we expect to access the capital market from time to time to supplement our existing fund and cash generated from operation in satisfying our need for working capital capital expenditure and debt service requirement our plan to pay dividend and repurchase stock and other business initiative we strategically plan to pursue including acquisition and licensing activity in the event of adverse capital and credit market condition we may be unable to obtain capital market financing on similar favorable term or at all which could have material adverse effect on our business and result of operation change in credit rating issued by nationally recognized credit rating agency could adversely affect our ability to obtain capital market financing and the cost of such financing and have an adverse effect on the market price of our security item unresolved staff commentsnone propertiesas of december we owned or leased approximately property the location and primary function of significant property are summarized in the following table location manufacturingadministrativer dsales marketingwarehousedistribution centerthousand oak ca ppppppsan francisco caplouisville kyppcambridge mapwoburn mappjuncos puerto ricoppppwest greenwich rippptampa flpother citiespp corporate headquartersex location manufacturingadministrativer dsales marketingwarehousedistribution centerbrazilpppppcanadapppchina ppgermanypppicelandppirelandppppjapanpppnetherlandspppppsingaporeppppswitzerlandppturkeypppppunited kingdompppother countriesppppexcluded from the information above are undeveloped land and leased property that have been abandoned and ii certain building we still own but that are no longer used in our business there are no material encumbrance on our owned property we believe our facility are suitable for their intended us and in conjunction with our third party contract manufacturing agreement provide adequate capacity and are sufficient to meet our expected need see item risk factor for discussion of the factor that could adversely impact our manufacturing operation and the global supply of our product see item business manufacturing distribution and raw material item legal proceedingscertain of the legal proceeding in which we are involved are discussed in part iv note contingency and commitment to the consolidated financial statement and are hereby incorporated by reference item mine safety disclosuresnot applicable iiitem market for registrant common equity related stockholder matter and issuer purchase of equity securitiescommon stockour common stock trade on the nasdaq global select market under the symbol amgn of february there were approximately holder of record of our common stock performance graphthe following graph show the value of an investment of on december in each of amgen common stock the amex biotech index the amex pharmaceutical index and standard poor index all value assume reinvestment of the pretax value of dividend and are calculated of december of each year the historical stock price performance of the company common stock shown in the performance graph is not necessarily indicative of future stock price performance amgn biotech btk pharmaceutical drg spx material in this performance graph is not soliciting material is not deemed filed with the sec and is not incorporated by reference in any filing of the company under the security act or the exchange act whether made on before or after the date of this filing and irrespective of any general incorporation language in such filing stock repurchase programduring the three month and year ended december we had one outstanding stock repurchase program under which the repurchasing activity wa follows totalnumber ofsharespurchasedaverageprice paidper share total numberof sharespurchased aspart ofpubliclyannouncedprogrammaximum dollarvalue that mayyet be purchasedunder theprogram october october november november december december january december average price paid per share includes related expense in december our board of director increased the amount authorized under the stock repurchase program by an additional billion dividendsfor the year ended december and we paid quarterly dividend we expect to continue to pay quarterly dividend although the amount and timing of any future dividend are subject to approval by our board of director additional information required by this item is incorporated herein by reference to part iv note stockholder equity to the consolidated financial statement security authorized for issuance under existing equity compensation plansinformation about security authorized for issuance under existing equity compensation plan is incorporated by reference from item security authorized for issuance under existing equity compensation plan selected financial data year ended december consolidated statement of income data in million except per share data revenue product sale other total revenue operating expense cost of sale research and development selling general and administrative net income diluted earnings per share dividend paid per share of december consolidated balance sheet data in million total asset total debt total stockholder equity in we recorded net charge of billion result of the tax act see part iv note financing arrangement to the consolidated financial statement for discussion of our financing arrangement in and in we issued billion of debt and repaid billion of debt in we issued billion of debt and repaid billion of debt throughout the five year ended december we had stock repurchase program authorized by the board of director through which we repurchased billion billion billion billion and billion respectively of amgen common stock in addition to the above note see item management discussion and analysis of financial condition and result of operation part iv consolidated financial statement and accompanying note well previously filed annual report on form for further information regarding our consolidated result of operation and financial position for period reported therein and for known factor that will affect the comparability of future result also see part iv note stockholder equity to the consolidated financial statement for information regarding cash dividend declared per share of common stock for each of the four quarter of and in addition our board of director declared dividend per share of and which were paid in each of the four quarter of and respectively management discussion and analysis of financial condition and result of operationsthe following management discussion and analysis md is intended to assist the reader in understanding amgen business md is provided supplement to and should be read in conjunction with our consolidated financial statement and accompanying note our result of operation discussed in md are presented in conformity with generally accepted accounting principle gaap amgen operates in one business segment human therapeutic therefore our result of operation are discussed on consolidated basis forward looking statementsthis report and other document we file with the sec contain forward looking statement that are based on current expectation estimate forecast and projection about our future performance our business our belief and our management assumption in addition we or others on our behalf may make forward looking statement in press release written statement or our communication and discussion with investor and analyst in the normal course of business through meeting webcasts phone call and conference call such word expect anticipate outlook could target project intend plan believe seek estimate should may assume and continue well variation of such word and similar expression are intended to identify such forward looking statement these statement are not guarantee of future performance and they involve certain risk uncertainty and assumption that are difficult to predict we describe our respective risk uncertainty and assumption that could affect the outcome or result of operation in part item risk factor we have based our forward looking statement on our management belief and assumption based on information available to our management at the time the statement are made we caution you that actual outcome and result may differ materially from what is expressed implied or forecasted by our forward looking statement reference is made in particular to forward looking statement regarding product sale regulatory activity clinical trial result reimbursement expense earnings per share eps liquidity and capital resource trend planned dividend stock repurchase collaboration and effect of pandemic except required under the federal security law and the rule and regulation of the sec we do not have any intention or obligation to update publicly any forward looking statement after the distribution of this report whether result of new information future event change in assumption or otherwise amgen is biotechnology company committed to unlocking the potential of biology for patient suffering from serious illness biotechnology pioneer since amgen ha grown to be one of the world leading independent biotechnology company ha reached million of patient around the world and is developing pipeline of medicine with breakaway potential in we celebrated our anniversary continuing our history of focusing on innovative medicine that have the potential to be first in class molecule and that have large effect size on serious disease our principal product those with the most significant annual commercial sale are enbrel prolia neulasta otezla xgeva aranesp kyprolis and repatha we also market number of other product including nplate vectibix mvasi parsabiv epogen kanjinti blincyto aimovig evenity amgevitatm sensipar mimpara neupogen imlygic corlanor and avsola for additional information about our product see part item business marketing distribution and selected marketed product our strategy includes integrated activity intended to maintain and strengthen our competitive position in the industry we focus on six commercial area inflammation oncology hematology bone health cv disease nephrology and neuroscience and we conduct discovery research primarily in three therapeutic area inflammation oncology hematology and cv metabolic disease in we advanced our innovative pipeline successfully integrated otezla acquired in november into our inflammation portfolio advanced our international expansion and continued to provide uninterrupted supply of our medicine globally through the covid pandemic we accomplished these objective while maintaining strategic and disciplined approach to capital allocation and advancing our environmental social and governance effort during the year while meeting the challenge of global pandemic and facing increased competition from biosimilars and generic total product sale increased driven by volume growth primarily from otezla partially offset by lower net selling price product sale increased and in the united state and rest of the world respectively total operating expense increased driven by expense related to otezla we continued to advance our pipeline including sotorasib and tezepelumab two molecule with respect to which we have achieved positive registration enabling data from our clinical trial activity we also continued to advance our biosimilar program with the launch of avsola and the approval of riabnitm in the united state our biosimilars are expected to launch in new market throughout lastly we broadened our international reach particularly in the asia pacific region with our investment in and strategic collaboration with beigene to expand our oncology presence in china well the establishment of our wholly owned affiliate in japan cash flow from operating activity totaled billion enabling to invest in our business while returning capital to shareholder through the payment of cash dividend and stock repurchase for we increased our quarterly cash dividend by to per share of common stock in december we declared cash dividend of per share of common stock for the first quarter of an increase of for this period to be paid in march we also repurchased million share of our common stock throughout at an aggregate cost of billion during the year we had proceeds from the issuance of debt of billion and repayment of debt of billion in addition we exchanged some of our higher interest rate debt for newly issued debt with lower interest rate and later maturity date amgen approach to and investment in human capital resource management is directed at attracting motivating and retaining talent to tackle the challenge of running an enterprise focused on the discovery development and commercialization of innovative medicine our compensation benefit and development program are designed to encourage performance promote accountability and adherence to company value and in alignment with the interest of the company shareholder further we believe that diverse and inclusive culture foster innovation which support our ability to serve patient we also believe our global presence is strengthened by having workforce that reflects the diversity of the patient we serve it is with these belief in mind that we have continued to strengthen and grow our culture of diversity inclusion and belonging our internal effort include in establishing diversity inclusion and belonging council we are engaging in activity and setting goal to improve our focus on diversity inclusion and belonging for further information on these and other effort see part item business human capital resource have long standing ambition to be environmentally responsible and we regularly set target to challenge to deliver further improvement in we met or exceeded our environmental sustainability target set out in that called for reducing fleet carbon output by up to facility carbon output by water consumption by and waste disposal by we achieved our target while growing revenue increasing production capacity and expanding to more than country over the same to period to continue on our path to greater environmental sustainability in january we announced new set of long term environmental target to achieve by including achieving carbon neutrality reducing water consumption by and reducing waste disposed by our long term success depends to great extent on our ability to continue to discover develop and commercialize innovative product and acquire or collaborate on therapy currently in development by other company we must develop new product to achieve revenue growth and to offset revenue loss when product lose their exclusivity or when competing product are launched certain of our product face increasing pressure from competition including biosimilars and generic for additional information including information on the expiration of patent for various product see part item business marketing distribution and selected marketed product patent and part item business marketing distribution and selected marketed product competition we devote considerable resource to activity but successful product development in the biotechnology industry is highly uncertain we also face increasing regulatory scrutiny of safety and efficacy both before and after product launch rising healthcare cost and uncertain economic condition continue to pose challenge to our business including increasing pressure by third party payer such government and private payer to reduce healthcare expenditure result of public and private healthcare provider focus the industry continues to experience significant pricing pressure and other cost containment measure finally wholesale and end user buying pattern can affect our product sale these effect can cause fluctuation in quarterly product sale and have generally not been significant when comparing full year product performance to the prior year see part item business marketing distribution and selected marketed product and part item risk factor for further discussion of certain factor that could impact our future product sale covid pandemicthe covid pandemic ha had moderate impact to our business in since the onset of the pandemic in early we have been carefully monitoring it impact on our global operation we have taken appropriate step to minimize the risk to our employee significant number of our employee have been working remotely with the exception of certain staff that require access to our manufacturing and laboratory research facility in accordance with applicable government health and safety protocol and guidance issued in response to the covid pandemic to date our remote working arrangement have not significantly affected our ability to maintain critical business operation and we have not experienced disruption or shortage of our supply of medicine since the beginning of the covid pandemic we have seen change in demand trend for some of our product including lower demand for certain product continuing patient access to those product ha been affected by covid particularly in the early phase of the pandemic for example near the end of march we began to observe decline in sale of prolia elderly patient who are relatively more vulnerable to covid avoided doctor office demand ha since recovered to varying degree by product local condition improved in certain geography that opened after an initial improvement in covid infection rate allowing patient to resume receiving their treatment during the second half of the year our own effort remain focused on assisting patient with improving their continuity of care to increase product access compared to what they experienced during the earlier stage of the pandemic recently higher rate of infection have been observed in certain geography including the united state and europe which may further restrict demand similar to early phase of the pandemic result we expect to see continued volatility through at least the duration of the pandemic government respond to current local condition represents reduction against established baseline taking into account only verified reduction project and doe not take into account change associated with contraction or expansion of the company majority of clinical trial that were paused at the onset of the pandemic to ensure subject safety or data integrity have resumed study enrollment wa affected negatively the most in the second quarter of the year and by the end of resumed to around pre pandemic level however going forward covid infection rate and related vaccination activity may impact future study enrollment we continuously monitor our ability for study enrollment on an institution by institution basis and reevaluate the status of study pausing when uncertainty arises with regard to the trial site ability to ensure safety or data integrity we remain focused on supporting our active clinical site in providing care for these patient and in providing investigational drug supply in addition our organization is supporting effort to combat the covid pandemic in number of way including by working to support production of therapeutic antibody that could diminish the impact of covid on patient ii joining public private partnership between leading company in our industry and government health agency to develop strategy for coordinated research response and iii participating in platform study to investigate treatment in adult patient hospitalized with severe covid infection we continue to believe that existing fund cash generated from operation and existing source of and access to financing are adequate to satisfy our need for working capital capital expenditure and debt service requirement well to engage in the capital return and other business initiative that we plan to strategically pursue for discussion of the risk presented by the covid pandemic to our result see part item risk factor of this form financial informationthe following is an overview of our result of operation in million except percentage and per share data year ended december ended december sale rest of world row total product other total revenue operating expense operating income net income diluted eps diluted in the following discussion of change in product sale any reference to unit demand growth or decline refers to change in the purchase of our product by healthcare provider such physician or their clinic dialysis center hospital and pharmacy in addition any reference to increase or decrease in inventory refers to change in inventory held by wholesaler customer and end user such pharmacy total product sale increased for primarily driven by unit demand increase from newer brand including otezla acquired in november mvasi kanjinti and repatha these unit demand increase were partially offset by decline in net selling price for certain product unit demand decline for mature brand that face biosimilar or generic competition and the effect of the covid pandemic for we expect that net selling price will continue to decline we also expect increasing competition against our biosimilar product further the first quarter historically represents the lowest product sale quarter for the year in part due to plan change insurance reverifications and higher co pay expense patient work through deductible particularly for our pharmacy benefit product during the initial stage of the covid pandemic we experienced change in demand trend for some of our product the pandemic interrupted many physician patient interaction which led to delay in diagnosis and treatment with varying degree of impact across our portfolio in general sale of negatively affected product fell the most in the early part of the second quarter with product demand beginning to show some recovery in the second half of the year but still below pre pandemic level nevertheless given the increased intensity exiting and the unpredictable nature of the pandemic we expect there could be intermittent disruption in physician patient interaction going forward and thus we continue to expect quarter to quarter variability see part item risk factor of this form in addition other change in the healthcare ecosystem introduce variability into product sale trend for example change in employment could lead to change to the insured population with growth in medicaid enrollee and uninsured individual having negative impact on revenue overall uncertainty ha increased around the timing and magnitude of our sale during the covid pandemic other revenue increased for primarily driven by higher royalty operating expense increased for primarily driven by acquisition and commercial related expense for otezla although change in foreign currency exchange rate result in increase or decrease in our reported international product sale the benefit or detriment that such movement have on our international product sale is partially offset by corresponding increase or decrease in our international operating expense and our related foreign currency hedging activity our hedging activity seek to offset the impact both positive and negative that foreign currency exchange rate change may have on our net income by hedging our net foreign currency exposure primarily with respect to product sale denominated in euro the net impact from change in foreign currency exchange rate wa not material in or of operationsproduct salesworldwide product sale were follows dollar amount in million year ended december ended december ended december prolia neulasta otezla xgeva aranesp kyprolis repatha other total product sale total total total product sale change in excess of future sale of our product will depend in part on the factor discussed in the overview part item business marketing distribution and selected marketed product competition in part item risk factor and any additional factor discussed in the individual product section below in addition for list of our product significant competitor see part item business marketing distribution and selected marketed product competition enbreltotal enbrel sale by geographic region were follows dollar amount in million year ended december ended december ended december enbrel total enbrel the decrease in enbrel sale for wa driven by lower unit demand and net selling price partially offset by favorable change to estimated sale deduction and inventory consistent with prior period enbrel ha continued to lose market share and this decline ha been compounded by reduction in the growth rate of the rheumatology market result of covid for we expect enbrel to follow the historic pattern of lower sale in the first quarter relative to subsequent quarter due to the impact of benefit plan change insurance reverification and increase co pay expense patient work through deductible in addition for we expect volume and net selling price decline to continue the increase in enbrel sale for wa primarily driven by favorable change to estimated sale deduction and an increase in net selling price partially offset by lower unit demand in april the fda approved second biosimilar version of enbrel and we are involved in patent litigation with the two company seeking to market their fda approved biosimilar version of enbrel see part iv note contingency and commitment to the consolidated financial statement company with approved biosimilar version of enbrel may seek to enter the market if we are not successful in our litigation or even earlier other company are also developing proposed biosimilar version of enbrel total prolia sale by geographic region were follows dollar amount in million year ended december ended december ended december prolia total prolia disruption in patient visit result of the covid pandemic affected demand during by altering the timing of patient receiving their semiannual dos and by lowering the diagnosis of osteoporosis in new patient this deceleration of demand ha softened the historical growth rate and altered demand pattern of prolia experienced in year prior to the pandemic for historical demand pattern may continue to be impacted by the pandemic the increase in global prolia sale for wa driven by higher unit demand and net selling price the increase in global prolia sale for wa driven by higher unit demand neulasta total neulasta sale by geographic region were follows dollar amount in million year ended december ended december ended december neulasta total neulasta the decrease in global neulasta sale for and were driven by the impact of biosimilar competition on net selling price and unit demand neulasta sale included million order from the government in the first quarter of we have increased competition in the united state and europe result of biosimilar version of neulasta which ha had and will continue to have material adverse impact on sale we also expect other biosimilar version to be approved in the future for discussion of ongoing patent litigation related to these and other biosimilars see part iv note contingency and commitment to the consolidated financial statement otezla total otezla sale by geographic region were follows dollar amount in million year ended december ended december ended december otezla total otezla change in excess of otezla wa acquired on november and generated billion and million in global sale for the year ended december and respectively for we expect otezla to follow the historic pattern of lower sale in the first quarter relative to subsequent quarter due to the impact of benefit plan change insurance reverification and increase co pay expense patient work through deductible for discussion of ongoing litigation related to otezla see part iv note contingency and commitment to the consolidated financial statement total xgeva sale by geographic region were follows dollar amount in million year ended december ended december ended december xgeva total xgeva the decrease in global xgeva sale for wa driven by lower unit demand result of the covid pandemic the increase in global xgeva sale for wa primarily driven by higher unit demand aranesp total aranesp sale by geographic region were follows dollar amount in million year ended december ended december ended december aranesp total aranesp the decrease in global aranesp sale for wa driven by decline in net selling price and unit demand the decrease in global aranesp sale for wa primarily driven by the impact of competition on unit demand in the united state aranesp face competition from long acting esa aranesp also face competition from biosimilar version of epogen for we expect that sale will continue to decline due to short and long acting competition kyprolis total kyprolis sale by geographic region were follows dollar amount in million year ended december ended december ended december kyprolis total kyprolis the increase in global kyprolis sale for wa primarily driven by an increase in net selling price and favorable change in inventory partially offset by lower unit demand the increase in global kyprolis sale for wa primarily driven by higher unit demand we are engaged in litigation with two company that are challenging certain of our patent related to kyprolis and that are seeking to market generic carfilzomib product separately we have entered into confidential settlement agreement with other company developing generic carfilzomib product and the court ha entered consent judgment enjoining those company from infringing certain of our patent subject to term of the confidential settlement agreement see part iv note contingency and commitment to the consolidated financial statement the fda reported that it ha granted tentative or final approval to abbreviated new drug application andas for generic carfilzomib product filed by number of company for generic carfilzomib product the date of approval of those andas for generic carfilzomib product is governed by the hatch waxman act and any applicable settlement agreement between the party total repatha sale by geographic region were follows dollar amount in million year ended december ended december ended december repatha total repatha the increase in global repatha sale for and were driven by higher unit demand partially offset by lower net selling price the decrease to the repatha net selling price in wa the result of contracting change to improve medicare part patient access for discussion of ongoing litigation related to repatha see part iv note contingency and commitment to the consolidated financial statement other productsother product sale by geographic region were follows dollar amount in million year ended december ended december ended december nplate vectibix vectibix mvasi mvasi parsabiv parsabiv epogen kanjinti kanjinti blincyto blincyto aimovig evenity evenity amgevitatm sensipar sensipar mimpara neupogen neupogen other other total other product sale total other product total row other total other product sale change in excess of expensesoperating expense were follows dollar amount in million year ended december ended december ended december expense cost of sale of product of total research and development of product of total selling general and administrative of product of total other change in excess of cost of salescost of sale increased to of total revenue for primarily driven by the amortization of expense related to our acquisition of otezla and higher royalty expense and profit share partially offset by lower manufacturing cost cost of sale increased to of total revenue for primarily driven by unfavorable product mix and amortization of intangible asset result of our acquisition of otezla partially offset by lower royalty and lower manufacturing cost research and developmentthe company group all of it activity and related expenditure into three category research and early pipeline ii later stage clinical program and iii marketed product these category are described below categorydescriptionresearch and early pipeline expense incurred in activity substantially in support of early research through the completion of phase clinical trial including drug discovery toxicology pharmacokinetics and drug metabolism and process developmentlater stage clinical programsr expense incurred in or related to phase and phase clinical program intended to result in registration of new product or new indication for an existing product primarily in the united state or the eumarketed productsr expense incurred in support of the company marketed product that are authorized to be sold primarily in the united state or the eu includes clinical trial designed to gather information on product safety certain of which may be required by regulatory authority and their product characteristic after regulatory approval ha been obtained well the cost of obtaining regulatory approval of product in new market after approval in either the united state or the eu ha been obtainedr expense by category wa follows in million year ended december and early pipeline later stage clinical marketed total expense increase in expense for wa driven by higher spend for later stage clinical program including sotorasib biosimilar program and otezla and higher spend for otezla included in marketed product support these increase were partially offset by recovery from our collaboration with beigene that reduced expense in later stage clinical program and in research and early pipeline and lower spend in certain oncology program included in research and early pipeline the increase in expense for wa primarily driven by higher spend in research and early pipeline in support of our oncology program partially offset by lower marketed product support selling general and administrativethe increase in selling general and administrative sg expense for wa driven by investment in certain marketed product primarily otezla and preparation for product launch partially offset by reduction in conference related expense due to the impact of covid the decrease in sg expense for wa primarily driven by lower general and administrative expense the end of certain amortization charge in and lower spend for launched and marketed product partially offset by spending for otezla commercial related expense otherother operating expense for primarily consisted of legal settlement expense other operating expense for included million in restructuring cost other operating expense for included million impairment charge associated with an ipr asset and million favorable net change in the fair value of contingent consideration liability see part iv note fair value measurement to the consolidated financial statement nonoperating expense income and income taxesnonoperating expense income and income tax were follows dollar amount in million year ended december expense net interest and other income net provision for income tax effective tax interest expense netthe decrease in interest expense net for wa primarily due to lower libor rate on debt for which we effectively pay variable rate of interest partially offset by net cost associated with the early retirement of debt the decrease in interest expense net for wa primarily due to reduction in outstanding long term debt result of maturity in interest and other income netthe decrease in interest and other income net for wa primarily due to reduced interest income result of lower average cash balance and decline in interest yield and loss incurred in connection with our beigene investment partially offset by gain recognized on our investment in publicly traded equity security and limited partnership we may continue to recognize loss in connection with our beigene investment in see part iv note investment to the consolidated financial statement the increase in interest and other income net for wa primarily due to net gain on sale of investment in interest bearing security liquidated to fund our acquisition of otezla and our investment in beigene compared with loss in the prior year partially offset by reduced interest income result of lower average cash balance and gain recognized in connection with our acquisition of kirin amgen inc in the first quarter of see part iv note acquisition to the consolidated financial statement taxesthe decrease in our effective tax rate for compared with wa primarily driven by favorable item including audit settlement adjustment to prior year tax liability lower interest expense on uncertain tax position and amortization related to the otezla acquisition partially offset by change in valuation allowance the increase in our effective tax rate for compared with wa primarily driven by prior year tax benefit associated with intercompany sale under corporate tax reform in march and december in response to the covid pandemic the care act and the consolidated appropriation act were passed into law and provide additional economic stimulus to address the impact of the covid pandemic we do not expect any significant benefit to our income tax provision result of this legislation in we received an rar and modified rar from the irs for the year and proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico we disagree with the proposed adjustment and calculation and have been pursuing resolution with the irs administrative appeal office however we have been unable to reach resolution at the administrative appeal level and we anticipate that we will receive notice of deficiency which we would expect to vigorously contest through the judicial process in addition in we received an rar and modified rar from the irs for the year and also proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico similar to those proposed for the year and we disagree with the and proposed adjustment and calculation and are pursuing resolution with the irs administrative appeal office the irs audit for year and is expected to start in the near term we are also currently under examination by number of other state and foreign tax jurisdiction final resolution of these complex matter is not likely within the next month we believe our accrual for income tax liability is appropriate based on past experience interpretation of tax law application of the tax law to our fact and judgment about potential action by tax authority however due to the complexity of the provision for income tax and uncertain resolution of these matter the ultimate outcome of any tax matter may result in payment substantially greater than amount accrued and could have material adverse impact on our consolidated financial statement see summary of critical accounting policy income tax and part iv note income tax to the consolidated financial statement financial condition liquidity and capital resourcesselected financial data wa follows in million december cash equivalent and marketable security total asset current portion of long term debt long term debt stockholder equity cash cash equivalent and marketable securitieswe have global access to our billion balance of cash cash equivalent and marketable security the primary objective of our investment portfolio is to maintain safety of principal prudent level of liquidity and acceptable level of risk our investment policy limit interest bearing security investment to certain type of debt and money market instrument issued by institution with primarily investment grade credit rating and it place restriction on maturity and concentration by asset class and issuer capital allocationconsistent with the objective to optimize our capital structure we deploy our accumulated cash balance in strategic manner and consider number of alternative including strategic transaction including those that expand our portfolio of product in area of therapeutic interest repayment of debt payment of dividend and stock repurchase intend to continue to invest in our business while returning capital to stockholder through the payment of cash dividend and stock repurchase thereby reflecting our confidence in the future cash flow of our business the timing and amount of future dividend and stock repurchase will vary based on number of factor including future capital requirement for strategic transaction availability of financing on acceptable term debt service requirement our credit rating change to applicable tax law or corporate law change to our business model and periodic determination by our board of director that cash dividend and or stock repurchase are in the best interest of stockholder and are in compliance with applicable law and the company agreement in addition the timing and amount of stock repurchase may also be affected by our overall level of cash stock price and blackout period during which we are restricted from repurchasing stock the manner of stock repurchase may include private block purchase tender offer and market transaction the board of director declared quarterly cash dividend of and per share of common stock paid in and respectively an increase of over the prior year in both and in december the board of director declared cash dividend of per share of common stock for the first quarter of an increase of for this period to be paid in march we also returned capital to stockholder through our stock repurchase program during we repurchased billion of common stock and had cash settlement of billion in we repurchased billion of common stock and had cash settlement of billion in we repurchased billion of common stock and had cash settlement of billion which included million share of common stock repurchased through billion tender offer in may and december our board of director increased the amount authorized under our stock repurchase program by an additional billion and billion respectively of december billion remained available under the stock repurchase program result of stock repurchase and quarterly dividend payment we have an accumulated deficit of december and our accumulated deficit is not anticipated to affect our future ability to operate repurchase stock pay dividend or repay our debt given our expected continued profitability and strong financial position we believe that existing fund cash generated from operation and existing source of and access to financing are adequate to satisfy our need for working capital capital expenditure and debt service requirement our plan to pay dividend and repurchase stock and other business initiative we plan to strategically pursue including acquisition and licensing activity we anticipate that our liquidity need can be met through variety of source including cash provided by operating activity sale of marketable security borrowing through commercial paper and or syndicated credit facility and access to other domestic and foreign debt market and equity market see part item risk factor global economic condition may negatively affect and may magnify certain risk that affect our business financing arrangementsthe current and noncurrent portion of our long term borrowing of december were billion and billion respectively the current and noncurrent portion of our long term borrowing of december were billion and billion respectively the carrying value of our long term borrowing are net of fair value adjustment for interest rate swap and unamortized discount premium and offering cost of december standard poor financial service llc moody investor service inc moody and fitch rating inc fitch assigned credit rating to our outstanding senior note of with stable outlook with stable outlook and bbb with stable outlook respectively which are considered investment grade unfavorable change to these rating may have an adverse impact on future financing during we issued debt with an aggregate principal amount of billion during and we did not issue any debt or debt security during and we repaid debt of billion billion and billion respectively in addition during we exchanged billion of certain of our outstanding note issuance with billion of newly issued note with lower interest rate and later maturity date to achieve desired mix of fixed rate and floating rate debt we entered into interest rate swap contract that effectively converted fixed rate interest coupon for certain of our debt issuance to floating libor based coupon over the life of the respective note these interest rate swap contract qualify and are designated fair value hedge of december and we had interest rate swap contract with aggregate notional amount of billion and billion respectively to hedge our exposure to foreign currency exchange rate risk associated with certain of our long term note denominated in foreign currency we entered into cross currency swap contract which effectively convert the interest payment and principal repayment of the respective note from euro pound sterling and swiss franc to dollar these cross currency swap contract qualify and are designated cash flow hedge of both december and we had cross currency swap contract with aggregate notional amount of billion of december we had commercial paper program that allows to issue up to billion of unsecured commercial paper to fund our working capital need during and we did not issue any commercial paper no commercial paper wa outstanding of december and in we amended and restated our billion syndicated unsecured revolving credit agreement which is available for general corporate purpose or liquidity backstop to our commercial paper program the commitment under the revolving credit agreement may be increased by up to million with the agreement of the bank each bank that is party to the agreement ha an initial commitment term of five year this term may be extended for up to two additional one year period with the agreement of the bank annual commitment fee for this agreement are of the unused portion of the facility based on our current credit rating generally we would be charged interest for any amount borrowed under this facility based on our current credit rating at libor plus or ii the highest of the syndication agent bank base commercial lending rate the overnight federal fund rate plus or one month libor plus the agreement contains provision related to the determination of successor rate to address the possible phase out or unavailability of designated reference rate of december and no amount were outstanding under this facility it is anticipated that libor will be phased out and replaced by while various replacement reference rate have been discussed an alternative reference rate to libor ha not yet been widely adopted therefore the mechanic to modify existing contract that reference libor have not been finalized we are currently evaluating the impact that the change in the reference rate will have on our financial condition see part item risk factor our sale and operation are subject to the risk of doing business internationally including in emerging market in february we filed shelf registration statement with the sec that allows to issue unspecified amount of debt security common stock preferred stock warrant to purchase debt security common stock preferred stock or depositary share right to purchase common stock or preferred stock security purchase contract security purchase unit and depositary share under this shelf registration statement all of the security available for issuance may be offered from time to time with term to be determined at the time of issuance this shelf registration statement expires in february certain of our financing arrangement contain nonfinancial covenant in addition our revolving credit agreement includes financial covenant that requires to maintain specified minimum interest coverage ratio of the sum of consolidated net income interest expense provision for income tax depreciation expense amortization expense unusual or nonrecurring charge and other noncash item consolidated ebitda to ii consolidated interest expense each defined and described in the credit agreement we were in compliance with all applicable covenant under these arrangement of december see part iv note financing arrangement and note derivative instrument to the consolidated financial statement cash flowsour summarized cash flow activity wa follows in million year ended december cash provided by operating activity net cash used in provided by investing activity net cash used in financing activity operatingcash provided by operating activity ha been and is expected to continue to be our primary recurring source of fund cash provided by operating activity increased during primarily due to higher net income after adding back the noncash amortization related to the acquisition of otezla the monetization of interest rate swap contract and working capital adjustment cash provided by operating activity decreased during primarily due to change in working capital an increase in payment to the irs related to an advance deposit and lower net income used in investing activity during wa primarily due to our billion of purchase of equity method investment primarily beigene and net cash outflow related to marketable security of billion cash provided by investing activity during and wa primarily due to net cash inflow related to marketable security of billion and billion respectively the liquidation of portion of our marketable security portfolio in wa primarily the result of funding the acquisition of otezla and our investment in beigene and in to fund our tender offer to repurchase our common stock capital expenditure were million million and million in and respectively we currently estimate spending on capital project to be approximately million majority of the increase in expenditure relates to expansion of manufacturing capacity to enable supply of product and product candidate financingcash used in financing activity during wa primarily due to repayment of debt of billion the payment of dividend of billion and payment to repurchase our common stock of billion partially offset by proceeds from issuance of debt of billion cash used in financing activity during wa primarily due to repurchase of our common stock of billion repayment of debt of billion and payment of dividend of billion cash used in financing activity during wa primarily due to repurchase of common stock of billion payment of dividend of billion and repayment of debt of billion see part iv note investment note financing arrangement and note stockholder equity to the consolidated financial statement off balance sheet arrangementswe do not have any off balance sheet arrangement that are material or reasonably likely to become material to our consolidated financial position or consolidated result of operation obligationscontractual obligation represent future cash commitment and liability under agreement with third party and exclude contingent liability for which we can not reasonably predict future payment additionally the expected timing of payment of the obligation presented below is estimated based on current information timing of payment and actual amount paid may be different depending on the timing of receipt of good or service or change to agreed upon term or amount for some obligation the following table represents our contractual obligation aggregated by type in million payment due by period of december obligationstotalyear and and and beyondlong term debt obligation operating lease obligation purchase obligation repatriation tax unrecognized tax benefit utbs total contractual obligation long term debt obligation includes future interest payment on our fixed rate obligation at the contractual coupon rate to achieve desired mix of fixed rate and floating rate debt we enter into interest rate swap contract that effectively convert fixed rate interest coupon for certain of our debt issuance to floating libor based coupon over the term of the related hedge contract we used an interest rate forward curve of december in computing net amount to be paid or received under our interest rate swap contract which resulted in an aggregate net decrease in future interest payment of million see part iv note financing arrangement to the consolidated financial statement long term debt obligation includes contractual interest payment and principal repayment of our foreign denominated debt obligation in order to hedge our exposure to foreign currency exchange rate risk associated with our euro pound sterling and swiss franc denominated long term debt we entered into cross currency swap contract that effectively converted interest payment and principal repayment on this debt from euro pound sterling and swiss franc to dollar for purpose of this table we used the contracted exchange rate in the cross currency swap contract to compute the net amount of future interest payment and principal repayment on this debt see part iv note derivative instrument to the consolidated financial statement operating lease obligation includes payment for lease that have not yet commenced net of lease incentive and excludes million of future receipt under noncancelable sublease of abandoned facility purchase obligation relates primarily to commitment including those related to clinical trial for new and existing product ii capital expenditure and iii open purchase order for the acquisition of good and service in the ordinary course of business our obligation to pay certain of these amount may be reduced based on certain future event under the tax act we elected to pay in eight annual installment the repatriation tax related primarily to our prior indefinitely invested earnings of our foreign operation see part iv note contingency and commitment commitment repatriation tax to the consolidated financial statement liability for utbs are not included in the table above because due to their nature there is high degree of uncertainty regarding the timing of future cash outflow and other event that extinguish these liability see part iv note income tax to the consolidated financial statement in addition to amount in the table above we are contractually obligated to pay additional amount that in the aggregate are significant upon the achievement of various development regulatory and commercial milestone for agreement we have entered into with third party including contingent consideration incurred in the acquisition of and biovex group inc biovex these payment are contingent upon the occurrence of various future event substantially all of which have high degree of uncertainty of occurring these contingent payment have not been included in the table above and except with respect to the fair value of the contingent consideration obligation are not recorded on our consolidated balance sheet of december the maximum amount that may be payable in the future for agreement we have entered into with third party is billion including million of contingent consideration payment in connection with the acquisition of biovex of critical accounting policiesthe preparation of our consolidated financial statement in conformity with gaap requires management to make estimate and assumption that affect the amount reported in the financial statement and the note to the financial statement some of those judgment can be subjective and complex and therefore actual result could differ materially from those estimate under different assumption or condition product sale and sale deductionsrevenue from product sale is recognized upon transfer of control of product to customer generally upon delivery based on an amount that reflects the consideration to which we expect to be entitled net of accrual for estimated rebate wholesaler chargebacks discount and other deduction collectively sale deduction and return established at the time of sale we analyze the adequacy of our accrual for sale deduction quarterly amount accrued for sale deduction are adjusted when trend or significant event indicate that adjustment is appropriate accrual are also adjusted to reflect actual result amount recorded in accrued liability in the consolidated balance sheet for sale deduction were follows in million rebateschargebacksother deductionstotalbalance of december amount charged against product payment balance of december amount charged against product payment balance of december amount charged against product payment balance of december for the year ended december and total sale deduction were and of gross product sale respectively the increase in the total sale deduction balance of december compared to december wa primarily driven by the increase in gross sale and the impact of higher commercial rebate rate included in the amount are immaterial net adjustment related to prior year sale due to change in estimate such amount represent le than of the aggregate sale deduction charged against product sale in the year ended december and in the united state we utilize wholesaler the principal mean of distributing our product to healthcare provider such physician or their clinic dialysis center hospital and pharmacy product we sell in europe are distributed principally to hospital and or wholesaler depending on the distribution practice in each country where the product are sold we monitor the inventory level of our product at our wholesaler by using data from our wholesaler and other third party and we believe wholesaler inventory have been maintained at appropriate level generally two to three week given end user demand accordingly historical fluctuation in wholesaler inventory level have not significantly affected our method of estimating sale deduction and return accrual for sale deduction are based primarily on estimate of the amount earned or to be claimed on the related sale these estimate take into consideration current contractual and statutory requirement specific known market event and trend internal and external historical data and forecasted customer buying pattern sale deduction are substantially product specific and therefore for any given year can be affected by the mix of product sold rebate include primarily amount paid to payer and provider in the united state including those paid to state medicaid program and are based on contractual arrangement or statutory requirement that vary by product by payer and by individual payer plan we sell product we estimate the amount of rebate we will pay based on the product sold contractual term estimated patient population historical experience and wholesaler inventory level and we accrue these rebate in the period the related sale are recorded we then adjust the rebate accrual more information becomes available and to reflect actual claim experience estimating such rebate is complicated in part because of the time delay between the date of sale and the actual settlement of the liability we believe the methodology we use to accrue for rebate is reasonable and appropriate given current fact and circumstance but actual result may differ chargebacks relate to our contractual agreement to sell product to healthcare provider in the united state at fixed price that are lower than the price we charge wholesaler when healthcare provider purchase our product through wholesaler at these reduced price wholesaler charge for the difference between their purchase price and the contractual price between amgen and the healthcare provider the provision for chargebacks is based on the expected sale by our wholesaler customer to healthcare provider accrual for wholesaler chargebacks are le difficult to estimate than rebate are and they closely approximate actual result because chargeback amount are fixed at the date of purchase by the healthcare provider and because we generally settle the liability for these deduction within few week product returnsreturns are estimated by comparison of historical return data to their related sale on production lot basis historical rate of return are determined for each product and are adjusted for known or expected change in the marketplace specific to each product when appropriate in each of the past three year sale return provision have amounted to le than of gross product sale change in estimate for prior year sale return provision have historically been immaterial income taxeswe provide for income tax based on pretax income and applicable tax rate in the various jurisdiction in which we operate we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authority based on the technical merit of the position the tax benefit recognized in the consolidated financial statement for particular tax position is measured based on the largest benefit that is more likely than not to be realized the amount of utbs is adjusted appropriate for change in fact and circumstance such significant amendment to existing tax law new regulation or interpretation by tax authority new information obtained during tax examination or resolution of an examination we believe our estimate for uncertain tax position are appropriate and sufficient for any assessment that may result from examination of our tax return we recognize both accrued interest and penalty where appropriate related to utbs in income tax expense certain item are included in our tax return at different time than they are reflected in the financial statement and they cause temporary difference between the tax base of asset and liability and their reported amount such temporary difference create deferred tax asset and liability deferred tax asset are generally item that can be used tax deduction or credit in the tax return in future year but for which we have already recorded the tax benefit in the consolidated financial statement we establish valuation allowance against our deferred tax asset when the amount of expected future taxable income is not likely to support the use of the deduction or credit deferred tax liability are either tax expense recognized in the consolidated financial statement for which payment ha been deferred ii expense for which we have already taken deduction on the tax return but have not yet recognized in the consolidated financial statement or iii liability for the difference between the book basis and tax basis of the intangible asset acquired in many business combination future expense associated with these asset most often will not be tax deductible we are vertically integrated enterprise with operation in the united state and various foreign jurisdiction we are subject to income tax in the jurisdiction where we conduct operation based on the tax law and principle of such jurisdiction and the function risk and activity performed therein our pretax income is therefore attributed to domestic or foreign source based on the operation performed and risk assumed in each location and the tax law and principle of the respective taxing jurisdiction for example we conduct significant operation in puerto rico territory of the united state that is treated foreign jurisdiction for tax purpose pertaining to manufacturing distribution and other related function to meet our worldwide product demand income from our operation in puerto rico is subject to tax incentive grant through previously disclosed in we received an rar and modified rar from the irs for the year and proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico we disagree with the proposed adjustment and calculation and have been pursuing resolution with the irs administrative appeal office however we have been unable to reach resolution at the administrative appeal level and we anticipate that we will receive notice of deficiency which we would expect to vigorously contest through the judicial process in addition in we received an rar and modified rar from the irs for the year and also proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico similar to those proposed for the year and we disagree with the and proposed adjustment and calculation and are pursuing resolution with the irs administrative appeal office the irs audit for year and is expected to start in the near term we are also currently under examination by number of other state and foreign tax jurisdiction final resolution of these complex matter is not likely within the next month we believe our accrual for income tax liability is appropriate based past experience interpretation of tax law application of the tax law to our fact and judgment about potential action by tax authority however due to the complexity of the provision for income tax and uncertain resolution of these matter the ultimate outcome of any tax matter may result in payment substantially greater than amount accrued and could have material adverse impact on our consolidated financial statement see part iv note income tax to the consolidated financial statement our operation are subject to the tax law regulation and administrative practice of the united state the territory of puerto rico state jurisdiction and other country in which we do business significant change in these rule could have material adverse effect on our result of operation see part item risk factor the adoption and interpretation of new tax legislation or exposure to additional tax liability could affect our profitability contingenciesin the ordinary course of business we are involved in various legal proceeding government investigation and other matter such intellectual property dispute contractual dispute and class action suit that are complex in nature and have outcome that are difficult to predict we describe our legal proceeding and other matter that are significant or that we believe could become significant in part iv note contingency and commitment to the consolidated financial statement we record accrual for loss contingency to the extent that we conclude it is probable that liability ha been incurred and the amount of the related loss can be reasonably estimated we evaluate on quarterly basis development in legal proceeding and other matter that could cause an increase or decrease in the amount of the liability that ha been accrued previously while it is not possible to accurately predict or determine the eventual outcome of these item an adverse determination in one or more of these item currently pending could have material adverse effect on our consolidated result of operation financial position or cash flow valuation of asset and liability in connection with acquisitionswe have acquired and continue to acquire intangible asset in connection with business combination and asset acquisition these intangible asset consist primarily of technology associated with currently marketed human therapeutic product and ipr product candidate discounted cash flow model are typically used to determine the fair value of these intangible asset for purpose of allocating consideration paid to the net asset acquired in an acquisition see part iv note acquisition to the consolidated financial statement these model require the use of significant estimate and assumption including but not limited to determining the timing and expected cost to complete in process project taking into account the stage of completion at the acquisition date projecting the probability and timing of obtaining marketing approval from the fda and other regulatory agency for product candidate estimating the timing of and future net cash flow from product sale resulting from completed product and in process project and developing appropriate discount rate to calculate the present value of the cash flow we believe the fair value used to record intangible asset acquired in connection with business combination and asset acquisition are based on reasonable estimate and assumption given the fact and circumstance of the related valuation date impairment of long lived assetswe review the carrying value of our property plant and equipment and our finite lived intangible asset for impairment whenever event or change in circumstance indicate that the carrying amount of an asset may not be recoverable if such circumstance exist an estimate of undiscounted future cash flow to be generated by the long lived asset is compared to the carrying value to determine whether an impairment exists if an asset is determined to be impaired the loss is measured based on the difference between the asset fair value and it carrying value we believe our estimation of future cash flow used for assessing impairment of long lived asset are based on reasonable assumption given the fact and circumstance of the related date of the assessment of equity method investmentswe review the carrying value of our equity method investment whenever event or change in circumstance indicate that the carrying amount of an investment may not be recoverable we record impairment loss on our equity method investment if we deem the impairment to be other than temporary we deem an impairment to be other than temporary based on various factor including but not limited to the length of time and the extent to which the fair value is below the carrying value volatility of the security price the financial condition of the issuer change in technology that may impair the earnings potential of the investment and our intent and ability to retain the investment to allow for recovery in fair value we believe our judgment used in assessing impairment of equity method investment are based on reasonable assumption given the fact and circumstance of the related date of the assessment recently issued accounting standardssee part iv note summary of significant accounting policy to the consolidated financial statement for discussion of recently adopted accounting pronouncement and recently issued accounting pronouncement not yet adopted of december item quantitative and qualitative disclosure about market riskwe are exposed to market risk that may result from change in interest rate foreign currency exchange rate and price of equity instrument well change in general economic condition in the country where we conduct business to reduce certain of these risk we enter into various type of foreign currency and interest rate derivative hedging transaction part of our risk management program we do not use derivative for speculative trading purpose in the discussion that follows we have assumed hypothetical change in interest rate of basis point from those of december and except noted below we have also assumed hypothetical change in foreign currency exchange rate against the dollar based on it position relative to other currency of december and interest rate sensitive financial instrumentsour portfolio of available for sale investment of december and wa composed of treasury security and money market mutual fund and with respect to investment of december corporate debt security and other short term interest bearing security the fair value of our available for sale investment were billion and billion of december and respectively duration is sensitivity measure that can be used to approximate the change in the value of security that will result from basis point change in interest rate applying duration model hypothetical basis point increase in interest rate of december and would not have resulted in material reduction in the fair value of these security in addition hypothetical basis point decrease in interest rate of december and would not result in material effect on income in the respective ensuing year of december we had outstanding debt with carrying value of billion and fair value of billion of december we had outstanding debt with carrying value of billion and fair value of billion our outstanding debt wa composed almost entirely of debt with fixed interest rate change in interest rate do not affect interest expense on fixed rate debt change in interest rate would however affect the fair value of fixed rate debt hypothetical basis point decrease in interest rate relative to interest rate of december and would have resulted in increase of billion and billion respectively in the aggregate fair value of our outstanding debt on each of these date analysis of the debt doe not consider the impact that hypothetical change in interest rate would have on the related interest rate swap contract and cross currency swap contract discussed below to achieve desired mix of fixed rate and floating rate debt we entered into interest rate swap contract that qualified and were designated for accounting purpose fair value hedge for certain of our fixed rate debt these interest rate swap contract effectively converted fixed rate interest coupon to floating rate libor based coupon over the life of the respective note interest rate swap contract with aggregate notional amount of billion and billion were outstanding of december and respectively hypothetical basis point increase in interest rate relative to interest rate of december and would have resulted in reduction in fair value of approximately million and million respectively on our interest rate swap contract on these date analysis of the interest rate swap contract doe not consider the impact that hypothetical change in interest rate would have on the related fair value of debt that these interest rate sensitive instrument were designed to offset of december and we had outstanding cross currency swap contract with aggregate notional amount of billion that hedge our foreign currency denominated debt and related interest payment these contract effectively convert interest payment and principal repayment of this debt to dollar from euro pound sterling and swiss franc and are designated for accounting purpose cash flow hedge hypothetical basis point adverse movement in interest rate relative to interest rate of december and would have resulted in reduction in the fair value of our cross currency swap contract of approximately million and million respectively foreign currency sensitive financial instrumentsour international operation are affected by fluctuation in the value of the dollar compared to foreign currency predominantly the euro increase and decrease in our international product sale from movement in foreign currency exchange rate are partially offset by the corresponding increase or decrease in our international operating expense increase and decrease in our foreign currency denominated asset from movement in foreign currency exchange rate are partially offset by the corresponding increase or decrease in our foreign currency denominated liability to further reduce our net exposure to foreign currency exchange rate fluctuation on our result of operation we enter into foreign currency forward option and cross currency swap contract of december we had outstanding euro pound sterling and swiss franc denominated debt with principal carrying value and fair value of billion and billion respectively of december we had outstanding euro pound sterling and swiss franc denominated debt with principal carrying value and fair value of billion and billion respectively hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate of december would have resulted in an increase in fair value of this debt of billion on this date and reduction in income in the ensuing year of billion hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate of december would have resulted in an increase in fair value of this debt of billion on this date and reduction in income in the ensuing year of million the impact on income from these hypothetical change in foreign currency exchange rate would be substantially offset by the impact such change would have on related cross currency swap contract which are in place for the related foreign currency denominated debt we have cross currency swap contract that are designated cash flow hedge of our debt denominated in euro pound sterling and swiss franc with aggregate notional amount of billion of both december and hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate on these date would have resulted in reduction in the fair value of these contract of billion and billion on these date respectively the impact of this hypothetical adverse movement in foreign currency exchange rate on ensuing year income from these contract would be fully offset by the corresponding hypothetical change in the carrying amount of the related hedged debt we enter into foreign currency forward and option contract that are designated for accounting purpose cash flow hedge of certain anticipated foreign currency transaction of december the fair value of these contract were million asset and million liability of december the fair value of these contract were million asset and million liability of december we had primarily euro based open foreign currency forward contract with notional amount of billion of december we had primarily euro based open foreign currency forward contract with notional amount of billion with regard to foreign currency forward and option contract that were open of december hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate of december would have resulted in reduction in fair value of these contract of approximately billion on this date and in the ensuing year reduction in income of approximately million with regard to contract that were open of december hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate of december would have resulted in reduction in fair value of these contract of million on this date and in the ensuing year reduction in income of million the analysis doe not consider the impact that hypothetical change in foreign currency exchange rate would have on anticipated transaction that these foreign currency sensitive instrument were designed to offset of december and we had open short duration foreign currency forward contract that mature in le than one month with notional amount of billion and billion respectively that hedged fluctuation of certain asset and liability denominated in foreign currency but were not designated hedge for accounting purpose these contract had no material net unrealized gain or loss of december and with regard to these foreign currency forward contract that were open of december and hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate on these date would not have material effect on the fair value of these contract or related income in the respective ensuing year the analysis doe not consider the impact that hypothetical change in foreign currency exchange rate would have on asset and liability that these foreign currency sensitive instrument were designed to offset price sensitive financial instrumentsas of december and we were exposed to price risk on equity security included in our portfolio of investment which were acquired primarily for the promotion of business and strategic objective these investment are generally in small capitalization stock in the biotechnology industry price risk relative to our equity investment portfolio of december and wa not material counterparty credit risksour financial instrument including derivative are subject to counterparty credit risk which we consider part of the overall fair value measurement our financial risk management policy limit derivative transaction by requiring that transaction be made only with institution with minimum credit rating of or equivalent by moody or fitch and it place exposure limit on the amount with any individual counterparty in addition we have an investment policy that limit investment to certain type of debt and money market instrument issued by institution with investment grade credit rating and place restriction on maturity and concentration by asset class and issuer item financial statement and supplementary datathe information required by this item is incorporated herein by reference to the financial statement and schedule listed in item and of part iv and included in this annual report on form item change in and disagreement with accountant on accounting and financial disclosurenone control and procedureswe maintain disclosure control and procedure such term is defined under the security exchange act rule that are designed to ensure that information required to be disclosed in amgen exchange act report is recorded processed summarized and reported within the time period specified in the sec rule and form and that such information is accumulated and communicated to amgen management including it chief executive officer and chief financial officer appropriate to allow timely decision regarding required disclosure in designing and evaluating the disclosure control and procedure amgen management recognized that any control and procedure no matter how well designed and operated can provide only reasonable assurance of achieving the desired control objective and in reaching reasonable level of assurance amgen management necessarily wa required to apply it judgment in evaluating the cost benefit relationship of possible control and procedure we have carried out an evaluation under the supervision and with the participation of our management including amgen chief executive officer and chief financial officer of the effectiveness of the design and operation of amgen disclosure control and procedure based upon their evaluation and subject to the foregoing the chief executive officer and chief financial officer concluded that our disclosure control and procedure were effective of december management determined that of december there were no change in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected or are reasonably likely to materially affect our internal control over financial reporting management report on internal control over financial reportingmanagement of the company is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule under the security exchange act of the company internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with gaap in the united state however all internal control system no matter how well designed have inherent limitation therefore even those system determined to be effective can provide only reasonable assurance with respect to financial statement preparation and reporting management assessed the effectiveness of the company internal control over financial reporting of december in making this assessment management used the criterion set forth by the committee of sponsoring organization of the treadway commission coso in internal control integrated framework framework based on our assessment management belief that the company maintained effective internal control over financial reporting of december based on the coso criterion the effectiveness of the company internal control over financial reporting ha been audited by ernst young llp an independent registered public accounting firm stated in their attestation report appearing below which express an unqualified opinion on the effectiveness of the company internal control over financial reporting of december of independent registered public accounting firmto the stockholder and the board of director of amgen inc opinion on internal control over financial reportingwe have audited amgen inc internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion amgen inc the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note and the financial statement schedule listed in the index at item and our report dated february expressed an unqualified opinion thereon basis for opinionthe company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate ernst young llplos angeles californiafebruary other informationnot applicable part iiiitem director executive officer and corporate governanceinformation about our director is incorporated by reference from the section entitled item election of director in our proxy statement for the annual meeting of stockholder to be filed with the sec within day of december the proxy statement information about the procedure by which stockholder may recommend nominee for the board of director is incorporated by reference from appendix amgen inc board of director guideline for director qualification and evaluation and other matter stockholder proposal for the annual meeting in our proxy statement information about our audit committee member of the committee and our audit committee financial expert is incorporated by reference from the section entitled corporate governance audit committee in our proxy statement information about our executive officer is contained in the discussion entitled part item business information about our executive officer code of ethicswe maintain code of ethic for the chief executive officer and senior financial officer applicable to our principal executive officer principal financial officer principal accounting officer or controller and other person performing similar function to view this code of ethic free of charge please visit our website at www amgen com this website address is not intended to function hyperlink and the information contained in our website is not intended to be part of this filing we intend to satisfy the disclosure requirement under item of form regarding an amendment to or waiver from provision of this code of ethic if any by posting such information on our website set forth above item executive compensationinformation about director and executive compensation is incorporated by reference from the section entitled executive compensation in our proxy statement information about compensation committee matter is incorporated by reference from the section entitled corporate governance compensation and management development committee and corporate governance compensation committee report in our proxy statement security ownership of certain beneficial owner and management and related stockholder matterssecurities authorized for issuance under existing equity compensation plansthe following table set forth certain information of december concerning the share of our common stock that may be issued under any form of award granted under our equity compensation plan in effect of december including upon the exercise of option upon the vesting of award of restricted stock unit rsus or when performance unit are earned and related dividend equivalent have been granted plan categorynumber of security to be issued upon exercise of outstanding option and rightsweighted average exercise price of outstanding option and rightsnumber of security remaining available for future issuance under equity compensation plan excluding security reflected in column equity compensation plan approved by amgen security holder amended and restated equity incentive plan amended and restated equity incentive plan amended and restated employee stock purchase plan total approved equity compensation plan not approved by amgen security holder amgen profit sharing plan for employee in ireland total unapproved plan total all the amended and restated equity incentive plan employ fungible share counting formula for determining the number of share available for issuance under the plan in accordance with this formula each option or stock appreciation right count one share while each rsu performance unit or dividend equivalent count share the number under column represents the actual number of share issuable under our outstanding award without giving effect to the fungible share counting formula the number under column represents the number of share available for issuance under this plan based on each such available share counting one share commencing with the grant made in april rsus and performance unit accrue dividend equivalent that are payable in share only to the extent and when the underlying rsus vest or underlying performance unit have been earned and the related share are issued to the grantee the performance unit granted under this plan are earned based on the accomplishment of specified performance goal at the end of their respective three year performance period the number of performance unit granted represent target performance and the maximum number of unit that could be earned based on our performance is of the performance unit granted in and of december the number of outstanding award under column includes share issuable upon the exercise of outstanding option with weighted average exercise price of ii share issuable upon the vesting of outstanding rsus including related dividend equivalent and iii share subject to outstanding and performance unit including related dividend equivalent the weighted average exercise price shown in column is for the outstanding option only the number of available share under column represents the number of share that remain available for future issuance under this plan of december employing the fungible share formula and presumes the issuance of target share under the performance unit granted in and and related dividend equivalent the number under column and do not give effect to the additional share that could be issuable in the event above target performance on the performance goal under these outstanding performance unit is achieved maximum performance under these goal could result in of target share being awarded for performance unit granted in and this plan ha terminated to future grant the number under column with respect to this plan includes share issuable upon the settlement of deferred rsus including related dividend equivalent the amgen profit sharing plan for employee in ireland the profit sharing plan wa approved by the board of director on july the profit sharing plan permit eligible employee of the company subsidiary located in ireland who participate in the profit sharing plan to apply portion of their qualifying bonus and salary to the purchase of the company common stock on the open market at the market price by third party trustee described in the profit sharing plan ownership of director and executive officer and certain beneficial ownersinformation about security ownership of certain beneficial owner and management is incorporated by reference from the section entitled security ownership of director and executive officer and security ownership of certain beneficial owner in our proxy statement item certain relationship and related transaction and director independenceinformation about certain relationship and related transaction and director independence is incorporated by reference from the section entitled certain relationship and related transaction and corporate governance director independence in our proxy statement item principal accounting fee and servicesinformation about the fee for professional service rendered by our independent registered public accountant is incorporated by reference from the section entitled audit matter independent registered public accountant in our proxy statement ivitem exhibit financial statement schedule index to financial statementsthe following consolidated financial statement are included herein pagenumberreport of independent registered public accounting firmf statement of income for each of the three year in the period ended december statement of comprehensive income for each of the three year in the period ended december balance sheet of december and statement of stockholder equity for each of the three year in the period ended december statement of cash flow for each of the three year in the period ended december to consolidated financial statementsf index to financial statement schedulesthe following schedule is filed part of this annual report on form pagenumberii valuation and qualifying accountsf other schedule are omitted because they are not applicable not required or because the required information is included in the consolidated financial statement or note thereto exhibitsexhibit no purchase agreement dated august by and between amgen inc and celgene corporation filed an exhibit to form on august and incorporated herein by reference no to the asset purchase agreement dated october by and between amgen inc and celgene corporation filed an exhibit to form on october and incorporated herein by reference no to the asset purchase agreement dated october by and between amgen inc and celgene corporation filed an exhibit to form for the year ended december on february and incorporated herein by reference agreement dated november by and between amgen inc and the party named therein treatment of certain product inventory in connection with amgen acquisition of otezla filed an exhibit to form for the year ended december on february and incorporated herein by reference guarantee dated august by and between amgen inc and bristol myers squibb company filed an exhibit to form on august and incorporated herein by reference certificate of incorporation of amgen inc restated march filed an exhibit to form for the quarter ended march on may and incorporated herein by reference and restated bylaw of amgen inc amended and restated february filed an exhibit to form on february and incorporated herein by reference of stock certificate for the common stock par value of the company filed an exhibit to form for the quarter ended march on may and incorporated herein by reference of indenture dated january filed an exhibit to form registration statement filed on december and incorporated herein by reference of resignation appointment and acceptance dated february filed an exhibit to form for the year ended december on february and incorporated herein by reference supplemental indenture dated february filed an exhibit to form on march and incorporated herein by reference debenture due april filed an exhibit to form on april and incorporated herein by reference certificate of amgen inc dated april establishing series of security entitled debenture due april filed an exhibit to form on april and incorporated herein by reference dated august filed an exhibit to form registration statement on august and incorporated herein by reference commercial paper master note between and among amgen inc issuer cede co nominee of the depository trust company and citibank paying agent filed an exhibit to form for the quarter ended march on may and incorporated herein by reference certificate of amgen inc dated may including form of the company senior note due filed an exhibit to form on may and incorporated herein by reference certificate of amgen inc dated may including form of the company senior note due filed exhibit to form on may and incorporated herein by reference certificate of amgen inc dated january including form of the company senior note due filed exhibit to form on january and incorporated herein by reference certificate of amgen inc dated march including form of the company senior note due filed exhibit to form on march and incorporated herein by reference certificate of amgen inc dated september including form of the company senior note due filed an exhibit to form on september and incorporated herein by reference certificate of amgen inc dated june including form of the company senior note due filed an exhibit to form on june and incorporated herein by reference certificate of amgen inc dated november including form of the company senior note due filed an exhibit to form on november and incorporated herein by reference certificate of amgen inc dated december including form of the company senior note due filed an exhibit to form on december and incorporated herein by reference certificate of amgen inc dated may including form of the company senior note due and senior note due filed an exhibit to form on may and incorporated herein by reference certificate of amgen inc dated september including form of the company senior note due filed an exhibit to form on september and incorporated herein by reference dated may between amgen inc and the bank of new york mellon trust company trustee filed an exhibit to form on may and incorporated herein by reference certificate of amgen inc dated may including form of the company senior note due filed an exhibit to form on may and incorporated herein by reference certificate of amgen inc dated may including form of the company senior note due senior note due and senior note due filed an exhibit on form on may and incorporated herein by reference certificate of amgen inc dated of february including form of the company senior note due and senior note due filed an exhibit on form on february and incorporated herein by reference of permanent global certificate for the company bond due filed an exhibit on form on march and incorporated herein by reference of the bond for the company bond due filed an exhibit on form on march and incorporated herein by reference certificate of amgen inc dated of june including form of the company senior note due and senior note due filed an exhibit to form on june and incorporated herein by reference certificate of amgen inc dated of august including form of the company senior note due and senior note due filed an exhibit to form on august and incorporated herein by reference certificate of amgen inc dated of may including form of the company senior note due filed an exhibit to form on may and incorporated herein by reference certificate of amgen inc dated of november including in the form of the company senior note due filed an exhibit to form on november and incorporated by reference certificate of amgen inc dated of february including form of the company senior note due senior note due senior note due senior note due and senior note due filed an exhibit to form on february and incorporated herein by reference certificate of amgen inc dated of may including form of the company senior note due filed an exhibit to form on may and incorporated herein by reference certificate of amgen inc dated of august including form of the company senior note due filed an exhibit to form on august and incorporated herein by reference right agreement dated of august by and among amgen inc bofa security inc and morgan security llc lead dealer manager and bnp paribas security corp deutsche bank security inc rbc capital market llc blaylock van llc and siebert williams shank co llc co dealer manager filed an exhibit to form on august and incorporated herein by reference description of amgen inc security registered pursuant to section of the security exchange act of amgen inc amended and restated equity incentive plan filed appendix to the definitive proxy statement on schedule on april and incorporated herein by reference first amendment to amgen inc amended and restated equity incentive plan effective march filed an exhibit to form for the quarter ended march on april and incorporated herein by reference second amendment to amgen inc amended and restated equity incentive plan effective march filed an exhibit to form for the quarter ended march on may and incorporated herein by reference form of grant of stock option agreement for the amgen inc amended and restated equity incentive plan amended on december form of restricted stock unit agreement for the amgen inc amended and restated equity incentive plan amended on december amgen inc performance award program amended on december filed an exhibit to form for the year ended december on february and incorporated herein by reference form of performance unit agreement for the amgen inc performance award program amended on december amgen inc director equity incentive program amended and restated on october form of grant of non qualified stock option agreement for the amgen inc director equity incentive program filed an exhibit to form on may and incorporated herein by reference form of restricted stock unit agreement for the amgen inc director equity incentive program amended on december filed an exhibit to form for the year ended december on february and incorporated herein by reference form of cash settled restricted stock unit agreement for the amgen director equity incentive program amended on december filed an exhibit to form for the year ended december on february and incorporated herein by reference amgen inc supplemental retirement plan amended and restated effective october filed an exhibit to form for the year ended december on february and incorporated herein by reference first amendment to the amgen inc supplemental retirement plan effective october filed an exhibit to form for the quarter ended september on october and incorporated herein by reference second amendment to the amgen inc supplemental retirement plan amended and restated effective october filed an exhibit to form for the year ended december on february and incorporated herein by reference amended and restated amgen change of control severance plan amended and restated effective december and subsequently amended effective march filed an exhibit to form for the quarter ended march on may and incorporated herein by reference amgen inc executive incentive plan amended and restated effective january filed an exhibit to form for the quarter ended september on november and incorporated herein by reference first amendment to the amgen inc executive incentive plan effective december filed an exhibit to form for the year ended december on february and incorporated herein by reference second amendment to the amgen inc executive incentive plan effective january filed an exhibit to form for the quarter ended march on april and incorporated herein by reference amgen nonqualified deferred compensation plan amended and restated effective october filed an exhibit to form for the year ended december on february and incorporated herein by reference first amendment to the amgen nonqualified deferred compensation plan effective october filed an exhibit to form for the quarter ended september on october and incorporated herein by reference second amendment to the amgen nonqualified deferred compensation plan amended and restated effective january filed an exhibit to form for the year ended december on february and incorporated herein by reference agreement between amgen inc and murdo gordon dated july filed an exhibit to form for the quarter ended september on october and incorporated herein by reference agreement between amgen inc and peter griffith dated october filed an exhibit to form for the quarter ended march on may and incorporated herein by reference amended and restated credit agreement dated december among amgen inc the bank therein named citibank administrative agent and jpmorgan chase bank syndication agent filed an exhibit to form on december and incorporated herein by reference and license agreement between amgen inc and celltech limited dated may portion of the exhibit have been omitted pursuant to request for confidential treatment and amendment no effective june to collaboration and license agreement between amgen inc and celltech limited portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the year ended december on july and incorporated herein by reference no to collaboration and license agreement effective november between amgen inc and celltech limited portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the year ended december on february and incorporated herein by reference agreement dated june by and between amgen inc and ucb celltech portion of the exhibit have been omitted because they are both not material and ii would be competitively harmful if publicly disclosed filed an exhibit to form for the quarter ended june on july and incorporated herein by reference agreement dated april by and between bayer corporation formerly mile inc and onyx pharmaceutical inc filed an exhibit to form for the quarter ended march by onyx pharmaceutical inc on may and incorporated herein by reference to collaboration agreement dated april by and between bayer corporation and onyx pharmaceutical inc filed an exhibit to form for the quarter ended march by onyx pharmaceutical inc on may and incorporated herein by reference to collaboration agreement dated february by and between bayer corporation and onyx pharmaceutical inc filed an exhibit to form for the quarter ended march by onyx pharmaceutical inc on may and incorporated herein by reference agreement and release dated october by and between bayer corporation bayer ag bayer healthcare llc and bayer pharma ag and onyx pharmaceutical inc filed an exhibit to form for the year ended december by onyx pharmaceutical inc on february and incorporated herein by reference amendment to collaboration agreement dated october by and between bayer corporation and onyx pharmaceutical inc filed an exhibit to form for the year ended december by onyx pharmaceutical inc on february and incorporated herein by reference letter regarding collaboration agreement dated may by and between bayer healthcare llc and onyx pharmaceutical inc filed an exhibit to form for the quarter ended june on august and incorporated herein by reference letter regarding collaboration agreement and stivarga agreement dated february by and between onyx pharmaceutical inc and bayer healthcare llc filed an exhibit to form for the quarter ended march on may and incorporated herein by reference and supply agreement dated january by and between amgen usa inc wholly owned subsidiary of amgen inc and davita inc portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the quarter ended march on april and incorporated herein by reference license and collaboration agreement dated august by and between amgen inc and novartis pharma ag portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the quarter ended june on july and incorporated herein by reference no to the exclusive license and collaboration agreement dated april by and between amgen inc and novartis pharma ag portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the quarter ended june on july and incorporated herein by reference no to the exclusive license and collaboration agreement dated april by and between amgen inc and novartis pharma ag portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the quarter ended june on july and incorporated herein by reference agreement dated april by and between amgen inc and novartis pharma ag portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the quarter ended june on july and incorporated herein by reference no to the collaboration agreement dated march by and between novartis pharma ag and amgen inc portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the quarter ended march on april and incorporated herein by reference no to the collaboration agreement dated august by and between amgen inc and novartis pharma ag portion of the exhibit have been omitted because they are both not material and ii would be competitively harmful if publicly disclosed filed an exhibit to form for the quarter ended september on october and incorporated herein by reference agreement dated october by and between amgen inc and beigene switzerland gmbh wholly owned subsidiary of beigene ltd portion of the exhibit have been omitted because they are both not material and ii would be competitively harmful if publicly disclosed filed an exhibit to form for the year ended december on february and incorporated herein by reference dated of october made by and among beigene ltd and amgen inc filed an exhibit to form for the year ended december on february and incorporated herein by reference purchase agreement dated october by and between amgen inc and beigene ltd portion of the exhibit have been omitted because they are both not material and ii would be competitively harmful if publicly disclosed filed an exhibit to schedule on january and incorporated herein by reference no to share purchase agreement dated december by and among beigene ltd and amgen inc filed an exhibit to schedule on january and incorporated herein by reference amendment no to share purchase agreement dated september by and among beigene ltd and amgen inc filed an exhibit to form for the quarter ended september on october and incorporated herein by reference agreement dated march by and between amgen inc and astrazeneca collaboration venture llc wholly owned subsidiary of astrazeneca pharmaceutical lp portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the quarter ended march on may and incorporated herein by reference no to the collaboration agreement dated october by and among amgen inc astrazeneca collaboration venture llc and astrazeneca pharmaceutical lp portion of the exhibit have been omitted pursuant to request for confidential treatment filed an exhibit to form for the year ended december on february and incorporated herein by reference no through to the march collaboration agreement between amgen inc and astrazeneca collaboration venture llc dated may and and october january and may respectively portion of the exhibit have been omitted because they are both not material and ii would be competitively harmful if publicly disclosed filed an exhibit to form for the quarter ended june on july and incorporated herein by reference amendment no to the collaboration agreement dated december by and between amgen inc and astrazeneca collaboration venture llc portion of the exhibit have been omitted because they are both not material and ii would be competitively harmful if publicly disclosed subsidiary of the company of the independent registered public accounting firm the consent is set forth on page of this annual report on the of attorney the power of attorney is set forth on page of this annual report on form rule certification section certification insinline xbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document sch inline xbrl taxonomy extension schema document cal inline xbrl taxonomy extension calculation linkbase document def inline xbrl taxonomy extension definition linkbase document lab inline xbrl taxonomy extension label linkbase document pre inline xbrl taxonomy extension presentation linkbase document page interactive data file formatted inline xbrl and contained in exhibit ____________________________ filed herewith furnished herewith and not filed for purpose of section of the security exchange act of amended management contract or compensatory plan or arrangement item form summarynot applicable to the requirement of the security exchange act of the registrant ha duly caused this annual report to be signed on it behalf by the undersigned thereunto duly authorized amgen inc registrant date february peter griffith peter griffith executive vice president and chief financial officer principal financial officer of independent registered public accounting firmwe consent to the incorporation by reference in the following registration statement registration statement form no of amgen inc registration statement form no pertaining to the amgen inc amended and restated equity incentive plan registration statement form no pertaining to the amgen inc amended and restated employee stock purchase plan registration statement form no amended by form no and pertaining to the amgen retirement and saving plan registration statement form no and pertaining to the retirement and saving plan for amgen manufacturing limited formerly known the retirement and saving plan for amgen manufacturing inc registration statement form no and pertaining to the amgen nonqualified deferred compensation plan and registration statement form no pertaining to the amgen profit sharing plan for employee in ireland of our report dated february with respect to the consolidated financial statement of amgen inc and the effectiveness of internal control over financial reporting of amgen inc included in this annual report form of amgen inc for the year ended december ernst young llplos angeles californiafebruary of attorneyknow all men and woman by these present that each person whose signature appears below constitutes and appoints robert bradway peter griffith and jonathan graham or any of them his or her attorney in fact each with the power of substitution and re substitution for or her in any and all capacity to sign any amendment to this report and to file the same with exhibit thereto and other document in connection therewith with the security and exchange commission hereby ratifying and confirming all that each of said attorney in fact or his or her substitute or substitute may do or cause to be done by virtue hereof pursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated signaturetitledate robert bradwaychairman of the board chief executive officerand president and director principal executive officer bradway peter griffithexecutive vice president andchief financial officer principal financial officer griffith linda louievice president finance andchief accounting officer principal accounting officer louie wanda austin brian druker robert eckert greg garland fred hassan charles holley jr holley jr tyler jack ellen kullman amy mile ronald sugar sander sander of independent registered public accounting firmto the stockholder and the board of director of amgen inc opinion on the financial statement we have audited the accompanying consolidated balance sheet of amgen inc the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note and the financial statement schedule listed in the index at item collectively referred to the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company at december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon basis for opinion these financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate deductionsdescription of the matteras of december the company recorded accrued sale deduction of billion described in note to the financial statement under the caption product sale and sale deduction revenue from product sale are recognized net of accrual for estimated rebate wholesaler chargebacks discount and other deduction collectively sale deduction which are established at the time of sale auditing the estimation of sale deduction which are netted against product sale is complex requires significant judgment and the amount involved are material to the financial statement taken whole revenue from product sale is recognized upon transfer of control of product to customer generally upon delivery and is based on an amount that reflects the consideration to which the company expects to be entitled which represents an amount that is net of accrual for estimated sale deduction the estimated sale deduction are based on current contractual and statutory requirement market event and trend internal and external historical data and forecasted customer buying pattern how we addressed the matter in our auditwe obtained an understanding evaluated the design and tested the operating effectiveness of internal control over the sale deduction process this included testing control over management review of significant assumption and input used in the estimate of sale deduction including actual sale contractual term historical experience wholesaler inventory level demand data and estimated patient population we also tested management control over the accuracy of forecasting demand activity well the completeness and accuracy of the significant component included in the final sale deduction estimate to test management estimated sale deduction we obtained management calculation for the respective estimate and performed the following procedure among others we tested management estimation process over the determination of sale discount accrual by developing an independent expectation of the estimated accrual balance including comparing accrual balance recorded by management to those implied by historical payment trend performing lookback analysis using actual historical data to evaluate the forecasted amount assessing subsequent event to determine whether there wa any new information that would require adjustment to the initial accrual evaluating trend in actual sale and discount accrual balance comparing cash receipt to product sale confirming term and condition for sample of contract with the company customer testing sample of credit issued and payment made throughout the year and agreeing rate to underlying contract term tax benefitsdescription of the matteras discussed in note and to the consolidated financial statement the company operates in various jurisdiction in which differing interpretation of complex tax law and regulation create uncertainty and necessitate the use of significant judgment in the determination of the company unrecognized tax benefit related to allocation of profit among various jurisdiction transfer pricing particularly in the federal tax jurisdiction where the company ha significant asset and operation in this regard the company us significant judgment in determining whether tax position technical merit are more likely than not to be sustained and measuring the amount of tax benefit that qualifies for recognition of december the company accrued billion of gross unrecognized tax benefit including transfer pricing auditing the assessment of the technical merit and measurement of the company unrecognized tax benefit is challenging because they can be complex highly judgmental and based on interpretation of tax law and regulation and application of those interpretation to the company fact and circumstance how we addressed the matter in our auditwe obtained an understanding evaluated the design and tested the operating effectiveness of internal control over the company process to ass the technical merit of it tax position well management process to measure the unrecognized tax benefit of those tax position particularly in regard to transfer pricing this included testing control over management review of the input calculation assumption and method selected to measure the amount of tax benefit that qualify for recognition we involved tax and transfer pricing professional to assist in assessing the technical merit and measurement of certain of the company unrecognized tax benefit depending on the nature of the specific tax position and applicable development with the relevant tax authority our procedure included obtaining and reviewing the company correspondence with such tax authority and evaluating certain third party advice to support the company evaluation and recorded position we used our knowledge of and experience with how the income tax law and regulation related to transfer pricing are applied by the relevant tax authority to evaluate the company accounting for it unrecognized tax benefit we evaluated development in the applicable regulatory environment to ass potential effect on the company recorded position we analyzed the assumption and data used by the company when it determined the amount of tax benefit to recognize including applicable interest and penalty and we tested the accuracy of those underlying calculation we have also evaluated the company income tax disclosure included in note in relation to these matter ernst young llpwe have served the company auditor since los angeles californiafebruary inc consolidated statement of incomeyears ended december and in million except per share data product sale other total operating expense cost of research and selling general and total operating operating interest expense interest and other income income before income provision for income net income earnings per share basic diluted share used in the calculation of earnings per share accompanying note inc consolidated statement of comprehensive incomeyears ended december and in million income other comprehensive loss income net of reclassification adjustment and tax gain loss on foreign currency loss gain on cash flow hedge loss gain on available for sale security other loss other comprehensive loss income net of tax comprehensive income see accompanying note inc consolidated balance sheetsdecember and in million except per share data asset cash and cash equivalent marketable trade receivables other current total current property plant and equipment intangible asset other total asset liability and stockholder equitycurrent liability account payable accrued current portion of long term total current long term long term tax other noncurrent contingency and commitmentsstockholders equity common stock and additional paid in capital par value per share share authorized outstanding share in and share in accumulated deficit accumulated other comprehensive loss total stockholder total liability and stockholder equity see accompanying note inc consolidated statement of stockholder equityyears ended december and in million except per share data numberof sharesof commonstockcommonstock andadditionalpaid in capitalaccumulateddeficitaccumulatedothercomprehensive loss incometotalbalance of december cumulative effect of change in accounting principle net of tax net income other comprehensive loss net of tax dividend declared on common stock per share issuance of common stock in connection with the company equity award stock based compensation expense tax impact related to employee stock based compensation expense repurchase of common stock balance of december net income other comprehensive income net of tax dividend declared on common stock per share issuance of common stock in connection with the company equity award stock based compensation expense tax impact related to employee stock based compensation expense repurchase of common stock balance of december cumulative effect of change in accounting principle net of tax net income other comprehensive loss net of tax dividend declared on common stock per share issuance of common stock in connection with the company equity award stock based compensation expense tax impact related to employee stock based compensation expense repurchase of common stock balance of december see accompanying note amgen inc consolidated statement of cash flowsyears ended december and in million flow from operating activity net income depreciation amortization and stock based compensation deferred income tax other item net change in operating asset and liability net of acquisition trade receivables net inventory other account accrued income tax net long term tax liability other net cash provided by operating cash flow from investing activity purchase of marketable security proceeds from sale of marketable proceeds from maturity of marketable purchase of property plant and equipment cash paid for acquisition net of cash acquired purchase of equity method investment other net cash used in provided by investing activity cash flow from financing activity net proceeds from issuance of repayment of debt repurchase of common stock dividend paid other net cash used in financing activity increase decrease in cash and cash cash and cash equivalent at beginning of cash and cash equivalent at end of year see accompanying note inc note to consolidated financial statementsdecember summary of significant accounting policiesbusinessamgen inc including it subsidiary referred to amgen the company we our or is global biotechnology pioneer that discovers develops manufacture and delivers innovative human therapeutic we operate in one business segment human therapeutic principle of consolidationthe consolidated financial statement include the account of amgen well it majority owned subsidiary we do not have any significant interest in any variable interest entity all material intercompany transaction and balance have been eliminated in consolidation use of estimatesthe preparation of consolidated financial statement in conformity with generally accepted accounting principle gaap requires management to make estimate and assumption that affect the amount reported in the consolidated financial statement and accompanying note actual result may differ from those estimate revenuesproduct sale and sale deductionsrevenue from product sale is recognized upon transfer of control of product to customer generally upon delivery based on an amount that reflects the consideration to which we expect to be entitled net of accrual for estimated rebate wholesaler chargebacks discount and other deduction collectively sale deduction and return established at the time of sale we analyze the adequacy of our accrual for sale deduction quarterly amount accrued for sale deduction are adjusted when trend or significant event indicate that an adjustment is appropriate accrual are also adjusted to reflect actual result accrual for sale deduction are based primarily on estimate of the amount earned or to be claimed on the related sale these estimate take into consideration current contractual and statutory requirement specific known market event and trend internal and external historical data and forecasted customer buying pattern sale deduction are substantially product specific and therefore for any given period can be affected by the mix of product sold included in sale deduction are immaterial net adjustment related to prior period sale due to change in estimate historically such amount have represented le than of the aggregate sale deduction charged against product sale return are estimated through comparison of historical return data to their related sale on production lot basis historical rate of return are determined for each product and are adjusted for known or expected change in the marketplace specific to each product when appropriate historically sale return provision have amounted to le than of gross product sale change in estimate for prior period sale return provision have historically been immaterial our payment term vary by type and location of customer and the product or service offered payment term differ by jurisdiction and customer but payment is generally required in term ranging from to day from date of shipment or satisfaction of the performance obligation for certain product or service and certain customer type we may require payment before product are delivered or service are rendered to customer indirect tax collected from customer and remitted to government authority and that are related to sale of the company product primarily in europe are excluded from revenue practical expedient sale commission are expensed when incurred because the amortization period would have been one year or le these cost are recorded in selling general and administrative sg expense in the consolidated statement of income revenuesother revenue consist primarily of royalty income and corporate partner revenue royalty from licensee are based on third party sale of licensed product and are recorded when the related third party product sale occurs royalty income is estimated based on historical and forecasted sale trend corporate partner revenue are composed mainly of license fee and milestone earned and our share of commercial profit generated from collaboration see arrangement with multiple performance obligation discussed below arrangement with multiple performance obligationsfrom time to time we enter into arrangement for the research and development manufacture and or commercialization of product and product candidate such arrangement may require to deliver various right service and or good including intellectual property right license service manufacturing service and or commercialization service the underlying term of these arrangement generally provide for consideration to amgen in the form of nonrefundable upfront license fee development and commercial performance milestone payment royalty payment and or profit sharing in arrangement involving more than one performance obligation each required performance obligation is evaluated to determine whether it qualifies distinct performance obligation based on whether the customer can benefit from the good or service either on it own or together with other resource that are readily available and ii the good or service is separately identifiable from other promise in the contract the consideration under the arrangement is then allocated to each separate distinct performance obligation based on it respective relative stand alone selling price the estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable wa regularly sold by on stand alone basis or by using an adjusted market assessment approach if selling price on stand alone basis is not available the consideration allocated to each distinct performance obligation is recognized revenue when control of the related good or service is transferred consideration associated with at risk substantive performance milestone is recognized revenue when it is probable that significant reversal of the cumulative revenue recognized will not occur we utilize the sale and usage based royalty exception in arrangement that resulted from the license of intellectual property recognizing revenue generated from royalty or profit sharing the underlying sale occur research and development costsr cost are expensed incurred and primarily include salary benefit and other staff related cost facility and overhead cost clinical trial and related clinical manufacturing cost contract service and other outside cost information system cost and amortization of acquired technology used in with alternative future us expense also include cost and cost recovery associated with third party arrangement including upfront fee and milestone paid to third party in connection with technology that had not reached technological feasibility and did not have an alternative future use net payment or reimbursement of cost is recognized when the obligation are incurred or we become entitled to the cost recovery see note collaboration selling general and administrative costssg cost are primarily composed of salary benefit and other staff related cost associated with sale and marketing finance legal and other administrative personnel facility and overhead cost outside marketing advertising and legal expense the healthcare reform federal excise fee on branded prescription pharmaceutical manufacturer and importer and other general and administrative cost advertising cost are expensed incurred and were million million and million during the year ended december and respectively sg expense also include cost and cost recovery associated with marketing and promotion effort under certain collaborative arrangement net payment or reimbursement of sg cost is recognized when the obligation are incurred or we become entitled to the cost recovery see note collaboration of new lease standardin february the financial accounting standard board fasb issued new accounting standard that amends the guidance for the accounting and disclosure of lease this new standard requires that lessee recognize the asset and liability that arise from lease on the balance sheet including lease classified operating lease and that they disclose qualitative and quantitative information about leasing arrangement the fasb subsequently issued additional amendment to address issue arising from the implementation of the new lease standard we adopted this standard of january using the modified retrospective method which provides method for recording existing lease at adoption we used the adoption date our date of initial application and thus comparative period financial information is not presented for period prior to the adoption date in addition we elected the package of practical expedient permitted under the transition guidance within the new standard which among other thing allowed to carry forward the historical lease classification adoption of the new standard resulted in total lease liability of million and right of use rou asset of million of january the difference between the initial lease liability and the rou asset is primarily related to previously existing lease liability the standard did not materially impact our consolidated statement of income and had no impact on our consolidated statement of cash flow our accounting policy under the new standard are described below see note lease lease recognitionat inception of contract we determine whether an arrangement is or contains lease for all lease we determine the classification either operating or financing operating lease are included in other asset accrued liability and other noncurrent liability in our consolidated balance sheet rou asset represent our right to use an underlying asset for the lease term and lease liability represent our obligation to make lease payment under the lease lease recognition occurs at the commencement date and lease liability amount are based on the present value of lease payment made during the lease term our lease term may include option to extend or terminate the lease when it is reasonably certain that we will exercise that option because most of our lease do not provide information to determine an implicit interest rate we use our incremental borrowing rate in determining the present value of lease payment rou asset also include any lease payment made prior to the commencement date le lease incentive received operating lease expense is recognized on straight line basis over the lease term we have lease agreement with both lease and nonlease component which are generally accounted for together single lease component in addition for certain vehicle and equipment lease we apply portfolio approach to determine the lease term and discount rate stock based compensationwe have stock based compensation plan under which various type of equity based award are granted including restricted stock unit rsus performance unit and stock option the fair value of rsus and stock option award which are subject only to service condition with graded vesting are recognized compensation expense generally on straight line basis over the service period net of estimated forfeiture the fair value of performance unit award are recognized compensation expense generally on straight line basis from the grant date to the end of the performance period see note stock based compensation income taxeswe provide for income tax based on pretax income and applicable tax rate in the various jurisdiction in which we operate significant judgment is required in determining our provision for income tax and income tax asset and liability including evaluating uncertainty in the application of accounting principle and complex tax law deferred income tax are recorded for the expected tax consequence of temporary difference between the base of asset and liability well for loss and tax credit carryforwards for financial reporting purpose and amount recognized for income tax purpose we record valuation allowance to reduce our deferred tax asset to the amount of future tax benefit that is more likely than not to be realized recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authority based on the technical merit of the position the tax benefit recognized in the consolidated financial statement for particular tax position is based on the largest benefit that is more likely than not to be realized the amount of unrecognized tax benefit utbs is adjusted appropriate for change in fact and circumstance such significant amendment to existing tax law new regulation or interpretation by tax authority new information obtained during tax examination or resolution of an examination we recognize both accrued interest and penalty where appropriate related to utbs in income tax expense see note income tax acquisitionswe first determine whether set of asset acquired constitute business and should be accounted for business combination if the asset acquired are not business we account for the transaction an asset acquisition business combination are accounted for by using the acquisition method of accounting under the acquisition method asset acquired including in process research and development ipr project and liability assumed are recorded at their respective fair value of the acquisition date in our consolidated financial statement the excess of the fair value of consideration transferred over the fair value of the net asset acquired is recorded goodwill contingent consideration obligation incurred in connection with business combination including the assumption of an acquiree liability arising from an acquisition it consummated prior to our acquisition are recorded at their fair value on the acquisition date and remeasured at their fair value each subsequent reporting period until the related contingency are resolved the resulting change in fair value are recorded in earnings in contrast asset acquisition are accounted for using cost accumulation and allocation model under this model the cost of the acquisition is allocated to the asset acquired and liability assumed contingent consideration obligation incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated see note acquisition and note fair value measurement cash equivalentswe consider cash equivalent to be only those investment that are highly liquid readily convertible to cash and which mature within three month from the date of purchase interest bearing securitieswe consider our interest bearing security investment portfolio available for sale and accordingly these investment are recorded at fair value with unrealized gain and loss recorded in accumulated other comprehensive income loss aoci investment with maturity beyond one year may be classified short term marketable security in the consolidated balance sheet due to their highly liquid nature and because they represent the company investment that are available for current operation see note investment and note fair value measurement inventoriesinventories are stated at the lower of cost or net realizable value cost which includes amount related to material labor and overhead is determined in manner that approximates the first in first out method net realizable value is the estimated selling price in the ordinary course of business le reasonably predictable cost of completion disposal and transportation see note inventory derivativeswe recognize all of our derivative instrument either asset or liability at fair value in the consolidated balance sheet the accounting for change in the fair value of derivative instrument depends on whether the derivative ha been formally designated and qualifies part of hedging relationship under the applicable accounting standard and further on the type of hedging relationship for derivative formally designated hedge we ass both at inception and quarterly thereafter whether the hedging derivative are highly effective in offsetting change in either the fair value or cash flow of the hedged item our derivative that are not designated and do not qualify hedge are adjusted to fair value through current earnings see note fair value measurement and note derivative instrument property plant and equipment netproperty plant and equipment is recorded at historical cost net of accumulated depreciation amortization and if applicable impairment charge we review our property plant and equipment asset for impairment whenever event or change in circumstance indicate that the carrying amount of an asset may not be recoverable depreciation is provided over the asset useful life on straight line basis leasehold improvement are amortized on straight line basis over the shorter of their estimated useful life or lease term see note property plant and equipment and other intangible assetsfinite lived intangible asset are recorded at cost net of accumulated amortization and if applicable impairment charge amortization of finite lived intangible asset is provided over their estimated useful life on straight line basis or based on the pattern in which economic benefit are consumed if reliably determinable we review our finite lived intangible asset for impairment whenever event or change in circumstance indicate that the carrying amount of an asset may not be recoverable see note goodwill and other intangible asset the fair value of ipr project acquired in business combination that are not complete are capitalized and accounted for indefinite lived intangible asset until completion or abandonment of the related effort upon successful completion of the project the capitalized amount is amortized over it estimated useful life if project is abandoned all remaining capitalized amount are written off immediately there are often major risk and uncertainty associated with ipr project we are required to obtain regulatory approval in order to be able to market the resulting product such approval require completing clinical trial that demonstrate product candidate is safe and effective consequently the eventual realized value of the acquired ipr project may vary from it fair value at the date of acquisition and ipr impairment charge may occur in future period capitalized ipr project are tested for impairment annually and whenever event or change in circumstance indicate that the carrying amount may not be recoverable we consider various factor for potential impairment including the current legal and regulatory environment and the competitive landscape adverse clinical trial result significant delay in obtaining marketing approval the inability to bring product to market and the introduction or advancement of competitor product could result in partial or full impairment of the related intangible asset we perform an impairment test of goodwill annually and whenever event or change in circumstance indicate that the carrying amount may not be recoverable to date an impairment of goodwill ha not been recorded see note goodwill and other intangible asset contingenciesin the ordinary course of business we are involved in various legal proceeding government investigation and other matter that are complex in nature and have outcome that are difficult to predict certain of these proceeding are discussed in note contingency and commitment we record accrual for loss contingency to the extent that we conclude that it is probable that liability ha been incurred and the amount of the related loss can be reasonably estimated we evaluate on quarterly basis development in legal proceeding and other matter that could cause an increase or decrease in the amount of the liability that ha been accrued previously foreign currency translationthe net asset of international subsidiary whose local currency have been determined to be the functional currency are translated into dollar using current exchange rate the dollar effect that arise from translating net asset of these subsidiary at changing rate are recognized in aoci the subsidiary earnings are translated into dollar using average exchange rate equity method investmentsthe equity method of accounting is used for equity investment that give the ability to exert significant influence but not control over an investee based on such factor our ownership percentage voting and other shareholder right board of director representation and the existence of other collaborative or business relationship the equity method of accounting requires to allocate the difference between the fair value of security acquired and our proportionate share of the carrying value of the underlying asset the basis difference to various item and amortize such difference over their useful life our share of the investees earnings or loss and amortization of basis difference if any are recorded one quarter in arrears in interest and other income net in the consolidated statement of income we record impairment loss on our equity method investment if we deem the impairment to be other than temporary we deem an impairment to be other than temporary based on various factor including but not limited to the length of time the fair value is below the carrying value volatility of the security price and our intent and ability to retain the investment to allow for recovery in fair value accounting pronouncementsin june the fasb issued new accounting standard that amends the guidance for measuring and recording credit loss on financial asset measured at amortized cost by replacing the incurred loss model with an expected loss model accordingly these financial asset are now presented at the net amount expected to be collected this new standard also requires that credit loss related to available for sale debt security be recorded an allowance through net income rather than reducing the carrying amount under the former other than temporary impairment model we adopted this standard of january using modified retrospective approach adoption of the standard did not have material impact on our consolidated financial statement in march the fasb issued new accounting standard to ease the financial reporting burden of the expected market transition from the london interbank offered rate libor and other interbank offered rate to alternative reference rate commonly referred to reference rate reform the new standard provides temporary optional expedient and exception to current gaap guidance on contract modification and hedge accounting specifically modification to transition to an alternative reference rate is treated an event that doe not require contract remeasurement or reassessment of previous accounting treatment moreover for all type of hedging relationship an entity may change the reference rate without having to dedesignate the hedging relationship the standard is generally effective for all contract modification made and hedging relationship evaluated through december in january the fasb issued new accounting standard to expand on the scope of the original march standard to include derivative instrument on discounting transaction we are currently evaluating the impact that both standard will have on our consolidated financial statement acquisition otezla apremilast on november we acquired worldwide right to otezla the only oral non biologic treatment for psoriasis and psoriatic arthritis along with certain related asset and liability from celgene corporation celgene otezla is primarily used for the treatment of patient with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than market outside the united state including the european union and japan the acquisition wa accounted for an asset acquisition under gaap because substantially all of the value of the asset acquired wa concentrated in the global intellectual property right of otezla the operation of otezla have been included in our consolidated financial statement commencing on the acquisition date the following table summarizes the consideration transferred and the allocation of the estimated accumulated cost including tax adjustment to the asset acquired and liability assumed in million amountscash purchase price transaction cost accumulated cost consideration transferred intangible asset developed product technology right marketing related deferred tax liability net deferred credit other liability net total asset acquired net amgen allocated the accumulated cost of the acquisition to the asset acquired based on their relative fair value the accumulated cost of the acquisition includes direct acquisition related cost and applicable tax goodwill is not recognized in the accounting for an asset acquisition rather the excess of the accumulated cost over the fair value of the net asset acquired is reallocated to the nonfinancial asset acquired developed product technology right acquired relate to otezla the estimated fair value wa determined by using multi period excess earnings income approach which is based on the present value of the incremental after tax cash flow attributable only to the intangible asset the developed product technology right will be amortized over weighted average period of year by using the straight line method the estimated fair value of marketing related right which relate to assembled workforce wa determined using replacement cost approach which consists of developing an estimate of the current cost of similar new asset having the nearest equivalent utility to the asset being valued the assembled workforce will be amortized over period of year by using the straight line method the estimated fair value of the acquired inventory wa determined using the comparative sale method which us actual or expected selling price of inventory the base amount to which adjustment for selling effort and profit on the buyer effort are applied inventory fair value adjustment will be amortized inventory turn over which we estimate to approximate year upon closing we had difference between the book basis and tax basis of the asset acquired the company used the simultaneous equation method to determine the assigned value of the net asset acquired and the related deferred tax asset or liability use of this methodology resulted in an increase to the carrying value of the intangible asset of million net deferred tax liability of million and deferred credit of million the tax effect of the acquisition are based on amgen estimated blended statutory tax rate of nuevolution abon july we acquired all of the outstanding stock of nuevolution ab nuevolution publicly traded denmark based biotechnology company with leading small molecule drug discovery platform for total consideration of million in cash the transaction which wa accounted for business combination expands our ability to discover novel small molecule against difficult to drug target and with greater speed and efficiency nuevolution operation which are not material have been included in our consolidated financial statement commencing on the acquisition date we allocated the consideration to acquire nuevolution to finite lived intangible asset of million primarily comprised of technology right for drug discovery platform with an estimated useful life of year goodwill of million which is not tax deductible deferred tax liability of million and other net asset of million the estimated fair value of intangible asset were determined primarily by using probability weighted income approach which discount expected future cash flow to present value by using discount rate that represents the estimated rate that market participant would use to value the intangible asset kirin amgen inc during the first quarter of we acquired the remaining ownership of kirin amgen inc from kirin holding company limited kirin making wholly owned subsidiary of amgen upon the acquisition operation have been included in our consolidated financial statement commencing on the share acquisition date the acquisition relieved amgen of future royalty obligation to prior to the share acquisition date we owned of and accounted for our interest in by using the equity method of accounting the transaction wa accounted for step acquisition of business in which we were required to remeasure our existing ownership interest at fair value in addition we were required to effectively settle our preexisting relationship with which resulted in loss together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in net gain of million which wa recorded in interest and other income net in the consolidated statement of income primary mean of consideration for this transaction wa payment of million in cash the aggregate share acquisition date consideration to acquire the remaining ownership in and the fair value of amgen preacquisition investment consisted of the following in million amountstotal cash paid to kirin fair value of contingent consideration loss on settlement of preexisting relationship total consideration transferred to acquire fair value of amgen investment in total acquisition date fair value in connection with this acquisition we are obligated to make single digit royalty payment to kirin contingent upon sale of brodalumab the estimated fair value of this contingent consideration obligation wa million of the share acquisition date the fair value of asset acquired and liability assumed consisted of cash of million licensing right of million deferred tax liability of million other asset and liability of million and goodwill of million the estimated fair value of acquired licensing right wa determined by using probability related income approach which is based on the present value of the incremental after tax cash flow attributable only to the intangible asset the projected cash flow were based on certain assumption including estimate of future revenue and expense and the time and resource needed to maintain the asset through commercialization the licensing right will be amortized over weighted average period of four year by using the straight line method the excess of the share acquisition date consideration over the fair value assigned to the asset acquired and the liability assumed of million wa recorded goodwill which is not deductible for tax purpose the million in other asset and liability primarily represents receivables for royalty earned by but not yet received partially offset by payable representing expense incurred but not yet reimbursed by pro forma result of operation for this acquisition have not been presented because this acquisition wa not material to our consolidated result of operation revenueswe operate in one business segment human therapeutic therefore result of our operation are reported on consolidated basis for purpose of segment reporting consistent with internal management reporting revenue by product and by geographic area based on customer location are presented below the majority of rest of world row revenue relates to product sold in europe revenue were follows in million year ended december ended december ended december rowtotalu rowtotalu rowtotalenbrel etanercept prolia denosumab neulasta pegfilgrastim otezla xgeva denosumab aranesp darbepoetin alfa kyprolis carfilzomib repatha evolocumab other total product sale other total revenue ____________ otezla wa acquired on november hedging gain and loss which are included in product sale were not material for the year ended december and in the united state we sell primarily to pharmaceutical wholesale distributor that we utilize the principal mean of distributing our product to healthcare provider outside the united state we sell principally to healthcare provider and or pharmaceutical wholesale distributor depending on the distribution practice in each country we monitor the financial condition of our larger customer and limit our credit exposure by setting credit limit and in certain circumstance by requiring letter of credit or obtaining credit insurance had product sale to three customer each of them accounting for more than of total revenue for each of the year ended december and for the year ended december on combined basis these customer accounted for of total gross revenue shown in the following table certain information with respect to these customer wa follows dollar amount in million year ended december corporation gross product sale of total gross mckesson corporation gross product sale of total gross cardinal health inc gross product sale of total gross of december and amount due from these three customer each exceeded of gross trade receivables and accounted for and respectively of net trade receivables on combined basis of december and and respectively of net trade receivables were due from customer located outside the united state the majority of which were from europe our total allowance for doubtful account of december and wa not material stock based compensationour amended and restated equity incentive plan the amended plan authorizes for issuance to employee of amgen and nonemployee member of our board of director share of our common stock pursuant to grant of equity based award including rsus stock option and performance unit the pool of share available under the amended plan is reduced by one share for each stock option granted and by share for other type of award granted including rsus and performance unit full value award in general if any share subject to an award granted under the amended plan expire or become forfeited terminated or canceled without the issuance of share the share subject to such award are added back into the authorized pool on the same basis that they were removed in addition under the amended plan share withheld to pay for minimum statutory tax obligation with respect to full value award are added back into the authorized pool on the basis of share of december the amended plan provides for future grant and or issuance of up to approximately million share of our common stock stock based award under our employee compensation plan are made with newly issued share reserved for this purpose the following table reflects the component of stock based compensation expense recognized in our consolidated statement of income in million year ended december performance stock total stock based compensation expense tax benefit from stock based compensation expense total stock based compensation expense net of tax restricted stock unit and stock optionseligible employee generally receive an annual grant of rsus and for certain executive level employee stock option with the size and type of award generally determined by the employee salary grade and performance level certain management and professional level employee typically receive rsu grant upon commencement of employment nonemployee member of our board of director also receive an annual grant of rsus rsu and stock option grant provide for accelerated or continued vesting in certain circumstance defined in the plan and related grant agreement including upon death disability termination in connection with change in control and the retirement of employee who meet certain service and or age requirement rsus and stock option generally vest in equal amount on the second third and fourth anniversary of the grant date rsus accrue dividend equivalent which are typically payable in share only when and to the extent the underlying rsus vest and are issued to the recipient restricted stock unitsthe grant date fair value of an rsu equal the closing price of our common stock on the grant date rsus accrue dividend equivalent during their vesting period the weighted average grant date fair value per unit of rsus granted during the year ended december and were and respectively the following table summarizes information regarding our rsus year ended december in million weighted averagegrant datefair valuebalance nonvested of december vested forfeited balance nonvested of december the total grant date fair value of rsus that vested during the year ended december and were million million and million respectively stock optionsthe exercise price of stock option is set the closing price of our common stock on the grant date and the related number of share granted is fixed at that point in time award expire year from the date of grant we use the black scholes option valuation model to estimate the grant date fair value of stock option the weighted average assumption used in the option valuation model and the resulting weighted average grant date fair value of stock option granted were follows year ended december price of our common stock on grant date expected volatility average of implied and historical volatility expected life in year free interest expected dividend fair value of stock option granted following table summarizes information regarding our stock option year ended december in million weighted averageexercise priceweighted averageremainingcontractuallife in year aggregateintrinsicvalue in million balance unexercised of december exercised expired forfeited balance unexercised of december vested or expected to vest of december exercisable of december the total intrinsic value of option exercised during the year ended december and were million million and million respectively the actual tax benefit realized from tax deduction from option exercise during the year ended december and were million million and million respectively of december million of unrecognized compensation cost wa related to nonvested rsus and unvested stock option which is expected to be recognized over weighted average period of year performance unitscertain management level employee also receive annual grant of performance unit which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goal over the performance period which is generally three year the performance goal for the unit granted during the year ended december and which are accounted for equity award are based on amgen stockholder return compared with comparator group of company which are considered market condition and are therefore reflected in the grant date fair value of the unit and ii amgen stand alone financial performance measure which are considered performance condition the expense recognized for award is based on the grant date fair value of unit multiplied by the number of unit expected to be earned with respect to the related performance condition net of estimated forfeiture depending on the outcome of these performance goal recipient may ultimately earn number of unit greater or le than the number of unit granted share of our common stock are issued on one for one basis for each performance unit earned in general performance unit award vest at the end of the performance period the performance award program provides for accelerated or continued vesting in certain circumstance defined in the plan including upon death disability change in control and retirement of employee who meet certain service and or age requirement performance unit accrue dividend equivalent that are typically payable in share only when and to the extent the underlying performance unit vest and are issued to the recipient including with respect to market and performance condition that affect the number of performance unit earned we use payout simulation model to estimate the grant date fair value of performance unit the weighted average assumption used in the payout simulation model and the resulting weighted average grant date fair value of performance unit granted were follows year ended december price of our common stock on grant date risk free interest fair value of unit granted the payout simulation model assumes correlation of return of the stock price of our common stock and the common stock of the comparator group of company and stock price volatility of the comparator group of company to simulate stockholder return over the performance period and their resulting impact on the payout percentage based on the contractual term of the performance unit of december and million and million performance unit were outstanding with weighted average grant date fair value per unit of and per unit respectively during the year ended december million performance unit with weighted average grant date fair value per unit of were granted and million performance unit with weighted average grant date fair value per unit of were forfeited the total fair value of performance unit paid during the year ended december and were million million and million respectively based on the number of performance unit earned multiplied by the closing stock price of our common stock on the last day of the performance period of december million of unrecognized compensation cost wa related to nonvested performance unit which is expected to be recognized over weighted average period of one year defined contribution planthe company ha defined contribution plan to which certain employee of the company and participating subsidiary may defer compensation for income tax purpose participant are eligible to receive matching contribution based on their contribution in addition to other company contribution defined contribution plan expense were million million and million for the year ended december and respectively income taxesincome before income tax included the following in million year ended december total income before income tax the provision for income tax included the following in million year ended december provision federal total current deferred benefit provision federal foreign total deferred benefit total provision for income tax income tax reflect the tax effect of temporary difference between the carrying amount of asset and liability for financial reporting purpose and the amount used for income tax purpose tax credit carryforwards and the tax effect of net operating loss nol carryforwards significant component of our deferred tax asset and liability were follows in million december income tax asset nol and credit carryforwards accrued expense capitalized for stock based total deferred income tax valuation allowance net deferred income tax deferred income tax liability acquired intangible asset debt fixed asset other total deferred income tax liability total deferred income tax net valuation allowance are provided to reduce the amount of our deferred tax asset to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence including estimate of future taxable income necessary to realize future deductible amount the valuation allowance increased in primarily driven by the company expectation that some state credit will not be utilized and that certain foreign net operating loss will expire unused of december we had million of federal tax credit carryforwards available to reduce future federal income tax and have provided no valuation allowance for those federal tax credit carryforwards the federal tax credit carryforwards expire between and we had million of state tax credit carryforwards available to reduce future state income tax and have provided valuation allowance for million of those state tax credit carryforwards of december we had million of federal nol carryforwards available to reduce future federal income tax and have provided valuation allowance for million of those federal nol carryforwards the federal nol carryforwards for which no valuation allowance ha been provided expire between and we had million of state nol carryforwards available to reduce future state income tax and have provided valuation allowance for all of the state nol carryforwards we had billion of foreign nol carryforwards available to reduce future foreign income tax and have provided valuation allowance for million of those foreign nol carryforwards for the foreign nols with no valuation allowance provided million ha no expiry and the remainder will expire between and reconciliation of the total gross amount of utbs were follows in million year ended december balance addition based on tax position related to the current addition based on tax position related to prior reduction for tax position of prior year settlement ending balance substantially all of the utbs of december if recognized would affect our effective tax rate during the year ended december we effectively settled certain issue with the irs result we remeasured our utbs accordingly interest and penalty related to utbs are included in our provision for income tax during the year ended december and we recognized million million and million respectively of interest and penalty through the income tax provision in the consolidated statement of income the decrease in interest expense for the year ended december wa primarily due to lower interest rate during of december and accrued interest and penalty associated with utbs were million and million respectively the reconciliation between the federal statutory tax rate applied to income before income tax and our effective tax rate were follows year ended december statutory tax foreign earnings foreign derived intangible income credit puerto rico excise tax tax act net impact on intercompany sale interest on uncertain tax credit primarily federal audit settlement other net effective tax the effective tax rate for the year ended december and differ from the federal statutory rate primarily due to impact of the jurisdictional mix of income and expense substantially all of the benefit to our effective tax rate from foreign earnings result from the company operation in puerto rico territory of the united state that is treated foreign jurisdiction for tax purpose our operation in puerto rico are subject to tax incentive grant through additionally the company operation conducted in singapore are subject to tax incentive grant through our foreign earnings are also subject to tax at reduced rate of the territory of puerto rico imposes an excise tax on the gross intercompany purchase price of good and service from our manufacturing site in puerto rico the rate of is effective through december we account for the excise tax manufacturing cost that is capitalized in inventory and expensed in cost of sale when the related product are sold for income tax purpose the excise tax result in foreign tax credit that are generally recognized in our provision for income tax when the excise tax is incurred income tax paid during the year ended december and were billion billion and billion respectively or more of our legal entity file income tax return in the federal jurisdiction various state jurisdiction and certain foreign jurisdiction our income tax return are routinely examined by tax authority in those jurisdiction significant dispute may arise with tax authority involving issue regarding the timing and amount of deduction the use of tax credit and allocation of income and expense among various tax jurisdiction because of differing interpretation of tax law regulation and relevant fact in we received revenue agent report rar and modified rar from the internal revenue service irs for the year and proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico we disagree with the proposed adjustment and calculation and have been pursuing resolution with the irs administrative appeal office however we have been unable to reach resolution at the administrative appeal level and we anticipate that we will receive notice of deficiency which we would expect to vigorously contest through the judicial process in addition in we received an rar and modified rar from the irs for the year and also proposing significant adjustment that primarily relate to the allocation of profit between certain of our entity in the united state and the territory of puerto rico similar to those proposed for the year and we disagree with the and proposed adjustment and calculation and are pursuing resolution with the irs administrative appeal office the irs audit for year and is expected to start in the near term we are also currently under examination by number of other state and foreign tax jurisdiction final resolution of these complex matter is not likely within the next month we believe our accrual for income tax liability is appropriate based on past experience interpretation of tax law application of the tax law to our fact and judgment about potential action by tax authority however due to the complexity of the provision for income tax and uncertain resolution of these matter the ultimate outcome of any tax matter may result in payment substantially greater than amount accrued and could have material adverse impact on our consolidated financial statement we are no longer subject to federal income tax examination for year ended on or before december earnings per sharethe computation of basic earnings per share eps is based on the weighted average number of our common share outstanding the computation of diluted eps is based on the weighted average number of our common share outstanding and dilutive potential common share which primarily include share that may be issued under our stock option restricted stock and performance unit award program collectively dilutive security determined by using the treasury stock method the computation for basic and diluted eps were follows in million except per share data year ended december numerator net income for basic and diluted eps share denominator weighted average share for basic effect of dilutive weighted average share for diluted basic eps diluted eps for each of the three year ended december the number of antidilutive employee stock based award excluded from the computation of diluted eps wa not significant collaborationsa collaborative arrangement is contractual arrangement that involves joint operating activity such arrangement involve two or more party that are both active participant in the activity and ii exposed to significant risk and reward dependent on the commercial success of the activity from time to time we enter into collaborative arrangement for the manufacture and or commercialization of product and or product candidate these collaboration generally provide for nonrefundable upfront license fee development and commercial performance milestone payment cost sharing royalty payment and or profit sharing our collaboration arrangement are performed with no guarantee of either technological or commercial success and each arrangement is unique in nature see note summary of significant accounting policy for additional discussion of revenue recognized for these type of arrangement operating expense for cost incurred pursuant to these arrangement are reported in their respective expense line item in the consolidated statement of income net of any payment due to or reimbursement due from our collaboration partner with such reimbursement being recognized at the time the party becomes obligated to pay our significant arrangement are discussed below beigene ltd on january we acquired stake in beigene ltd beigene for approximately billion in cash part of collaboration to expand our oncology presence in china under the collaboration beigene commenced selling xgeva and will commercialize kyprolis and blincyto blinatumomab in china and amgen will share profit and loss equally during the initial product specific commercialization period thereafter product right may revert to amgen and amgen will pay royalty to beigene on sale in china of such product for specified period in addition we will jointly develop portion of our oncology portfolio with beigene sharing in global cost by providing cash and development service up to billion upon regulatory approval beigene will assume commercialization right in china for specified period and amgen and beigene will share profit equally until certain of these product right revert to amgen upon return of the product right amgen will pay royalty to beigene on sale in china for specified period for product sale outside of china amgen will also pay beigene royalty during the year ended december net cost recovered from beigene for oncology product candidate were million and were recorded an offset to expense in the consolidated statement of income profit share payment and product sale between amgen and beigene were not material for the year ended december of december the amount owed from beigene for net cost recovered wa million which is included in other current asset in the consolidated balance sheet in connection with this collaboration we acquired an ownership interest in beigene see note investment novartis pharma agwe are in collaboration with novartis pharma ag novartis to jointly develop and commercialize aimovig erenumab aooe in the united state amgen and novartis jointly develop and collaborate on the commercialization of aimovig amgen the principal recognizes product sale of aimovig in the united state share commercialization cost with novartis and pay novartis significant royalty on net sale in the united state novartis hold global co development right and exclusive commercial right outside the united state and japan for aimovig novartis pay amgen double digit royalty on net sale of the product in the novartis exclusive territory and fund portion of global expense in addition novartis will make payment to amgen of up to million if certain commercial and expenditure threshold are achieved with respect to aimovig in the united state amgen manufacture and supply aimovig worldwide the migraine collaboration will continue for the commercial life of the product unless terminated in accordance with it term we are currently involved in litigation with novartis over our collaboration agreement for the development and commercialization of aimovig see note contingency and commitment during the year ended december and net cost recovered from novartis for migraine product were million and million respectively and were recorded primarily in sg expense in the consolidated statement of income during the year ended december net cost paid to novartis for migraine product were million and were recorded primarily in sg expense in the consolidated statement of income during the year ended december and royalty due to novartis for aimovig were million million and million respectively and were recorded in cost of sale in the consolidated statement of income during the year ended december and royalty due from novartis for aimovig were not material result of certain regulatory and commercial event we received milestone payment from novartis of million during the year ended december which wa recorded in other revenue in the consolidated statement of income healthcare llcwe are in licensing arrangement with bayer healthcare llc bayer for nexavar nexavar is currently marketed and sold in more than country around the world for the treatment of unresectable liver cancer and advanced kidney cancer in the united state nexavar is also approved for the treatment of patient with locally recurrent or metastatic progressive differentiated thyroid carcinoma refractory to radioactive iodine treatment in we amended the term of our agreement with bayer which transferred all our operational responsibility outside the united state to bayer including commercial and medical affair activity prior to the amendment of the agreement we shared equally in the profit outside the united state excluding japan in lieu of this profit share bayer now pay royalty on sale of nexavar at percentage rate in the low the right to develop and market nexavar in japan are reserved to bayer in the united state bayer pay royalty on sale of nexavar at percentage rate in the high the agreement with bayer will terminate at the later of the date when patent expire that were issued in connection with product candidate discovered under the agreement or on the last day that we or bayer market or sell product commercialized under the agreement anywhere in the world patent related to nexavar began to expire in result of the amendment to the collaboration agreement royalty due from bayer for nexavar were million and net profit were not material for the year ended december during the year ended december and royalty due from bayer for nexavar were million and million respectively during the year ended december and amgen recorded nexavar net profit of million and million respectively royalty and profit share due from nexavar were recorded in other revenue in the consolidated statement of income net expense related to the agreement were not material for the year ended december and otherin addition to the collaboration discussed above we have various other collaboration that are not individually significant to our business at this time pursuant to the term of those agreement we may be required to pay additional amount or we may receive additional amount upon the achievement of various development and commercial milestone which in the aggregate could be significant we may also incur or have reimbursed to significant cost if the related product candidate were to advance to late stage clinical trial in addition if any product related to these collaboration are approved for sale we may be required to pay significant royalty or we may receive significant royalty on future sale the payment of these amount however is contingent upon the occurrence of various future event which have high degree of uncertainty of occurrence investmentsavailable for sale investmentsthe amortized cost gross unrealized gain gross unrealized loss and fair value of interest bearing security all of which are considered available for sale by type of security were follows in million type of security of december treasury note treasury corporate debt security financial industrial other residential mortgage backed security money market mutual other short term interest bearing total available for sale investment type of security of december treasury note treasury bill corporate debt security residential mortgage backed money market mutual other short term interest bearing total available for sale investment the fair value of available for sale investment by location in the consolidated balance sheet were follows in million december consolidated balance sheet and cash equivalent marketable total available for sale investment cash and cash equivalent in the above table excludes bank account cash of million and million of december and respectively fair value of available for sale investment by contractual maturity except for mortgage and asset backed security that do not have single maturity date were follows in million december contractual in one year or le maturing after one year through three maturing after three year through five year residential mortgage backed security total available for sale investment for the year ended december and realized gain on interest bearing security were million million and million respectively and realized loss on interest bearing security were million million and million respectively realized gain and loss on interest bearing security are recorded in interest and other income net in the consolidated statement of income the cost of security sold is based on the specific identification method the primary objective of our investment portfolio is to maintain safety of principal prudent level of liquidity and acceptable level of risk our investment policy limit interest bearing security investment to certain type of debt and money market instrument issued by institution with investment grade credit rating and it place restriction on maturity and concentration by asset class and issuer we review our available for sale investment for decline in fair value below our cost basis each quarter or whenever circumstance indicate that the cost basis of an asset may not be recoverable and ass whether the decline wa due to credit related factor or other factor our evaluation is based on number of factor including the extent to which the fair value is below our cost basis well adverse condition related specifically to the security such any change to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of it amortized cost basis our assessment of whether security is impaired could change in the future based on new development or change in assumption related to that particular security equity securitieswe held investment in equity security with readily determinable fair value of million and million of december and respectively which are included in other asset in the consolidated balance sheet for the year ended december and net unrealized gain on publicly traded security were million million and million respectively realized gain and loss on publicly traded security for the year ended december and were not material we held investment of million and million in equity security without readily determinable fair value of december and respectively which are included in other asset in the consolidated balance sheet gain and loss recognized on these security including adjustment to the carrying value of these security were not material for the year ended december and equity method investmentslimited partnership investmentswe held limited partnership investment of million and million of december and respectively which are included in other asset in the consolidated balance sheet these investment primarily investment fund of early stage biotechnology company are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset value of the underlying investment held by the limited partnership practical expedient these investment are typically redeemable only through distribution upon liquidation of the underlying asset of december unfunded additional commitment to be made for these investment during the next several year were not material for the year ended december and net gain recognized from our limited partnership investment were million million and million respectively january we acquired ownership interest in beigene for billion of which billion wa attributed to the fair value of equity security upon closing with the remainder attributed to prepaid our equity investment in beigene is included in other asset in the consolidated balance sheet the fair value of equity security acquired exceeded our proportionate share of the carrying value of the underlying net asset of beigene by approximately billion this investment is accounted for by using the equity method of accounting which requires to identify and allocate amount to the item that give rise to the basis difference and to amortize these item over their useful life this amortization along with our share of the result of operation of beigene is included in interest and other income net in our consolidated statement of income recognition occurs one quarter in arrears which began in the second quarter of the basis difference wa allocated to finite lived intangible asset indefinite lived intangible asset equity method goodwill and related deferred tax the finite lived intangible asset are being amortized over period ranging from to year during the year ended december we recognized an increase in the carrying value of our investment by purchasing additional share to maintain our ownership interest for an aggregate cost of million and recognized million for the impact of other beigene ownership transaction the carrying value of the investment during the year ended december wa reduced for our share of beigene net loss of million and amortization of the basis difference of million of december the carrying value and fair value of our approximately ownership interest in beigene totaled billion and billion respectively we believe that of december the carrying value of our equity investment in beigene is fully recoverable for information on collaboration agreement we entered into with beigene in connection with this investment see note collaboration inventoriesinventories consisted of the following in million december material work in finished total inventory property plant and equipmentproperty plant and equipment consisted of the following dollar amount in million december useful life in year building and manufacturing laboratory fixed capitalized construction in progress property plant and equipment le accumulated depreciation and amortization property plant and equipment net the year ended december and we recognized depreciation and amortization expense associated with our property plant and equipment of million million and million respectively geographic informationcertain geographic information with respect to property plant and equipment net long lived asset wa follows in million december state puerto total property plant and equipment net goodwill and other intangible assetsgoodwillthe change in the carrying amount of goodwill were follows in million december balance addition from acquisition currency translation adjustment ending balance other intangible assetsother intangible asset consisted of the following in million december grosscarryingamountsaccumulatedamortizationother intangibleassets netgrosscarryingamountsaccumulatedamortizationother intangibleassets netfinite lived intangible asset developed product technology right licensing marketing related technology total finite lived intangible indefinite lived intangible asset ipr total other intangible asset developed product technology right consists of right related to marketed product acquired in acquisition licensing right consists primarily of contractual right acquired in acquisition to receive future milestone royalty and profit sharing payment capitalized payment to third party for milestone related to regulatory approval to commercialize product and up front payment associated with royalty obligation for marketed product marketing related right consists primarily of right related to the sale and distribution of marketed product technology right pertains to technology used in that have alternative future us consists of project acquired in business combination that are not complete at the time of acquisition due to remaining technological risk and or lack of receipt of required regulatory approval all ipr project have major risk and uncertainty associated with the timely and successful completion of the development and commercialization of product candidate including our ability to confirm safety and efficacy based on data from clinical trial our ability to obtain necessary regulatory approval and our ability to successfully complete these task within budgeted cost we are not permitted to market human therapeutic without obtaining regulatory approval and such approval require the completion of clinical trial that demonstrate that product candidate is safe and effective in addition the availability and extent of coverage and reimbursement from third party payer including government healthcare program and private insurance plan well competitive product launch affect the revenue product can generate consequently the eventual realized value if any of acquired ipr project may vary from their estimated fair value we review ipr project for impairment annually whenever event or change in circumstance indicate that the carrying amount may not be recoverable and upon the establishment of technological feasibility or regulatory approval during the year ended december and we recognized amortization associated with our finite lived intangible asset of billion billion and billion respectively amortization of intangible asset is included primarily in cost of sale in the consolidated statement of income the total estimated amortization for our finite lived intangible asset for the year ending december and are billion billion billion billion and billion respectively leaseson january we adopted new accounting standard that amends the guidance for the accounting and reporting of lease certain required disclosure have been made on prospective basis in accordance with the standard guidance see note summary of significant accounting policy we lease certain facility and equipment related primarily to administrative and sale and marketing activity lease with term of month or le are expensed on straight line basis over the term and are not recorded in the consolidated balance sheet most lease include one or more option to renew with renewal term that may extend the lease term up to seven year the exercise of lease renewal option is at our sole discretion in addition some of our lease agreement include rental payment adjusted periodically for inflation our lease agreement neither contain residual value guarantee impose significant restriction or covenant we sublease certain real estate to third party our sublease portfolio consists of operating lease from former and administrative space the following table summarizes information related to our lease all of which are classified operating included in our consolidated balance sheet in million december consolidated balance sheet other asset liability accrued liability other noncurrent total lease liability the component of net lease cost were follows in million year ended december lease sublease income total net lease cost ____________ includes short term lease and variable lease cost which were not material for the year ended december and of lease liability of december were follows in million maturity total lease payment le imputed interest present value of lease liability ____________ includes future rental commitment for abandoned lease of million we expect to receive total future rental income of million related to noncancelable sublease for abandoned facility the weighted average remaining lease term and weighted average discount rate were follows december average remaining lease term in year average discount cash and noncash information related to our lease wa follows in million year ended december paid for amount included in the measurement of lease liability operating cash flow for operating lease rou asset obtained in exchange for lease obligation operating lease of december we have entered into lease that have not yet commenced with total undiscounted future lease payment of million these lease will commence in with lease term from month to year rental expense on operating lease under the prior lease guidance for the year ended december wa million other current asset and accrued liabilitiesother current asset consisted of the following in million december expense corporate partner tax total other current asset accrued liability consisted of the following in million december deduction employee compensation and dividend income tax sale return total accrued liability financing arrangementsour borrowing consisted of the following in million december note due note note due note floating rate note due note due note note due note note due note note due note note due note million note due euro note note due note note due note note due note million bond due swiss franc bond note due note note due note note due note note due note million note due euro note note due note million note due pound sterling note note due note note due note million note due pound sterling note note due note note due note note due note note due note note due note note due note note due note note due note note due note note due note note due note note due note note due note note due note note due note note due note other note due unamortized bond discount premium and issuance cost net fair value total carrying value of le current portion total long term debt there are no material difference between the effective interest rate and the coupon rate of any of our borrowing except for the note the note and the note which have effective interest rate of and respectively the term of all of our outstanding note except our other note due in the event of change in control triggering event we may be required to purchase all or portion of these debt security at price equal to of the principal amount of the note plus accrued and unpaid interest in addition all of our outstanding note except our swiss franc bond and other note due may be redeemed at any time at our option in whole or in part at the principal amount of the note being redeemed plus accrued and unpaid interest and make whole amount which are defined by the term of the note certain of the redeemable note do not require the payment of make whole amount if redeemed during specified period of time immediately prior to the maturity of the note such time period range from one month to six month prior to maturity debt issuancesduring the year ended december we issued debt security in the following offering in february we issued billion of debt consisting of million of the note million of the note billion of the note billion of the note and billion of the note in may we issued billion of debt consisting of billion of the note million of the note and billion of the note which represents further issuance of and which form single series with each of the corresponding series of note issued in february and billion of the note we did not issue any debt or debt security during the year ended december and debt repayment redemptionswe made debt repayment redemption during the year ended december and follows in we repaid redeemed billion of debt including the repayment at maturity of the million aggregate principal amount of the note the million aggregate principal amount of the note the million floating rate note due and the million aggregate principal amount of the note in connection with the redemption of the million aggregate principal amount of the note the billion aggregate principal balance of the note the million aggregate principal balance of the note and the billion aggregate principal balance of the note we paid total of million in make whole amount plus associated accrued and unpaid interest all of which wa recognized in interest expense net in the consolidated statement of income in we repaid billion of debt including the billion aggregate principal amount of the note the billion aggregate principal amount of the note the million aggregate principal amount million upon settlement of the related cross currency swap of the euro note the million aggregate principal amount of the note and the million floating rate note due in we repaid billion of debt including the million aggregate principal amount of the note and the million aggregate principal amount of the note revalued at million upon maturity interest rate swapsto achieve desired mix of fixed rate and floating rate debt we entered into interest rate swap contract that effectively converted fixed rate interest coupon for certain of our debt issuance to floating libor based coupon over the life of the respective note these interest rate swap contract qualified and are designated fair value hedge in connection with the redemption of certain of the note discussed above associated interest rate swap contract with an aggregate notional value of billion were terminated in addition because of historically low interest rate during the year ended december we terminated interest rate swap with an aggregate notional amount of billion that hedged the note the note the note and portion of the note and the note which resulted in the receipt of million of cash and reduced counterparty credit risk immediately following the termination of these contract we entered into new interest rate swap agreement at then current interest rate on the same billion principal amount of note see note derivative instrument effective interest rate on note for which we have entered into interest rate swap contract and the related notional amount of these contract were follows dollar amount in million december amountseffective interest ratesnotional amountseffective interest note libor libor note libor libor note libor libor libor libor libor libor libor libor libor libor note libor libor total notional amount ____________ excludes an additional of interest for the difference between the coupon rate paid to noteholders and the fixed rate received under the interest rate swap contract debt exchangein we completed private offering to exchange portion of certain outstanding senior note due through collectively old note listed below for the million principal amount of the newly issued note the exchange offer the following principal amount of each series of old note were validly tendered and subsequently cancelled in connection with the exchange offer in million principal amount note the note bear interest at lower fixed coupon rate while requiring higher principal repayment at later maturity date compared to those of the old note that were exchanged there were no other significant change to the term between the old note and the note in connection with the exchange offer million wa paid to holder of the old note the cash consideration the exchange offer wa accounted for debt modification and accordingly deferred financing cost and discount associated with the old note the cash consideration and the million discount associated with the note are being accreted over the term of these newly issued note and recorded interest expense net in the consolidated statement of income currency swapsin order to hedge our exposure to foreign currency exchange rate risk associated with certain of our long term note denominated in foreign currency we entered into cross currency swap contract the term of these contract effectively convert the interest payment and principal repayment on our euro note swiss franc bond euro note pound sterling note and pound sterling note from euro pound sterling and swiss franc to dollar these cross currency swap contract have been designated cash flow hedge for information regarding the term of these contract see note derivative instrument shelf registration statement and other facilitiesas of december we have commercial paper program that allows to issue up to billion of unsecured commercial paper to fund our working capital need of december and we had no amount outstanding under our commercial paper program in we amended and restated our billion syndicated unsecured revolving credit agreement which is available for general corporate purpose or liquidity backstop to our commercial paper program the commitment under the revolving credit agreement may be increased by up to million with the agreement of the bank each bank that is party to the agreement ha an initial commitment term of five year this term may be extended for up to two additional one year period with the agreement of the bank annual commitment fee for this agreement are of the unused portion of the facility based on our current credit rating generally we would be charged interest for any amount borrowed under this facility based on our current credit rating at libor plus or ii the highest of the syndication agent bank base commercial lending rate the overnight federal fund rate plus or one month libor plus the agreement contains provision relating to the determination of successor rate to address the possible phase out or unavailability of designated reference rate of december and no amount were outstanding under this facility in february we filed shelf registration statement with the security and exchange commission that allows to issue unspecified amount of debt security common stock preferred stock warrant to purchase debt security common stock preferred stock or depository share right to purchase common stock or preferred stock security purchase contract security purchase unit and depository share under this shelf registration statement all of the security available for issuance may be offered from time to time with term to be determined at the time of issuance this shelf registration statement expires in february certain of our financing arrangement contain nonfinancial covenant in addition our revolving credit agreement includes financial covenant which requires to maintain specified minimum interest coverage ratio of the sum of consolidated net income interest expense provision for income tax depreciation expense amortization expense unusual or nonrecurring charge and other noncash item consolidated ebitda to ii consolidated interest expense each defined and described in the credit agreement we were in compliance with all applicable covenant under these arrangement of december contractual maturity of debt obligationsthe aggregate contractual maturity of all borrowing due subsequent to december are follows in million maturity total interest costsinterest cost are expensed incurred except to the extent such interest is related to construction in progress in which case interest is capitalized interest cost capitalized for the year ended december and were not material interest paid including the ongoing impact of interest rate and cross currency swap contract during the year ended december and were billion billion and billion respectively stockholder equitystock repurchase programactivity under our stock repurchase program on trade date basis wa follows in million year ended december dollarsshares dollarsfirst second third fourth total stock total share do not add due to rounding in december our board of director increased the amount authorized under our stock repurchase program by an additional billion of december billion remained available under our stock repurchase program dividendsour board of director declared quarterly dividend per share of and which were paid in each of the four quarter of and respectively historically we have declared dividend in december of each year which were paid in the first quarter of the following fiscal year and in march july and october which were paid in the second third and fourth quarter respectively of the same fiscal year additionally on december the board of director declared quarterly cash dividend of per share of common stock which will be paid on march to all stockholder of record of the close of business on february other comprehensive lossthe component of aoci were follows in million foreigncurrencytranslationcash flowhedgesavailable for salesecuritiesotheraocibalance of december cumulative effect of change in accounting principle net of tax foreign currency translation adjustment unrealized gain loss reclassification adjustment to income other loss income tax balance of december foreign currency translation adjustment unrealized gain reclassification adjustment to income other loss income tax balance of december foreign currency translation unrealized loss gain reclassification adjustment to income other loss income tax balance of december with respect to the table above income tax expense or benefit for unrealized gain and loss and the related reclassification adjustment to income for cash flow hedge were million benefit and million benefit in million expense and million benefit in and million expense and million expense in respectively income tax expense or benefit for unrealized gain and loss and the related reclassification adjustment to income for available for sale security were million expense and million benefit in million expense and million benefit in and million benefit and million expense in respectively out of aoci and into earnings were follows in million year ended december component of statement of income locationscash flow hedge foreign currency contract gain loss product salescross currency swap contract gain loss interest and other income income before income tax provision for income tax net incomeavailable for sale security net realized gain loss interest and other income net provision for income tax net incomeotherin addition to common stock our authorized capital includes million share of preferred stock par value of december and no share of preferred stock were issued or outstanding fair value measurementto estimate the fair value of our financial asset and liability we use valuation approach within hierarchy that maximizes the use of observable input and minimizes the use of unobservable input by requiring that observable input be used when available observable input are input that market participant would use in pricing an asset or liability based on market data obtained from source independent of the company unobservable input are input that reflect the company assumption about the input that market participant would use in pricing an asset or liability and are developed based on the best information available in the circumstance the fair value hierarchy is divided into three level based on the source of input follows level valuation based on unadjusted quoted price in active market for identical asset or liability that the company ha the ability to accesslevel valuation for which all significant input are observable either directly or indirectly other than level inputslevel valuation based on input that are unobservable and significant to the overall fair value measurementthe availability of observable input can vary among the various type of financial asset and liability to the extent that the valuation is based on model or input that are le observable or unobservable in the market the determination of fair value requires more judgment in certain case the input used for measuring fair value may fall into different level of the fair value hierarchy in such case for financial statement disclosure purpose the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement fair value of each major class of the company financial asset and liability measured at fair value on recurring basis were follows in million fair value measurement of december using quoted price inactive market foridentical asset level significant otherobservableinputs level significantunobservableinputs level totalassets available for sale security treasury note treasury corporate debt security financial industrial other residential mortgage backed security money market mutual other short term interest bearing security equity derivative foreign currency contract cross currency swap contract interest rate swap contract total asset liability derivative foreign currency contract cross currency swap contract interest rate swap contract contingent consideration obligation total liability value measurement of december using quoted price inactive market foridentical asset level significant otherobservableinputs level significantunobservableinputs level totalassets available for sale security treasury note treasury bill corporate debt security financial industrial other residential mortgage backed security money market mutual other short term interest bearing security equity derivative foreign currency contract cross currency swap contract interest rate swap contract total asset liability derivative foreign currency contract cross currency swap contract interest rate swap contract contingent consideration obligation total liability interest bearing and equity securitiesthe fair value of our treasury security money market mutual fund and equity security are based on quoted market price in active market with no valuation adjustment we estimate the fair value of our corporate debt security by taking into consideration valuation obtained from third party pricing service the pricing service use industry standard valuation model including both income and market based approach for which all significant input are observable either directly or indirectly to estimate fair value the input include reported trade of and broker dealer quote on the same or similar security issuer credit spread benchmark security and other observable input we estimate the fair value of our residential mortgage backed security by taking into consideration valuation obtained from third party pricing service the pricing service use industry standard valuation model including both income and market based approach for which all significant input are observable either directly or indirectly to estimate fair value the input include reported trade of and broker dealer quote on the same or similar security issuer credit spread benchmark security prepayment or default projection based on historical data and other observable input we value our other short term interest bearing security at amortized cost which approximates fair value given their near term maturity date of our foreign currency forward and option derivative contract have maturity of three year or le and all are with counterparties that have minimum credit rating of or equivalent by standard poor financial service moody investor service inc moody or fitch rating inc fitch we estimate the fair value of these contract by taking into consideration valuation obtained from third party valuation service that us an income based industry standard valuation model for which all significant input are observable either directly or indirectly these input include foreign currency exchange rate libor swap rate and obligor credit default swap rate in addition input for our foreign currency option contract include implied volatility measure these input when applicable are at commonly quoted interval see note derivative instrument our cross currency swap contract are with counterparties that have minimum credit rating of or equivalent by moody or fitch we estimate the fair value of these contract by taking into consideration valuation obtained from third party valuation service that us an income based industry standard valuation model for which all significant input are observable either directly or indirectly these input include foreign currency exchange rate libor swap rate obligor credit default swap rate and cross currency basis swap spread see note derivative instrument our interest rate swap contract are with counterparties that have minimum credit rating of or equivalent by moody or fitch we estimate the fair value of these contract by using an income based industry standard valuation model for which all significant input are observable either directly or indirectly these input include libor swap rate and obligor credit default swap rate see note derivative instrument during the year ended december and there were no transfer of asset or liability between fair value measurement level and there were no material remeasurements to the fair value of asset and liability that are not measured at fair value on recurring basis during the year ended december we discontinued the internal development of program that resulted in an impairment of an ipr asset of million which wa recognized in other operating expense in the consolidated statement of income and included in other item net in the consolidated statement of cash flow summary of the fair value of other financial instrumentscash equivalentsthe fair value of cash equivalent approximate their carrying value due to the short term nature of such financial instrument borrowingswe estimated the fair value of our borrowing by using level input of december and the aggregate fair value of our borrowing were billion and billion respectively and the carrying value were billion and billion respectively investment in beigenewe estimated the fair value of our investment in beigene by using level input of december the fair value and carrying value were billion and billion respectively derivative instrumentsthe company is exposed to foreign currency exchange rate and interest rate risk related to it business operation to reduce our risk related to such exposure we use or have used certain derivative instrument including foreign currency forward foreign currency option cross currency swap forward interest rate and interest rate swap contract we do not use derivative for speculative trading purpose cash flow hedgeswe are exposed to possible change in the value of certain anticipated foreign currency cash flow resulting from change in foreign currency exchange rate associated primarily with our euro denominated international product sale increase and decrease in the cash flow associated with our international product sale due to movement in foreign currency exchange rate are partially offset by corresponding increase and decrease in the cash flow from our international operating expense resulting from these foreign currency exchange rate movement to further reduce our exposure to foreign currency exchange rate fluctuation with regard to our international product sale we enter into foreign currency forward and option contract to hedge portion of our projected international product sale primarily over three year time horizon with at any given point in time higher percentage of nearer term projected product sale being hedged than in successive period of december and we had outstanding foreign currency forward contract with aggregate notional amount of billion billion and billion respectively of december we had outstanding foreign currency option contract with aggregate notional amount of million and no such outstanding contract of december and we have designated these foreign currency forward and foreign currency option contract which are primarily euro based cash flow hedge accordingly we report the unrealized gain and loss on these contract in aoci in the consolidated balance sheet and we reclassify them to product sale in the consolidated statement of income in the same period during which the hedged transaction affect earnings to hedge our exposure to foreign currency exchange rate risk associated with certain of our long term debt denominated in foreign currency we enter into cross currency swap contract under the term of such contract we paid euro pound sterling and swiss franc and received dollar for the notional amount at the inception of the contract and based on these notional amount we exchange interest payment at fixed rate over the life of the contract by paying dollar and receiving euro pound sterling and swiss franc in addition we will pay dollar to and receive euro pound sterling and swiss franc from the counterparties at the maturity of the contract for these same notional amount the term of these contract correspond to the related hedged debt thereby effectively converting the interest payment and principal repayment on the debt from euro pound sterling and swiss franc to dollar we have designated these cross currency swap contract cash flow hedge accordingly the unrealized gain and loss on these contract are reported in aoci in the consolidated balance sheet and reclassified to interest and other income net in the consolidated statement of income in the same period during which the hedged debt affect earnings the notional amount and interest rate of our cross currency swap of december were follows notional amount in million foreign currencyu dollarshedged notesnotional amountsinterest ratesnotional amountsinterest euro note swiss franc euro note pound sterling note pound sterling note during the year ended december our euro note matured and the related cross currency swap were settled in connection with the anticipated issuance of long term fixed rate debt we occasionally enter into forward interest rate contract in order to hedge the variability in cash flow due to change in the applicable treasury rate between the time we enter into these contract and the time the related debt is issued gain and loss on forward interest rate contract which are designated cash flow hedge are recognized in aoci in the consolidated balance sheet and are amortized into interest expense net in the consolidated statement of income over the life of the associated debt issuance amount recognized in connection with forward interest rate swap during the year ended december and amount expected to be recognized during the subsequent month are not material the unrealized loss and gain recognized in aoci for our derivative instrument designated cash flow hedge were follows in million year ended december derivative in cash flow hedging currency contract cross currency swap forward interest rate contract total unrealized loss gain value hedgesto achieve desired mix of fixed rate and floating rate debt we entered into interest rate swap contract that qualified for and were designated fair value hedge these interest rate swap contract effectively convert fixed rate coupon to floating rate libor based coupon over the term of the related hedge contract of december and we had interest rate swap contract with aggregate notional amount of billion and billion respectively that hedge certain portion of our long term debt issuance interest rate swap with an aggregate notional value of billion were terminated during the year ended december in connection with the redemption of certain of our note the termination of these interest rate swap resulted in gain of million recognized in interest expense net in the consolidated statement of income additionally we terminated billion aggregate notional amount of interest rate swap which resulted in the receipt of million from the counterparties that wa included in net cash provided by operating activity in the consolidated statement of cash flow for the year ended december this amount will be recognized reduction in interest expense net in the consolidated statement of income over the remaining life of the underlying note immediately following the termination of these interest rate swap contract we entered into new interest rate swap agreement at then current interest rate on the same billion principal amount of note see note financing arrangement for information on our interest rate swap for interest rate swap contract that qualify for and are designated fair value hedge we recognize in interest expense net in the consolidated statement of income the unrealized gain or loss on the derivative resulting from the change in fair value during the period well the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk if hedging relationship involving an interest rate swap contract is terminated the gain or loss realized on contract termination is recorded an adjustment to the carrying value of the debt and amortized into interest expense net over the remaining life of the previously hedged debt the hedged liability and related cumulative basis adjustment for fair value hedge of those liability were recorded in the consolidated balance sheet follows in million carrying amount ofhedged liability cumulative amount of fair value hedging adjustment related to the carrying amount of the hedged liability december december consolidated balance sheet portion of long term debt long term debt ____________ current portion of long term debt includes million of carrying value with discontinued hedging relationship of december long term debt includes million and million of carrying value with discontinued hedging relationship of december and december respectively current portion of long term debt includes million of hedging adjustment on discontinued hedging relationship of december long term debt includes million and million of hedging adjustment on discontinued hedging relationship of december and december respectively of hedging transactionsthe following table summarize the amount recorded in income and expense line item and the effect thereon from fair value and cash flow hedging including discontinued hedging relationship in million year ended december salesinterest and other income netinterest expense nettotal amount recorded in income and expense line item presented in the consolidated statement of income the effect of cash flow and fair value hedging gain on cash flow hedging relationship reclassified out of aoci foreign currency contract cross currency swap contract gain loss on fair value hedging relationship interest rate swap agreement hedged item derivative designated hedging instrument year ended december salesinterest and other income netinterest expense nettotal amount recorded in income and expense line item presented in the consolidated statement of income the effect of cash flow and fair value hedging gain on cash flow hedging relationship reclassified out of aoci foreign currency contract cross currency swap contract loss gain on fair value hedging relationship interest rate swap agreement hedged item derivative designated hedging instrument year ended december salesinterest and other income expense netinterest expense nettotal amount recorded in income and expense line item presented in the consolidated statement of income the effect of cash flow and fair value hedging loss on cash flow hedging relationship reclassified out of aoci foreign currency contract cross currency swap contract gain loss on fair value hedging relationship interest rate swap agreement hedged item derivative designated hedging instrument __________ gain on hedged item do not completely offset loss on the related designated hedging instrument due to amortization of the cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged debt for discontinued hedging relationship and the recognition of gain on terminated hedge where the corresponding hedged item wa paid down in the period no portion of our cash flow hedge contract were excluded from the assessment of hedge effectiveness of december we expected to reclassify million of net loss on our foreign currency and cross currency swap contract out of aoci and into earnings during the next month not designated hedgesto reduce our exposure to foreign currency fluctuation in certain asset and liability denominated in foreign currency we enter into foreign currency forward contract that are not designated hedging transaction most of these exposure are hedged on month to month basis of december and the total notional amount of these foreign currency forward contract were billion billion and million respectively gain and loss recognized in earnings for our derivative instrument not designated hedging instrument were not material for the year ended december and the fair value of derivative included in the consolidated balance sheet were follows in million derivative assetsderivative liabilitiesdecember balance sheet locationsfair valuesconsolidated balance sheet locationsfair valuesderivatives designated hedging instrument foreign currency contractsother current asset other asset accrued liability other noncurrent liability cross currency swap contractsother current asset other accrued liability other noncurrent interest rate swap contractsother current asset other accrued liability other noncurrent total derivative designated hedging derivative not designated hedging instrument foreign currency contractsother current asset accrued liability total derivative not designated hedging instrument total derivative derivative assetsderivative liabilitiesdecember balance sheet locationsfair valuesconsolidated balance sheet locationsfair valuesderivatives designated hedging instrument foreign currency contractsother current asset other asset accrued liability other noncurrent liability cross currency swap contractsother current asset other accrued liability other noncurrent interest rate swap contractsother current asset other accrued liability other noncurrent liability total derivative designated hedging derivative not designated hedging instrument foreign currency contractsother current accrued liability total derivative not designated hedging total derivative derivative contract that were in liability position of december contain certain credit risk related contingent provision that would be triggered if we were to undergo change in control and ii our or the surviving entity creditworthiness deteriorates which is generally defined having either credit rating that is below investment grade or materially weaker creditworthiness after the change in control if these event were to occur the counterparties would have the right but not the obligation to close the contract under early termination provision in such circumstance the counterparties could request immediate settlement of these contract for amount that approximate the then current fair value of the contract in addition our derivative contract are not subject to any type of master netting arrangement and amount due either to or from counterparty under the contract may be offset against other amount due either to or from the same counterparty only if an event of default or termination defined were to occur the cash flow effect of our derivative contract in the consolidated statement of cash flow are included in net cash provided by operating activity except for the settlement of notional amount of cross currency swap which are included in net cash used in financing activity contingency and commitment contingenciesin the ordinary course of business we are involved in various legal proceeding government investigation and other matter that are complex in nature and have outcome that are difficult to predict see part item risk factor our business may be affected by litigation and government investigation we describe our legal proceeding and other matter that are significant or that we believe could become significant in this footnote we record accrual for loss contingency to the extent that we conclude it is probable that liability ha been incurred and the amount of the related loss can be reasonably estimated we evaluate on quarterly basis development in legal proceeding and other matter that could cause an increase or decrease in the amount of the liability that ha been accrued previously our legal proceeding involve various aspect of our business and variety of claim some of which present novel factual allegation and or unique legal theory in each of the matter described in this filing in which we could incur liability our opponent seek an award of not yet quantified amount of damage or an amount that is not material in addition number of the matter pending against are at very early stage of the legal process which in complex proceeding of the sort we face often extend for several year result none of the matter described in this filing in which we could incur liability have progressed sufficiently through discovery and or the development of important factual information and legal issue to enable to estimate range of possible loss if any or such amount are not material while it is not possible to accurately predict or determine the eventual outcome of these matter an adverse determination in one or more of these matter currently pending could have material adverse effect on our consolidated result of operation financial position or cash flow recent development concerning our legal proceeding and other matter are discussed below abbreviated new drug application anda patent litigationkyprolis anda patent litigationonyx therapeutic inc cipla limited et al between october and april onyx therapeutic inc onyx therapeutic wholly owned subsidiary of amgen filed separate lawsuit in the district court for the district of delaware the delaware district court against cipla limited and cipla usa inc collectively cipla sagent pharmaceutical inc sagent breckenridge pharmaceutical inc breckenridge and fresenius kabi usa llc fresenius kabi usa inc fresenius kabi pharmaceutical holding inc and fresenius kabi oncology limited teva pharmaceutical usa inc and teva pharmaceutical industry ltd msn laboratory private limited and msn pharmaceutical inc collectively msn dr reddy laboratory ltd and dr reddy laboratory inc collectively drl qilu pharma inc and qilu pharmaceutical co ltd collectively qilu apotex inc and apotex corp apotex innopharma inc innopharma and aurobindo pharma usa inc each for infringement of one or more of our following patent which are listed in the approved drug product with therapeutic equivalence evaluation the orange book for kyprolis patent no the patent the patent the patent the patent the patent the patent the patent the patent and the patent each of these lawsuit wa based on each defendant submission of an anda seeking food and drug administration fda approval to market generic version of kyprolis in each lawsuit onyx therapeutic sought an order of the delaware district court making any fda approval of the respective defendant anda effective no earlier than the expiration of the applicable patent the delaware district court consolidated these lawsuit for purpose of discovery into single case onyx therapeutic inc cipla limited et al in january by stipulation with onyx therapeutic fresenius kabi pharmaceutical holding inc and fresenius kabi oncology limited were dismissed from the lawsuit leaving fresenius kabi usa llc and fresenius kabi usa inc collectively fresenius the remaining fresenius defendant in september and february respectively by joint stipulation with onyx therapeutic teva pharmaceutical industry ltd and teva pharmaceutical usa inc were each dismissed from the lawsuit and in february qilu wa dismissed from the lawsuit by joint stipulation between onyx therapeutic and qilu between april and july of the delaware district court entered order on stipulation between onyx therapeutic and each of apotex drl sagent fresenius breckenridge aurobindo pharma usa inc cipla and innopharma respectively that each defendant infringes the and patent onyx therapeutic provided those defendant either through stipulated order or other agreement covenant that it would not assert patent infringement of the and patent against certain of the respective defendant anda application and product in june the delaware district court entered an order on stipulation between onyx therapeutic and msn that msn infringes the patent in december apotex drl fresenius innopharma sagent breckenridge aurobindo pharma usa inc and cipla amended their response to the complaint to add the defense of unclean hand and to seek declaration of unenforceability of the asserted patent based on allegation of inequitable conduct in january msn amended it response to the complaint to add the defense of unclean hand on january onyx therapeutic filed separate lawsuit in the delaware district court against breckenridge for infringement of the and patent in connection with it anda that seek approval to market generic version of kyprolis on march the delaware district court entered an order on stipulation between onyx therapeutic and breckenridge providing that breckenridge infringes the asserted claim of the and patent and consolidated this lawsuit against breckenridge into the existing consolidated case onyx therapeutic inc cipla limited et al for all purpose on may the delaware district court commenced trial in the onyx therapeutic inc cipla limited et al consolidated case during trial the delaware district court signed consent judgment filed by onyx therapeutic and each of aurobindo pharma usa inc innopharma sagent apotex fresenius drl and breckenridge in which the party stipulated to entry of judgment dismissing with prejudice all of the party claim counterclaim affirmative defense and demand and an injunction prohibiting infringement of the and patent by the manufacture use sale offer to sell or importation into the united state of the applicable defendant carfilzomib product unless specifically authorized pursuant to the applicable confidential settlement agreement during trial the delaware district court also entered consent judgment between onyx therapeutic and msn in which the party stipulated to entry of judgment dismissing with prejudice all of the party claim counterclaim affirmative defense and demand and an injunction prohibiting infringement of the patent by the manufacture use sale offer to sell or importation into the united state of msn carfilzomib product unless specifically authorized pursuant to the confidential settlement agreement on may trial concluded between onyx therapeutic and the lone remaining defendant cipla may consistent with it may decision and order the delaware district court entered final judgment in favor of onyx therapeutic and against cipla on infringement validity and enforceability of claim and of the patent claim of the patent and claim of the patent the delaware district court entered judgment in favor of cipla and against onyx therapeutic on cipla counterclaim for invalidity of claim of the patent and ordered that the effective date of any final approval by the fda of cipla anda must be after expiration of the three asserted patent the and patent and any regulatory exclusivity to which onyx therapeutic may become entitled the final judgment includes an injunction prohibiting cipla from making using offering to sell selling or importing into the united state cipla carfilzomib product during the term of the three asserted patent on may cipla filed notice of appeal to the court of appeal for the federal circuit the federal circuit court the federal circuit court ha set the hearing date on cipla appeal for march otezla anda patent litigationamgen inc sandoz inc et al beginning in june celgene filed separate lawsuit in the district court for the district of new jersey the new jersey district court against alkem laboratory ltd alkem amneal pharmaceutical llc annora pharma private ltd and hetero usa inc collectively hetero aurobindo pharma ltd and aurobindo pharma usa inc collectively aurobindo cipla limited cipla ltd drl emcure pharmaceutical ltd and heritage pharmaceutical inc collectively emcure glenmark pharmaceutical ltd glenmark macleod pharmaceutical ltd macleod mankind pharma ltd mankind msn laboratory private limited pharmascience inc pharmascience prinston pharmaceutical inc prinston sandoz inc shilpa medicare ltd shilpa teva pharmaceutical usa inc and actavis llc collectively actavis torrent pharmaceutical ltd torrent unichem laboratory ltd unichem and zydus pharmaceutical usa inc each for infringement of one or more of the following patent patent no the patent the patent the patent the patent the patent the patent the patent the patent and the patent which are listed in the orange book for otezla each of the defendant is seeking to market generic version of otezla before expiration of the asserted patent the new jersey district court consolidated these lawsuit for discovery and case management purpose into single case celgene corp sandoz inc et al each lawsuit seek an order of the new jersey district court making any fda approval of the respective defendant anda effective no earlier than the expiration of the applicable patent in august celgene filed amended complaint against alkem amneal pharmaceutical llc aurobindo cipla ltd drl glenmark pharmascience sandoz inc actavis unichem and zydus pharmaceutical usa inc additionally asserting patent no the patent which is listed in the orange book for otezla between october and november celgene filed amended complaint against alkem amneal pharmaceutical llc hetero aurobindo cipla ltd drl emcure glenmark macleod mankind msn laboratory private limited pharmascience prinston sandoz inc actavis torrent unichem and zydus pharmaceutical usa inc additionally asserting patent no the patent which is listed in the orange book for otezla between march and april celgene filed amended complaint against hetero msn laboratory private limited and emcure for infringement of one or more of the above listed patent on october celgene filed an amended complaint against mankind for infringement of the and patent on october celgene filed separate lawsuit against zydus pharmaceutical usa inc in the new jersey district court for infringement of patent no the patent and the patent which are not listed in the orange book for otezla on december the new jersey district court consolidated this lawsuit for discovery and case management purpose into the existing consolidated case celgene corp sandoz inc et al each defendant ha filed an answer to the above listed complaint and amended complaint disputing infringement and or validity of the patent asserted against it along with their answer each of alkem hetero cipla ltd drl emcure glenmark macleod mankind pharmascience sandoz inc shilpa actavis torrent unichem and zydus pharmaceutical usa inc filed declaratory judgment counterclaim asserting that some or all of the patent are not infringed and or are invalid in august based on joint request by celgene and glenmark the new jersey district court entered consent judgment and injunction prohibiting the making having made using selling offering to sell importing or distributing of glenmark apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement following amgen acquisition of the patent in suit and the new drug application for otezla on february the new jersey district court issued an order substituting amgen for celgene plaintiff in the consolidated action and all related action terminating celgene plaintiff in the consolidated action and all related action and amending the case caption in the consolidated action and all related action to reflect amgen the sole plaintiff march based on joint request by amgen and unichem the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of unichem apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement on april based on joint request by amgen and hetero the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of hetero apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement on may based on joint request by amgen and emcure the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of emcure apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement on july the new jersey district court ordered stipulated dismissal without prejudice of all claim counterclaim and affirmative defense between amgen and sandoz inc with respect to the and patent leaving the and patent asserted by amgen against sandoz inc in the litigation on august based on joint request by amgen and mankind the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of mankind apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement on august based on joint request by amgen and macleod the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of macleod apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement on october based on joint request by amgen and amneal pharmaceutical llc the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of amneal pharmaceutical llc apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement on december based on joint request by amgen and shilpa the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of shilpa apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement on january based on joint request by amgen and actavis the new jersey district court entered consent judgment and injunction prohibiting the making using selling offering to sell or importing of actavis apremilast product during the term of the and patent unless authorized pursuant to confidential settlement agreement trial in the consolidated action against the remaining defendant is scheduled to commence on june sensipar cinacalcet anda patent litigationamgen inc amneal pharmaceutical llc et al formerly amgen inc aurobindo pharma ltd et al beginning in september amgen filed separate lawsuit in the delaware district court for infringement of our patent no the patent against number of manufacturer of purported generic version of our sensipar product in february the delaware district court consolidated these lawsuit into single case amgen inc aurobindo pharma ltd et al in june amgen filed an additional lawsuit in the delaware district court for infringement of the patent which wa consolidated into amgen inc aurobindo pharma ltd et al in august the patent is entitled rapid dissolution formulation of calcium receptor active compound and expires in all defendant responding to the complaint denied infringement and sought judgment that the patent is invalid and or not infringed between september and november of amgen filed and the delaware district court signed stipulated dismissal of the lawsuit against micro lab ltd and micro lab usa inc and the lawsuit against apotex well consent judgment filed by amgen and each of sun pharma global fze sun pharmaceutical industry ltd and sun pharmaceutical industry inc collectively sun ajanta pharma limited and ajanta pharma usa inc hetero usa inc hetero lab ltd and hetero lab ltd unit and breckenridge each consent judgment stipulated to an entry of judgment of infringement and validity of the patent and an injunction prohibiting the manufacture use sale offer to sell importation of or distribution into the united state of the respective defendant cinacalcet product during the term of the patent unless specifically authorized pursuant to the confidential settlement agreement march the delaware district court commenced trial on the infringement claim and defense in the amgen inc aurobindo pharma ltd et al consolidated lawsuit against the defendant that remained in the lawsuit collectively consisting of watson laboratory inc and actavis pharma inc collectively watson amneal pharmaceutical llc and amneal pharmaceutical of new york llc collectively amneal zydus pharmaceutical usa inc and cadila healthcare ltd collectively zydus and piramal healthcare uk limited piramal prior to trial the delaware district court signed consent judgment filed by amgen and each of cipla and stride pharma global pte limited and stride pharma inc collectively stride and consent judgment filed by amgen and aurobindo in each consent judgment the party stipulated to an entry of judgment of infringement and validity of the patent and an injunction prohibiting the manufacture use sale offer to sell importation of or distribution into the united state of the applicable defendant cinacalcet product during the term of the patent unless specifically authorized pursuant to the applicable confidential settlement agreement just prior to trial the delaware district court also entered order dismissing each of drl and mylan pharmaceutical inc and mylan inc collectively mylan on stipulation between amgen and such party respectively subject to the term of confidential settlement agreement in july the delaware district court issued trial order finding on the infringement claim and defense in the amgen inc aurobindo pharma ltd et al consolidated lawsuit that zydus infringes the patent and that amneal piramal and watson do not infringe the patent in august the delaware district court issued an order dismissing without prejudice the invalidity counterclaim of amneal piramal and watson and entered judgment of noninfringement of the patent in favor of amneal piramal and watson in september amgen filed notice of appeal to the federal circuit court in october the delaware district court dismissed without prejudice the invalidity counterclaim of zydus and entered judgment of infringement of the patent by zydus in favor of amgen including an order that the effective date of the fda approval of zydus generic version of sensipar shall be no earlier than the expiry date of our patent also in october zydus filed notice of appeal to the federal circuit court and the federal circuit court consolidated the appeal of zydus and amgen in december the fda approved watson generic version of sensipar and watson parent company teva pharmaceutical industry ltd teva began selling it product at risk notwithstanding that the appeal were pending at the federal circuit court on january amgen watson and teva entered into settlement agreement in which teva agreed to stop selling it generic product until the mid year or earlier under certain circumstance and to pay amgen an undisclosed amount on january watson and amgen filed motion asking the delaware district court to vacate it final judgment of noninfringement to watson and to enter proposed consent judgment of infringement and validity of the patent and an injunction prohibiting the making having made using selling offering to sell or distributing watson cinacalcet product in the united state or importing watson cinacalcet product into the united state consistent with the confidential settlement agreement on january the federal circuit court stayed the pending appeal by amgen of the judgment of noninfringement to watson in order for the delaware district court to rule on the motion of watson and amgen on march the delaware district court denied the joint motion for indicative ruling of watson and amgen on april amgen filed an appeal to the federal circuit court and the federal circuit court lifted the stay of amgen appeal of the judgment of noninfringement to watson and consolidated it with amgen appeal of the delaware district court denial of the joint motion for indicative ruling on september the federal circuit court denied amgen motion and lifted the stay of the briefing schedule which had been stayed pending disposition of amgen motion to vacate on july the federal circuit court granted motion filed by amgen and watson to dismiss amgen appeal of the delaware district court judgment of noninfringement to watson and denial of the joint motion for indicative ruling on march amgen filed an emergency motion for an injunction pending appeal seeking an order from the delaware district court enjoining defendant piramal from making using selling offering for sale or importing it generic cinacalcet product amgen motion follows an announcement that slate run pharmaceutical llc slate run in partnership with piramal had begun selling piramal generic cinacalcet product at risk notwithstanding the appeal pending at the federal circuit court on april the delaware district court signed an order enjoining piramal and slate run from selling their generic cinacalcet product until certain event occur related to decision by the federal circuit court on the party appeal the order ha no effect on the product that piramal and slate run had already sold to third party on january the federal circuit court issued an opinion affirming the judgment of noninfringement with respect to piramal affirming the judgment of infringement with respect to zydus and vacating and remanding to the delaware district court for further consideration the judgment of noninfringement with respect to amneal on april the federal circuit court issued mandate returning the case to the delaware district court on september the delaware district court entered judgment of validity and infringement of the patent in the lawsuit filed against amneal and except to the extent specifically authorized in confidential settlement agreement enjoined amneal from infringing the patent by making using selling offering to sell or importing amneal cinacalcet product during the term of the patent hearing before the delaware district court on the request of piramal to recover damage for being enjoined during the pendency of amgen appeal ha been rescheduled for march on october the delaware district court issued an order permitting slate run piramal business partner to intervene in the pending action enbrel patent litigationimmunex corporation et al sandoz inc et al in february two affiliate of amgen inc immunex corporation and amgen manufacturing limited collectively amgen along with hoffmann la roche inc roche filed lawsuit in the new jersey district court against sandoz inc sandoz international gmbh and sandoz gmbh collectively sandoz this lawsuit stem from sandoz submission of an application for fda licensure of an etanercept product biosimilar to amgen enbrel amgen and roche have asserted infringement of five patent patent no the patent the patent the patent the patent and the patent by their complaint amgen and roche seek an injunction to prohibit sandoz from commercializing it biosimilar etanercept product in the united state prior to the expiry of such patent all sandoz defendant responded by denying infringement and or asserting that the patent at issue are invalid in august and subject to the term of confidential stipulation the new jersey district court entered preliminary injunction prohibiting sandoz from making using importing selling or offering for sale sandoz etanercept product sandoz erelzitm biosimilar to enbrel wa approved by the fda in august in september the new jersey district court entered an order that the making using offering to sell or selling in the united state or the importation into the united state by sandoz of sandoz biosimilar etanercept product infringes the and patent and held bench trial focusing on sandoz challenge to the validity of these patent on august the new jersey district court issued it decision upholding the validity of the and patent on october by stipulation of amgen and sandoz the new jersey district court entered final judgment and permanent injunction prohibiting sandoz from making using importing selling or offering for sale sandoz etanercept product and on the same day sandoz appealed the final judgment to the federal circuit court following motion by sandoz the federal circuit court ordered an expedited briefing schedule for the appeal on march the federal circuit court heard oral argument on the appeal on july the federal circuit court affirmed the judgment of the new jersey district court upholding the validity of the and patent on september the federal circuit court denied the petition for rehearing of sandoz filed on july on january sandoz filed petition for certiorari with the supreme court seeking review of the federal circuit court affirmance of the validity of the and patent immunex corporation et al samsung bioepis co ltd on april two affiliate of amgen inc immunex corporation and amgen manufacturing limited collectively amgen along with roche filed lawsuit in the new jersey district court against samsung bioepis co ltd bioepis this lawsuit stem from bioepis submission of an application for fda licensure of an etanercept product biosimilar to amgen enbrel amgen and roche have asserted infringement of five patent the and patent by their complaint amgen and roche seek an injunction to prohibit bioepis from commercializing it biosimilar etanercept product in the united state prior to the expiry of such patent on august bioepis responded to the complaint denying infringement and seeking judgment that the patent in suit are invalid unenforceable and or not infringed on january and subject to the term of confidential stipulation and court order of january the new jersey district court entered consent injunction that prohibits bioepis from making using offering to sell selling or importing into the united state bioepis etanercept product amgen and bioepis entered into an agreement with respect to an injunction regarding etanercept set out in the new jersey district court order of january on january the new jersey district court entered an order administratively staying the case pursuant to joint request of amgen and bioepis patent litigationamgen inc et al sanofi et al in october amgen initiated series of lawsuit that were consolidated by the delaware district court in december into single case against sanofi sanofi aventis llc and aventisub llc formerly doing business aventis pharmaceutical inc collectively sanofi and regeneron pharmaceutical inc regeneron addressing seven of our patent patent no the patent the patent and these patent describe and claim monoclonal antibody to proprotein convertase subtilisin kexin type by it complaint amgen seek an injunction to prevent the infringing manufacture use and sale of sanofi and regeneron alirocumab monoclonal antibody targeting in january the delaware district court granted amgen motion to amend the complaint to add it affiliate amgen manufacturing limited and amgen usa inc plaintiff and to add the allegation that sanofi and regeneron infringement of amgen patent is willful in february the delaware district court entered stipulated order finding alirocumab and the drug product containing it praluent infringe certain of amgen patent including claim and of the patent and claim of the patent in march the delaware district court entered judgment in favor of amgen following five day jury trial and unanimous jury verdict that these patent claim are all valid in january the delaware district court denied sanofi and regeneron post trial motion seeking new trial and for judgment matter of law and granted amgen motion for permanent injunction prohibiting the infringing manufacture use sale offer for sale or import of alirocumab in the united state sanofi and regeneron filed an appeal of the judgment and the permanent injunction to the federal circuit court in february following motion by sanofi and regeneron the federal circuit court entered stay of the permanent injunction during the pendency of the appeal in october the federal circuit court reversed in part the judgment of the delaware district court and remanded for new trial two of the patent validity defense lack of written description and enablement of the claimed invention and affirmed the delaware district court judgment of infringement of claim and of the patent and claim of the patent and the third patent validity defense finding that the claimed invention were not obvious to person of ordinary skill in the field of the patent in march the federal circuit court issued mandate returning the case to the delaware district court for new trial on two of sanofi and regeneron challenge to the validity of our patent lack of written description and enablement of the claimed invention and for further consideration of permanent injunction in july amgen filed petition for certiorari with the supreme court seeking review of the federal circuit court conclusion that the judgment affirming the validity of amgen patent wa based in part on an erroneous application of the law of written description on january the supreme court denied amgen petition for certiorari on remand the delaware district court scheduled new trial on sanofi and regeneron challenge to the validity of our patent based on lack of written description and enablement of the claimed invention the delaware district court also entered judgment on the pleading for sanofi and regeneron on amgen claim of willful infringement on february jury of the delaware district court unanimously upheld the validity of claim and of the patent and claim of the patent the jury also found that claim and of the patent meet the enablement requirement but are invalid for failure to meet the written description requirement on march sanofi and regeneron filed post trial motion seeking to reverse judgment matter of law or for new trial with respect to claim and of the patent and claim of the patent and amgen filed motion for permanent injunction on june and the delaware district court held evidentiary hearing on amgen motion for permanent injunction against praluent on august the delaware district court ruled on the post trial motion denying sanofi and regeneron request for new trial and their request to reverse the jury verdict that the patent and the patent provide written description support for the claimed invention the delaware district court also ruled matter of law that claim and of the patent and claim of the patent are invalid for failing to meet the enablement requirement overturning the jury verdict on october amgen filed notice of appeal to the federal circuit court on december the federal circuit court heard oral argument on the appeal patent dispute in the international regionwe are involved in and expect future involvement in additional dispute regarding our patent in other jurisdiction and region this includes matter filed against and that we have filed in the united kingdom germany france the netherlands italy spain and japan in february the european patent office epo granted european patent no ep to amgen this patent describes and claim monoclonal antibody to and method of treatment and sanofi filed an opposition to the patent in the epo seeking to invalidate it in november sanofi aventis deutschland gmbh sanofi aventis groupe and sanofi winthrop industrie filed joint opposition against amgen patent and each of eli lilly and company regeneron and strawman ltd also filed opposition to amgen patent in november the epo confirmed the validity of amgen ep which wa appealed to the technical board of appeal tba on october the tba upheld the validity of certain claim including claim that protect repatha but ruled that broader claim encompassing praluent were invalid result of the tba decision national litigation regarding praluent in europe are in the process of being resolved on april the supreme court of japan declined to hear sanofi appeal making final the japanese high court decision that praluent infringes amgen valid patent right in japan on june amgen filed written answer to the invalidity trial initiated by regeneron on february before the japan patent office seeking to invalidate amgen japanese patent that were previously held infringed by praluent and valid over challenge filed by sanofi damage proceeding against sanofi are ongoing before the tokyo district court where sanofi ha initiated new validity challenge to amgen patent in japan neupogen filgrastim neulasta patent litigationamgen inc et al pfizer inc et al in july amgen inc and it wholly owned subsidiary amgen manufacturing limited collectively amgen filed lawsuit in the delaware district court against pfizer inc and hospira inc collectively pfizer this lawsuit stem from pfizer submission of an application for fda licensure of filgrastim product biosimilar to amgen neupogen amgen ha asserted infringement of patent no the patent and seek among other remedy injunctive relief to prohibit pfizer from infringing the patent in july the fda approved pfizer nivestymtm biosimilar to neupogen which wa subsequently launched in october in august pfizer answered the complaint and counterclaimed seeking declaration that pfizer doe not infringe amgen patent and that the patent is invalid on march amgen filed an amended complaint against pfizer in the delaware district court narrowing the patent claim at issue in the infringement dispute and adding request for damage on april pfizer answered amgen amended complaint including counterclaim seeking declaratory judgment of noninfringement and invalidity on february the delaware district court entered an amended scheduling order moving the trial on the infringement of our patent to may to enable amgen to seek additional discovery into pfizer invalidity defense on april amgen filed separate lawsuit in the delaware district court against pfizer for infringement of patent no the patent and seek among other remedy damage and injunctive relief to prohibit pfizer from infringing the patent by the manufacture import and sale of pfizer nivestymtm on january the delaware district court granted pfizer request to stay the patent infringement lawsuit on the patent until the co pending patent infringement lawsuit on the patent is resolved amgen inc et al hospira inc et al on february amgen inc and it wholly owned subsidiary amgen manufacturing limited collectively amgen filed lawsuit in the delaware district court against pfizer this lawsuit stem from pfizer submission of an application for fda licensure of pegfilgrastim product biosimilar to amgen neulasta amgen ha asserted infringement of patent no the patent and seek among other remedy injunctive relief to prohibit pfizer from infringing the patent on march pfizer filed motion requesting the delaware district court to dismiss the complaint by amgen alleging noninfringement of the patent in june the fda approved pfizer nyvepria biosimilar to amgen neulasta patent trial and appeal board ptab challengelupin ptab challengeon december lupin limited lupin filed petition to institute inter party review ipr proceeding at the patent and trademark office uspto of patent no the patent challenging claim of the patent unpatentable amgen preliminary response is due on april and the ptab will then have no more than three month to decide whether to institute proceeding ptab challengein february the ptab of the uspto granted apotex petition to institute ipr proceeding of patent no the patent challenging claim of the patent unpatentable in may amgen filed it response in february the ptab issued final decision holding all but one claim of the patent unpatentable and apotex filed request for rehearing in march on may the ptab issued decision denying apotex request for rehearing on the ptab finding and sua sponte amending the final decision with finding that the one remaining claim in amgen patent is unpatentable on july amgen filed notice of appeal to the federal circuit court with respect to all claim held to be unpatentable on august apotex provided notice that it would not participate in the appeal on september the uspto filed notice of intervention on the appeal on march the federal circuit court vacated the decision by the ptab and remanded the case to the ptab for proceeding consistent with the federal circuit court decision in arthrex inc smith nephew inc fed cir on july amgen and apotex filed joint motion to terminate the ipr proceeding stating that there is no current dispute between the party with respect to the patent on july the government filed petition for writ of certiorari with respect to the case that the federal circuit court remanded to the ptab including the case regarding the patent for proceeding consistent with it decision in arthrex inc smith nephew inc fed cir requesting that such remanded case be held pending the supreme court disposition of the petition for writ of certiorari in united state arthrex inc no on august amgen filed it response to the government petition for writ of certiorari indicating that amgen did not intend to respond unless requested by the supreme court breach of contract actionnovartis pharma ag amgen inc on april amgen filed lawsuit in the district court for the southern district of new york the new york southern district court against novartis pharma ag novartis seeking declaratory judgment that novartis materially breached two collaboration agreement amgen and novartis entered into in and the agreement and the agreement respectively related to the development and commercialization of aimovig due to novartis affiliate sandoz gmbh entering into contract manufacturing agreement with alder biopharmaceuticals inc alder related to eptinezumab an expected direct competitor to aimovig and entrant in the calcitonin gene related peptide cgrp related migraine therapy market amgen seek to terminate it collaboration agreement with novartis and also seek damage from novartis for breach of contract and negligent misrepresentation also on april novartis initiated separate lawsuit against amgen in the same court seeking declaratory judgment that novartis alternatively did not materially breach the collaboration agreement or even if it did breach the collaboration agreement such breach wa not material and ha been cured and that amgen may not terminate the collaboration agreement on april amgen answered novartis complaint and filed counterclaim seeking declaratory judgment that novartis materially breached the collaboration agreement due to it affiliate sandoz gmbh entering into the contract manufacturing agreement with alder in it counterclaim amgen seek to terminate it collaboration agreement with novartis and also seek damage from novartis for breach of contract and negligent misrepresentation on july novartis filed an amended complaint adding claim for breach of contract alleging novartis is owed amount associated with budget overrun and amgen responded with counterclaim alleging additional breach by novartis of the collaboration agreement on september and october novartis and amgen respectively each filed it motion for judgment on the pleading on february amgen wa granted leave to file it amended counterclaim on february amgen filed it amended answer to novartis first amended complaint and second amended counterclaim for affirmative relief to add fraudulent inducement claim on february novartis filed it answer and affirmative defense to amgen second amended counterclaim on june the new york southern district court entered an order granting novartis motion for judgment on the pleading that novartis did not breach the agreement and denying amgen motion for judgment on the pleading seeking dismissal of novartis amended complaint that novartis did not breach the agreement or the agreement and novartis timely cured any breach on june amgen filed motion for clarification and or reconsideration of the june order which wa denied on september class actionsensipar antitrust class actionsfrom february to april four plaintiff filed putative class action lawsuit against amgen and various entity affiliated with teva alleging anticompetitive conduct in connection with settlement between amgen and manufacturer of generic cinacalcet product two of those action were brought in the delaware district court captioned ufcw local welfare fund amgen inc et al february local and cesar castillo inc amgen inc et al february castillo the third action wa brought in the new jersey district court captioned teamster local welfare fund et al amgen inc et al march local and the fourth action wa brought in the district court for the eastern district of pennsylvania the eastern pennsylvania district court captioned kph healthcare service inc kinney drug inc amgen inc et al april kph each of the lawsuit is brought on behalf of putative class of direct or indirect purchaser of sensipar and alleges that the plaintiff have overpaid for sensipar result of amgen conduct that allegedly improperly delayed market entry by manufacturer of generic cinacalcet product the lawsuit focus predominantly on the settlement among amgen watson and teva of the party patent infringement litigation each of the lawsuit seek among other thing treble damage equitable relief and attorney fee and cost on april the plaintiff in the kph lawsuit filed motion seeking to have the four lawsuit consolidated and designated multidistrict litigation mdl in the eastern pennsylvania district court and the plaintiff in the local lawsuit filed motion seeking to have the four lawsuit along with cipla ltd amgen inc consolidated and designated mdl in the delaware district court on july the mdl panel entered an order consolidating in the delaware district court the four class action lawsuit on september the plaintiff filed amended complaint and on october amgen filed it motion to dismiss both the direct purchaser plaintiff consolidated class action complaint and the indirect purchaser end payor plaintiff complaint on december the plaintiff responded to amgen motion to dismiss and on january amgen filed it response on february the motion in the class action lawsuit were transferred to the magistrate judge for the district of delaware magistrate judge for recommendation the mdl panel certified it conditional transfer order on february transferring the additional class action lawsuit brought in the district court for the southern district of florida captioned msp recovery claim amgen inc et al to the delaware district court on july the magistrate judge issued recommendation to the delaware district court that the claim against amgen be dismissed but leave be given to plaintiff to amend their complaint on august the plaintiff filed objection to the magistrate judge report and recommendation on august amgen filed response to the plaintiff objection on november the district court adopted the magistrate judge recommendation in part and denied it in part denying amgen motion to dismiss on the ground that plaintiff adequately alleged reverse payment claim but granted amgen motion to dismiss with respect to the other federal antitrust claim on december teva watson and actavis filed motion for interlocutory appeal and for stay pending appeal and amgen filed it joinder the motion on january joint status report wa filed advising the delaware district court that the defendant are still considering whether to withdraw the motion and plaintiff offer to stay discovery pending further ruling on motion to dismiss the amended complaint on january joint status report wa filed pursuant to the delaware district court january order along with stipulation to defer the motion until after ruling on the amended complaint humira biosimilar antitrust class action from march to may twelve purported class action against amgen along with abbvie inc and abbvie biotechnology ltd collectively abbvie were filed in the district court for the northern district of illinois the illinois northern district court the case are captioned ufcw local welfare fund abbvie inc et al march local fraternal order of police miami lodge insurance trust fund abbvie inc et al march mayor and city council of baltimore abbvie inc et al march pipe trade service mn welfare fund abbvie inc et al march st paul electrical worker health plan abbvie inc et al march welfare plan of the international union of operating engineer local and abbvie inc et al april law enforcement health benefit inc abbvie inc et al april law enforcement kentucky laborer district council health and welfare fund abbvie inc et al april sheet metal worker local union no welfare fund abbvie inc et al april sheet metal worker local of the international union of operating engineer employer construction industry health and security trust fund abbvie inc et al april construction industry louisiana health service indemnity co blue cross and blue shield of louisiana and hmo louisiana inc abbvie inc et al april louisiana health and cleveland baker and teamster health and welfare fund abbvie inc et al may cleveland baker collectively humira antitrust class action each of the humira antitrust class action the plaintiff bring federal antitrust claim along with various state law claim under common law and antitrust consumer protection and unfair competition statute in each case the plaintiff specifically allege that abbvie ha unlawfully monopolized the alleged market for humira and biosimilars of humira including by creating an allegedly unlawful so called patent thicket around humira in the local sheet metal worker and construction industry case the plaintiff further allege that abbvie entered into allegedly unlawful market division agreement with amgen and other company that had developed humira biosimilars including bioepis mylan sandoz inc fresenius kabi usa llc pfizer inc and momentum pharmaceutical inc in connection with the settlement of patent litigation relating to humira whereby amgen and the other defendant that have developed humira biosimilars were permitted to market those product in europe early october while remaining off the market in the united state until in each of the humira antitrust class action other than the local and construction industry case the plaintiff allege that abbvie and amgen entered into an allegedly unlawful settlement agreement under which amgen allegedly agreed to delay it entry into the market with amgevitatm adalimumab it humira biosimilar in exchange for an alleged promise of exclusivity the sole humira biosimilar in that market for five month beginning in january in each of the humira antitrust class action plaintiff seek injunctive relief treble damage and attorney fee on behalf of putative class of third party payer and or consumer that have indirectly purchased paid for or provided reimbursement for humira in the united state defendant response to the first six complaint were stayed by the court on june the illinois northern district court entered an order consolidating the twelve purported class action case for pre trial purpose on august the plaintiff filed their consolidated complaint naming defendant amgen along with abbvie bioepis sandoz inc and fresenius kabi usa llc on october the defendant filed joint motion to dismiss the consolidated complaint well brief individual motion challenging the legal sufficiency of the plaintiff allegation to state any claim for relief under the law on november plaintiff filed their opposition to the motion to dismiss on december defendant filed their reply in support of the motion to dismiss on june the illinois northern district court issued an order granting the motion by the defendant to dismiss the consolidated class action complaint on june the plaintiff filed status report asking the illinois northern district court to convert the dismissal to one with prejudice on june the illinois northern district court granted the motion on july the plaintiff filed notice of appeal on october the plaintiff appellant filed their opening brief to the court of appeal for the seventh circuit plaintiff appellant amicus brief were filed in october including one by the federal trade commission and one on behalf of state each filed on october on december the defendant appellees filed their opposition brief defendant appellees amicus brief including one by the department of justice were filed on december the plaintiff appellant reply brief wa filed on february and oral argument ha been scheduled for february commitment repatriation taxunder the tax act we elected to pay in eight annual installment the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operation the following table summarizes the remaining scheduled repatriation tax payment of december in million total remaining repatriation tax commitment quarterly financial data unaudited the following table summarize the company unaudited financial data on quarterly basis the sum of the quarterly earnings per share amount may not equal the amount reported for the full year because per share amount are computed independently for each quarter and for the full year based on respective weighted average share outstanding and dilutive security quarterly financial data is summarized follows in million except per share data quarter endeddecember sale gross profit from product sale net income earnings per share basic diluted quarter endeddecember sale gross profit from product sale net income earnings per share basic diluted iiamgen inc valuation and qualifying accountsyears ended december and in million allowance for doubtful accountsbalanceat beginningof periodadditionscharged tocosts andexpensesotheradditionsdeductionsbalanceat endof periodyear ended december year ended december year ended december